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ABSTRACT 
 
Murine malaria models have proved to be a valuable preclinical tool, particularly in 
the development of new concepts in the research of human malaria.  Plasmodium 
berghei (P. berghei), is the most extensively studied and manipulated rodent 
parasite and as a laboratory model, is largely selected for studies relating to 
developmental biology of parasites and investigation into new and innovative drug 
therapies.  Whilst direct extrapolation from rodent biology to human malarias 
should be generally avoided, murine malaria models may contribute a greater 
understanding of important characteristics for antimalarial drug development and 
drug efficacy studies.  However, there is currently a paucity of murine 
pharmacological data available for both commonly used, and emerging, antimalarial 
therapies.  The findings of the studies in this thesis are seen as an important 
contribution to the preclinical knowledge of the investigated drugs which to date, 
have not been adequately studied.   
 
The aim of the thesis was to investigate the efficacy, pharmacokinetic and/or 
pharmacodynamic properties of various antimalarial drugs, in a P. berghei murine 
malaria model.  Specific aims were to:  
(i) Evaluate the pharmacodynamic effects of dihydroartemisinin (DHA) in 
asplenic P. berghei infected mice.   
(ii) Investigate the pharmacokinetic and pharmacodynamic properties of 
single dose piperaquine (PQ) in healthy and P. berghei infected mice.   
(iii) Investigate the extended antimalarial effect of PQ concentrating on drug 
efficacy, re-inoculation outcomes and parasite viability. 
(iv) Evaluate the pharmacokinetic and pharmacodynamic properties of single 
and multiple doses of chloroquine (CQ) in healthy and P. berghei 
infected mice.  
 
Using an asplenic model of P. berghei malaria, the efficacy of single doses of DHA (0, 
10, 30 and 100 mg/kg) were evaluated in uninfected and P. berghei infected, intact 
and asplenic mice.  Haematology, liver biochemistry and histopathology were 
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performed to investigate the responses of key organs to malaria infection.  Whilst 
overall efficacy of single dose DHA in asplenic mice was shown to be similar to 
intact mice, the rate of parasite recrudescence after parasite nadir (20 h at all doses 
studied) was significantly higher in the asplenic mice, particularly at higher doses 
(30 and 100 mg/kg DHA).  Histopathology of the liver and associated blood 
chemistries, demonstrated an increased stimulation of liver function during malaria 
infection in asplenic mice, when compared to intact mice.   
 
Whilst studying the pharmacokinetic and pharmacodynamic responses of PQ in the 
P. berghei malaria treatment model, particular focus was placed on (i) 
pharmacodynamic properties of single doses of PQ (0, 10, 30 and 90 mg/kg PQ 
phosphate (PQP)); (ii) pharmacokinetic parameters of PQ in healthy and P. berghei 
infected mice; (iii) efficacy of combined doses of 10 mg/kg PQP and 30 mg/kg DHA.  
Single dose administration of PQP resulted in a median survival time of 4, 10 and 54 
days after doses of 0, 10 and 30 mg/kg PQP, respectively, while mice receiving a 
single 90 mg/kg dose showed a medium survival time exceeding 60 days 
(experimental endpoint). Pharmacokinetic analysis determined the elimination half-
life of PQ in healthy and P. berghei infected mice was 18 and 16 days, respectively.  
Furthermore, extrapolation of PQ concentrations suggested that at 60 days the 
plasma drug concentration would be ineffective at suppressing the P. berghei 
infection (<10 μg/L).  Combination of PQP and DHA resulted in a significantly lower 
parasite nadir (22 ± 12 fold) than for either drug given individually. 
 
Given that high dose PQP (90 mg/kg) demonstrated extended antimalarial efficacy, 
further invetsigations were pursued on drug efficacy, re-inoculation outcomes and 
parasite viability after a single 90 mg/kg dose of PQP.   Investigation showed that 
after initial dosing, PQ concentrations were not adequate to suppress parasitaemia 
after 25 days.  Furthermore, although viable parasites were present up to 90 days 
after drug administration, once these viable parasites were passaged into naive 
mice they were found to be generally resistant to PQ when exposed to the drug for 
a second time.  Overall, PQ was found to have a substantial antimalarial effect in 
this model with this effect appearing to be sufficient for a host immunological 
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response to be established thus resulting in the long term survival of P. berghei 
infected mice.   
 
Although CQ is widely used in preclinical animal studies, there is a paucity of 
comprehensive pharmacokinetic data of CQ in animal models. In this thesis robust 
pharmacokinetic and pharmacodynamic data of CQ is presentated after single and 
multiple dose administration of CQ in the P. berghei malaria model.  The 
pharmacokinetics of desethyl-CQ (DECQ), the major active metabolite of CQ, were 
estimated. Pharmacodynamic data demonstrated that parasite nadir was reached 
79 h after a single dose of 60 mg/kg CQ, with all mice developing parasite 
recrudescence.  Multiple dose (5 x 50 mg/kg CQ; dosed every 24 h) administration 
resulted in parasitaemia falling below the limit of detection.  Despite a short period 
of recrudescence (between 10 and 24 days after initial dose), parasitaemia 
remained undetectable until the experimental end point (35 days after the initial 
dose).  Pharmacokinetic analysis determined an elimination half-life of 46.6 h in 
healthy mice and 99.3 h in malaria-infected mice (single dose data; non-
compartmental analysis).  The mean rate of formation of DCQ from CQ was 0.63 ± 
0.55 h-1 with a formation half-life of 1.7 ± 1.0 h.  
 
Consequently, the drug efficacy, pharmacodynamic and pharmacokinetic data 
included in this thesis demonstrates that the current P. berghei murine malaria 
treatment model can be used as a valuable preclinical conceptual tool for the 
investigation of antimalarial drugs such as DHA, PQ and CQ.   
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 MALARIA 
The transmission of malaria from the mosquito vector was first described by Ronald 
Ross in 1898, at which time his discovery was described as ‘important as the 
discovery of America’ (386).  Notwithstanding the massive strides in biology and 
medicine in the past 100 years, malaria still poses the greatest threat of all known 
parasites to human health (386, 577, 584).  Despite an increased awareness of the 
disease, improved access to antimalarial drugs and global economic development,   
more people die from malaria today than 40 years ago with an estimated incidence 
of infection increasing 2-3 fold over the last 35 years (197, 386). Furthermore, with 
increasing drug resistance as well as changes in world climate, malaria is returning 
to areas from which it had previously been eradicated and is now entering new 
areas such as Eastern Europe and Central Asia (197, 386).   
 
Malaria is caused by transmission of single-celled protozoan parasites of genus 
Plasmodium from an Anopheles mosquito vector, to a suitable vertebrate host.  
Whilst there are over 200 species of Plasmodium, only five species have the 
capability to cause malarial illness in humans.  Plasmodium falciparum (P. 
falciparum), P. vivax, P. ovalae and P. malariae are all human specific parasites 
which cause both serious (P. falciparum) and milder forms (P. vivax, P. ovalae and P. 
malariae) of the disease (26, 85, 382, 573).  More recently a fifth human species P. 
knowlesi has being identified which can cause human infections from zoonotic 
transfer from macaques monkeys (Macaca fascicularis) (112, 247).  At the present 
time the most dominant parasite is P. falciparum which accounts for 40-60% of 
malaria cases worldwide and >95% of all malaria deaths (421).   In tropical Africa, 
where P. falciparum is the dominant pathogen, it is estimated that a child will die 
every 12-30 sec from malaria (386).  
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1.1.1 Epidemiology 
The 2008 World Malaria Report (580) estimated that in 2006 there were 3.3 billion 
people at risk of malaria infection of whom 247 million had a reported malaria 
infection, resulting in nearly 1 million deaths.  Those most at risk from fatal malarial 
infections included children under the age of 5, pregnant women and the 
immunocompromised (580).  It has been suggested that reported figures from the 
World Health Organization (WHO) could be an underestimation of the annual 
burden of this parasitic disease (458).   
 
Malaria is endemic throughout the tropical areas of sub-Saharan Africa, Southeast 
Asia, the Pacific Islands, India and Central and South America (Fig. 1.1)(382, 579, 
580).  In 2008, 109 countries were declared to be malaria endemic with 45 of these 
countries falling within the WHO African region (579, 580).  Statistically, this 
equates to approximately 40% of the world’s population being under threat from 
this parasitic disease (26, 386).    
 
 
Figure 1.1 Distribution of malaria transmission in 2007 (580).  Worldwide 
distribution of malaria-free and malaria-endemic countries including those that are 
currently in phases of malaria control, pre-elimination, elimination and prevention 
of reintroduction (580).   
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In Southeast Asia, particularly along the borders of Thailand with Myanmar and 
Cambodia, P. falciparum is multidrug resistant with chloroquine (CQ), sulphadoxine-
pyrimethamine (Fansidar) and mefloquine monotherapies all ineffective and 
quinine therapy rapidly losing potency (Fig. 1.2)(578).  In sub-Saharan Africa CQ 
resistance to falciparum malaria is widespread and antifolate resistance is rapidly 
developing (26).   
 
 
Figure 1.2 Range of reported in vivo antimalarial drug treatment failures for  
P. falciparum malaria in Southeast Asian countries, 1981 – 2006 (578). 
 
 
1.1.2 Pathophysiology and aetiology 
1.1.2.1 Historical background 
The symptoms of a disease resembling malaria were first described over 4,000 years 
ago in the Nei Ching (The Canon of Medicine), the ancient Chinese medical writings 
edited by Emperor Huang Ti in 2700 BC (341).  Features of the disease, later named 
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mal’aria, Italian for bad air, became widely recognized in 4th century BC after 
Hippocrates characterised the clinical symptoms and complications of this seasonal 
intermittent fever (181, 341).  By 6th century BC the symptoms of malarial fever, 
which were attributed to the bites of certain insects, were extensively described in 
the Susruta, a Sanskri text (341). During the same time period Roman writers 
associated the incidence of malarial fever to swampy regions (341, 442).   Despite 
the continued characterization of disease processes, the cause of malaria was not 
isolated until 1880 (73, 341, 442).   
 
In November 1880, Charles Laveran, microscopically observed the exflaggelation of 
a male gametocyte which led to the conclusion that the causative agent of malaria 
was a protozoan parasite (73, 341, 442).  During the next 10-20 years, four different 
human species of malaria parasite were identified and named by Italian and 
American scientists (P. vivax and P. malariae, Giovanni Grassi and Raimondo Fileeti, 
1890; P. falciparum, William Welch, 1897; P. ovalae, John Stephens, 1922) (442).  
 
Perhaps the greatest advancement in the study of malaria was the discovery of the 
role of the Anopheles mosquito in the transmission of malaria.  On 20th August 1897 
Ronald Ross found the malaria parasite within the stomach tissue of an Anopheline 
mosquito that had fed on a malaria-infected patient four days earlier (73, 341).  In 
further malaria research Ross showed the transmission of malaria parasites 
between birds demonstrating that the mosquito acted as an intermediate host for 
the avian malaria.  After feeding mosquitoes with blood from infected birds he 
showed that the malaria parasite developed in the mosquito stomach and later 
migrated to the salivary glands, allowing the mosquito to then infect other birds 
during subsequent blood meals (341).  The complete sporogenic cycles of P. 
falciparum, P. vivax and P. malariae were soon after described by a team of Italian 
scientists led by Giovanni Grassi (1898-1899).  Thus, the process of malaria 
transmission was established (341).  
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1.1.2.2 Life cycle 
The genus Plasmodium may be identified taxonomically by the presence of 
protozoa with two forms of asexual division, schizogony and sporogony, and a 
single stage of sexual division.  Schizogony is the phase of parasitic asexual division 
and maturation occurring within the vertebrate host, while sporogony is the sexual 
and asexual and divisional stage occurring with a mosquito vector (446).  In order to 
successfully complete the parasitic life cycle (Fig. 1.3) two hosts, the definitive and 
intermediate hosts, must be present.  
 
The female Anopheles mosquito is the sole vector of Plasmodium parasites and 
whilst there are over 600 species of Anopheles mosquitoes worldwide, only 60 
species have been found to transmit malaria (382, 421).  The schizogonic cycle is 
initiated when a malaria-infected mosquito takes a blood meal from a person, 
releasing on average 15-20 (26), but up to 100 sporozoites (422), into the blood 
circulation from the salivary glands.  After entering the bloodstream the sporozoites 
take about 30-45 min to travel to the liver where they invade hepatocytes and 
begin to multiply.  This cycle, referred to as the pre-erythrocytic cycle, takes 
approximately 6-14 days and results in the production of merozoites.  Growth and 
division in the liver takes approximately 6, 6, 10 and 15 days for P. falciparum, P. 
vivax, P. ovalae and P. malariae, respectively (382, 386).  In P. vivax and P. ovalae 
infections some sporozoites appear to develop for the first 24 h at which stage they 
become dormant, as single-celled forms known as hypnozoites, which can remain in 
the hepatocytes for months to years until they are reactivated causing a relapsed 
malaria infection (382, 386, 421).  
 
At the conclusion of the pre-erythrocytic cycle, the host liver cells burst releasing 
thousands of merozoites into the blood circulation which attach to and invade 
erythrocytes within 20 sec of release (319, 386).  This process initiates the 
erythrocytic cycle.  Within the erythrocytes the parasites begin to again multiply 
resulting in erythrocyte (red blood cell) rupture 48–72 h later, depending on 
parasite species. Following erythrocyte rupture, both merozoites and pyrogenic 
materials are released resulting in both an increase in parasite biomass and malarial  
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Figure 1.3 The life cycle of human malarial parasites (85).  The malaria parasite 
life cycle involves two hosts.  During a blood meal, a malaria-infected female 
Anopheles mosquito inoculates sporozoites into the human host .  Sporozoites 
infect liver cells and mature into schizonts , which rupture and release 
merozoites .  (Of note, in P. vivax and P. ovalae a dormant stage [hypnozoites] can 
persist in the liver and cause relapses by invading the bloodstream weeks, or even 
years later.)  After this initial replication in the liver (exo-erythrocytic schizogony ), 
the parasites undergo asexual multiplication in the erythrocytes (erythrocytic 
schizogony ). Merozoites infect red blood cells .  The ring stage trophozoites 
mature into schizonts, which rupture releasing merozoites .  Some parasites 
differentiate into sexual erythrocytic stages (gametocytes) .  Blood stage parasites 
are responsible for the clinical manifestations of the disease.  
 
The gametocytes, male (microgametocytes) and female (macrogametocytes), are 
ingested by an Anopheles mosquito during a blood meal .  The parasites’ 
multiplication in the mosquito is known as the sporogonic cycle .  While in the 
mosquito's stomach, the microgametes penetrate the macrogametes generating 
zygotes .  The zygotes in turn become motile and elongated (ookinetes)  which 
invade the midgut wall of the mosquito where they develop into oocysts .  The 
oocysts grow, rupture, and release sporozoites , which make their way to the 
mosquito's salivary glands.  Inoculation of the sporozoites into a new human host 
perpetuates the malaria life cycle .  
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symptoms of fever and anaemia (26, 382, 386).  This asexual erythrocytic cycle 
usually continues until it is either controlled through immune responses, drug 
therapy or until host death.  The morbidity and mortality associated with malaria 
are derived primarily from the erythrocytic cycle (386).   
 
After several erythrocytic cycles a yet unidentified trigger diverts the development 
of certain intraerythrocytic merozoites into sexual forms known as gametocytes.  
The male and female gametocytes are taken up by a mosquito and in the mosquito 
midgut they mature as gametes (26, 382, 386). The sporogonic cycle is initiated 
through the fertilization of the gametes producing zygotes which within 24 h 
matures to a motile ookinete.  The ookinetes burrow through the mosquito midgut 
wall to encyst on the basal lamina where, within the developing oocyts, there are 
many miotic divisions resulting in the formation of sporozoites.  When the infective 
oocysts rupture sporozoites are released at which time they migrate through the 
haemocoel to the salivary glands completing the sporogonic cycle, approximately 7 
to 30 days after gametocyte ingestion (depending on the host, infective parasite 
species and environmental conditions (26, 382, 386).   
 
1.1.2.3 Malaria and the immune system 
Clinical immunity to severe non-cerebral falciparum malaria usually occurs after one 
or two infections, however, immunity against mild disease takes much longer to 
acquire (200, 519). In malaria endemic regions, children born to immune mothers 
are protected against malaria infections, although they may be exposed to 
infections, for the first 6 months after birth by maternal antibodies transferred 
through breast milk (200, 369, 454, 519).  During this period of time the immune 
system in the infants compiles a repertoire of specific humoral and cellular immune 
responses against the infecting parasites (519). However, as exposure to maternal 
antibodies wanes, the child will have a period of 1 to 2 years of increased 
susceptibility to malaria infections before they are able to acquire active immunity 
(369).   
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Innate immunity, the immunity not associated with specific antigens, may be 
classified into genetically based resistance and cell mediated mechanisms (455). 
During malaria infections genetically based resistance mechanisms may influence 
the progression of disease through the impairment of merozoite invasion of 
erythrocytes, reduction in the growth of parasites within an erythrocyte, impaired 
liberation of merozoites from schizonts and the reduction in vitality of merozoites 
after they are released from the rupturing schizont (309, 455).  Cell mediated 
mechanisms are responsible for the phagocytosis of merozoites or parasitised 
erythrocytes by neutrophils, monocytes or macrophages, and through the 
production of cytotoxic molecules (i.e. cytokines or nitric oxide) which are produced 
by various immunological cells against both the free parasites or parasitised 
erythrocytes (103, 455, 519).  Whilst the innate immune system, comprising mainly 
dendritic cells, monocytes and macrophages, natural killer cells, and T cells, is an 
important defence mechanism against malaria infections it also plays a very 
important role in shaping the adaptive immune response to blood-stage malaria 
(519).   
 
In malaria endemic regions a person will often be exposed to a number of malaria 
infections during childhood.  Surviving the malaria infection may result in the 
development of a state of immunity, referred to as acquired immunity, where a low 
level parasitaemia is maintained whilst remaining asymptomatic (369, 393).  
Acquired immunity, immunity developed in response to foreign antigens in the 
body, is both species- and stage- specific and results from the generation of specific 
antibodies to several variant antigenic proteins, most notably P. falciparum 
erythrocyte membrane protein 1 (PfEMP-1), which are produced by trophozoite and 
schizont stage parasites and expressed on the surface of parasitised erythrocytes 
(301, 369, 393, 455).  However, as there are over 50 genes that encode PfEMP-1 
molecules, acquired immunity to P. falciparum arises after multiple infections.  
Whilst acquired immunity does not prevent future re-infection with P. falciparum, 
the inflammatory response to the parasites, which causes the acute febrile 
symptoms, are limited and mechanisms to kill parasites or inhibit parasite 
replication are enhanced (25, 455).   
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The difficulties that confront immunologists studying host responses of human 
malarias has led to the use of experimental models of rodent malaria (159).   
Although it is readily acknowledged that murine models cannot accurately reflect all 
aspects of human infections, there is commonality between the immune responses 
to malaria parasites in humans and rodents (159).  Studies in both humans and mice 
have demonstrated an important role of dendritic cells (274, 370, 395, 519, 585) 
and T cells (103, 196, 369, 393), among others,  for the formation and maintenance 
of malarial immunity (159). 
 
1.1.3 Diagnosis of malaria 
Clinical diagnosis of malaria is imprecise but in many cases is the basis of 
therapeutic care for patients presenting with fever in malaria endemic areas, 
particularly if laboratory support is not available or delayed (225, 565).  Due to the 
life-threatening nature of the disease, the correct and timely diagnosis of malaria 
infection is critically important (16, 52, 197, 225). 
 
Diagnosis of malaria infection as a cause of disease is multifactorial and includes 
both the presence of parasites in the blood and clinical symptoms of infection (576). 
The detection of parasites on a blood film does not always indicate the cause of 
disease, as children who are indigenous to an endemic area may continually have 
low level parasitaemias, however, this does not present as symptomatic disease 
(197).  Diagnosis also plays an important role in patient management and follow-up 
chemotherapy.  Apart from detecting parasites in the blood, laboratory testing is 
also imperative to detect signs of poor prognosis (i.e. haemoglobin levels, blood 
glucose, lactate and the presence of protein or free haemoglobin in the urine) or to 
guide the methods of chemotherapy (glucose-6-phosphate dehydrogenase (G6PD)) 
(225).  Despite the obvious need for improvement of malaria diagnosis, this area 
remains the most neglected aspect of all malaria research and development (565). 
 
Whatever the method used, a diagnostic test should be able to correctly 
differentiate between individuals who are infected with malaria and those that are 
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not (16, 197, 298).  Consequently, the validity of the test is usually determined on 
its sensitivity and its specificity (225). 
 
1.1.3.1 Presumptive diagnosis  
In the vast majority of malaria endemic countries, national poverty ensures that 
laboratory support cannot be relied on for the diagnosis and treatment of malaria 
(225).  Clinical diagnosis is the least expensive thus most commonly used diagnostic 
method and often is the basis for patient self-treatment (565).  Although malaria 
infection has a number of distinct clinical symptoms, the overlapping of malaria 
symptoms with other tropical diseases (including influenza, pneumonia, viral 
hepatitis or typhoid) impairs its specificity  (225, 565).  In areas of high malarial 
endemicity fever is most often related to malaria infection therefore, the vast 
majority of patients presenting with fever will be presumptively diagnosed and 
treated with antimalarials (565).     
 
1.1.3.2 Blood examination for malaria parasites 
Light microscopic examination of Giemsa stained blood films is the most widely 
practiced and most appropriate diagnostic instrument for parasite detection (59, 
197, 576).  Examination of a correctly prepared blood film allows an inexpensive, 
yet definitive, diagnosis of malaria infection including speciation and quantification 
(59, 225, 565).  Thick and thin blood films should be prepared and appropriately 
stained. The most commonly used stain used in the field setting is Giemsa stain 
(225).   
 
Disadvantages of light microscopy as a diagnostic method are that the processes of 
blood collection, slide preparation, staining and reading can be time-consuming and 
the microscopist requires adequate training and supervision to ensure accuracy and 
consistency (59).  Whilst availability of microscopic diagnosis has shown to reduce 
drug use in some clinical trials (248), in clinical practice the results may be 
disregarded by the clinicians who tend to favour presumptive diagnostic techniques  
(43, 59). 
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To increase the sensitivity and specificity of malaria diagnosis, modifications to 
simple microscopy have been made. The quantitative buffy coat method (QBCTM, 
Becton-Dickinson) works by staining parasites with acridine orange stain (59, 275).  
Blood is placed in microhaematocrit tubes precoated in acridine orange stain which 
are then centrifuged.  Any parasites that may be present in the blood will spin at a 
specific density and be easily identifiable at a predetermined position on the 
microhaematocrit tube (41, 59).    Advantages of this system are that it requires less 
training to operate and read the tests compared to normal Giemsa stained blood 
films, as well as taking less time to complete diagnosis compared to light 
microscopy.  Under ideal conditions, the QBC system has been found to be slightly 
more sensitive than routine light microscopy for the diagnosis of malaria (41, 275),  
however, its disadvantages of higher cost, requirement of electricity, specialized 
equipment and supplies as well as a decreased specificity for species identification 
has led to the QBC system not being routinely incorporated into diagnostic 
laboratories (59).   
 
1.1.3.3 Detection of malarial antigen 
Rapid diagnostic tests (RDTs) detect malarial antigen in small quantities of blood (5–
15 μL) by immunochromatographic assay with monoclonal antibodies directed 
against the target parasite antigens that are abundant in the blood during a malaria 
infection (325, 334, 565). A positive result on an antigen detection assay suggests 
infection with malaria parasites (225).  Current antigen detection methods diagnose 
active malaria infections, primarily P. falciparum, rapidly and reliably in an easy to 
use immunochromatographic kit which does not need a microscope for diagnosis.  
The two predominant antigen testing kits commercially available today are based 
on the detection of the malarial antigen Histidine-Rich Protein 2 (HRP-2) or the 
enzyme parasite Lactate Dehydrogenase (pLDH) (292, 299). 
 
1.1.3.4 Serology 
Serological testing methods have been used for the detection of malaria infection 
since the early 1960s, when indirect fluorescent antibody tests (IFAT) and indirect 
haemagglutination assays (IHA) were described.  A disadvantage of serological 
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testing methods is that as they detect antimalarial antibodies, current and past 
infections cannot be differentiated and the tests have limited value in the 
treatment or management of malaria infections.  Therefore the only reliable use of 
these testing procedures is for the detection of negative serological assays, thus 
demonstrating that the patient does not have malaria (225).  
 
1.1.3.5 Molecular Methods 
The application of DNA or RNA hybridization via polymerase chain reaction (PCR) 
based probes, to malaria diagnosis has several advantages over traditional 
methods, although the feasibility of implementing into the field setting is limited.   
However,  it may have a place as a research tool to monitor malaria control 
programs, or to perform quality control checks on microscopic diagnosis or to 
determine the distribution of important genes, particularly those associated with 
drug resistance (225, 327).  Recent publications (206, 325, 575) have suggested that 
PCR is able to detect blood parasitaemias of less than 0.00002%, if performed under 
the best possible conditions.  This level of parasitaemia is theoretically the 
detection of a single parasite in an entire sample, although this is rarely achieved 
(225).  A detection of a parasitaemia of 0.00002%, which equates to 5 parasites per 
μL blood, is a detection threshold at least five times lower than that achieved by a 
thick blood film performed in optimal conditions (i.e. 0.0001%), assuming that an 
experienced scientist has spent at least 10 min examining 100 fields of view (205, 
206, 325).  Whilst in field conditions the sensitivity of PCR may only be comparable 
or slightly better than examination of a thick blood film by a trained microscopist 
(206), the specificity of PCR is generally considered to be better than microscopy, 
particularly if the patient has a mixed infection (225).       
 
1.1.3.6 Value of diagnostic methods  
In most situations, the ‘gold standard’ for individual diagnosis is microscopic 
examination of thick and thin blood films (197, 576). However, there are situations 
when this form of diagnosis is not ideal (225).  In areas of high malarial endemicity, 
clinical diagnosis alone is usually the only feasible and cost-effective method for the 
recommendation of first-line antimalarial treatment.  For example, in a country that 
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has an annual health budget of US$2 per person, it is difficult to justify diagnostic 
assays costing more than US$1 if the cost of treatment is only US$0.04 (225).  
Unfortunately, all modern diagnostic tests are likely to cost at least US$1 and the 
use of less costly microscopy requires a health care infrastructure and expertise that 
may not exist in the field setting.  When microscopy is not available, the use of 
dipstick antigen tests may be of value, particularly in areas of low endemicity where 
infection usually coincides with infection (225, 325).   
 
1.1.4 Enumeration of malaria parasites 
It has long been established that there is a strong correlation between parasite 
density and the severity of malaria (116, 163, 225). It is currently considered that 
any P. falciparum infection above 250,000 parasites/μL (approximately 5% of 
erythrocytes) should be regarded as a severe parasitaemia requiring urgent 
antimalarial treatment and emergency care (507, 509).  The presence of P. 
falciparum schizonts in peripheral circulation may also be taken as a sign of severity 
as due to sequestration mechanisms, mature P. falciparum parasites are rarely 
visualized in the peripheral circulation (225).  
 
The enumeration of parasites serves as a useful guide for the clinical management 
of infection and furthermore provides an valuable guide for the success of clinical 
trials and epidemiological studies (205, 298).  Thick and thin blood films are 
routinely used to monitor infection, to determine the development of resistance to 
antimalarial drugs and to serve as an important information base in the 
development of appropriate national and international drug policies (298, 390).  
Whilst observation of thick and thin blood films remain the first choice of 
enumerative studies (325), with several methods of parasite density estimation 
(151, 193, 205, 298, 367), no standard procedure exists for counting parasites on a 
thick blood film (565).   
 
In 1910, Ross and Thompson described a method of parasite enumeration where 
thick blood films were prepared, using a measured volume of blood, 
dehaemoglobinised and then stained.   Parasite density was then determined by 
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thoroughly searching the entire volume of blood using a sliding stage (427).  This 
method was further modified by Earl and Perez (151) who used a fixed volume of 
blood in a pre-established area. This varied from the methods described by Ross 
and Thompson where blood volume was not restricted to a specific area.  In the 
field and clinical laboratory three different techniques are routinely employed; (i) 
determining the percentage of infected erythrocytes (from a thin blood film), (ii) 
determining the number of parasites per white blood cell (WBC) or (iii)  determine 
the number of parasites in a field of view (145, 298).   Despite the method used for 
parasite enumeration, all determined values can be transformed into an index to 
determine the number of parasites per volume of blood.  This is determined by 
assuming that a constant number of erythrocytes, leukocytes or microscopic fields 
in that volume of blood (i.e. 5,000,000 erythrocytes, 8,000 leukocytes or 400 
microscope fields) per microlitre (μL) of blood (193, 298).  Although these indices 
appear crude, differences between the methods are not important as they would 
rarely vary by more than a factor of 1 (145).  However, variability in blood film 
preparation techniques and the method employed for parasite enumeration 
accounts for the majority of variability observed in parasite counts (145, 260).  For 
example, a large difference in parasitaemia is observed when comparing counting 
of parasites against leukocytes on a thick blood film and against erythrocytes on a 
thin blood film (354).  Such variability could significantly affect research results and 
outcomes (565).   
 
For the accurate determination of parasite density the number of parasitised 
erythrocytes are determined in a thin blood film (193).  To ensure accuracy, at least 
100,000 erythrocytes should be counted (193).  A drawback of this enumeration 
technique is that it is time-consuming and therefore not a feasible method for large-
scale field studies.  As a result two indirect methods, using a thick blood film, are 
currently employed for the determination of parasite density (193).   The first 
method determines parasite density by counting the number of parasites per 
leukocyte then multiplying the figure by 8000, the average white blood cell count 
per μL.  The second indirect method counts the average number of parasites per 
high powered field of view with parasite density calculated from this value and the 
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estimated volume of blood in the thick blood film (193, 510).  Although these two 
indirect methods are substantially quicker alternatives for the determination of 
parasite density, disadvantages of these methods are related to the accuracy of 
parasite counts.  The first method will be inaccurate if the total white blood cell 
count differs markedly from the assumed value of 8,000 leukocytes per μL, as can 
occur if the patient has an underlying bacterial infection, inflammation or as seen in 
children with malaria (193, 311).  The second method will be inaccurate if the thick 
smears are prepared incorrectly or the volume of blood is not known (193, 510).   
 
In a comparative study conducted by Greenwood et al. (193) it was demonstrated 
that there was little difference between the two indirect enumeration methods 
using thick blood films .  ‘True’ malaria parasite density was determined by counting 
the number of parasitised erythrocytes within 100,000 erythrocytes then 
multiplying this percentage by the total red blood cell count (RBCC), determined 
using a Coulter Counter.  Parasite density was then determined using both of the 
indirect thick blood film methods and the results compared to the ‘true’ malaria 
density.  They concluded that although both indirect methods were reasonably 
accurate and allocated levels of parasitaemia within broad bands, it was easier and 
slightly faster to determine parasite density using the high powered fields of view 
method (193).   This was due to the fact that only parasites needed counting, 
compared to the other method where both parasites and leukocytes needed to be 
enumerated.  Although the parasite density results determined in both of these 
indirect methods were assessed to be acceptable for the clinical management of 
malaria cases, for an accurate parasite enumeration the percentage parasitaemia 
should be determined using the thin blood film method (193).   
 
A number of attempts to rationalize and define the reliability of microscopic 
diagnosis of malaria in the field and laboratory have been described.  In 1966, 
Raghavan used a statistical approach with special reference to the efficacy of cross-
checking procedures in malaria eradication programs (403).  It was found that thick 
blood film examinations, using the standard 100-field of view criteria, could only 
detect with “reasonable certainty” parasite densities of 44 parasites in 1,000 thick 
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blood film fields.  However, as it was not made clear what a ‘standard film’ was, it 
made it difficult to draw any definitive conclusions from this study.  In an attempt to 
standardize counting techniques, Dowling and Shute (145) calculated the average 
thickness of thick and thin blood films that they used in comparative studies.  
Through these comparative studies they concluded that whilst a high proportion of 
parasites were lost during film dehaemoglobinization, a parasite count as low as 
one parasite per µL could be detected after 10 min close examination of a thick 
blood film.  Whilst this is not equated to the number of fields examined, it is similar 
to procedures using a detection threshold of four or more parasites identified after 
6 minutes of thick blood film examination (367).   
 
A further consideration, when determining parasite density as a measure of clinical 
success, is that without understanding the behaviour of the sequestered population 
of P. falciparum parasites it is difficult to obtain a reliable measure of treatment 
success (129, 191).  This is an important factor in the clinical setting as parasite 
sequestration is responsible for the majority of severe malaria pathology (184, 191).  
In an attempt to overcome this shortcoming in parasite enumeration of P. 
falciparum infections, a mathematical model was proposed by Gravenor et al. (191) 
which allowed the number of sequestered parasites to be estimated using 
sequential peripheral blood films.  However, despite the predicted value of such a 
simple model in providing insight into the success of antimalarial therapy against all 
blood stages of P. falciparum parasites, it is acknowledged that the parasitaemias 
determined will only be a conceptual parasite density (129, 130, 191).   
 
1.1.5 Antimalarial drug resistance 
The antimalarial drug CQ was first introduced into the clinical setting in 1945 but 
within 12 years CQ-resistant falciparum malaria was reported in Southeast Asia and 
South America (546, 566). By the late 1980s, the Thai-Cambodain and Thai-
Myanmar borders were declared to be multidrug-resistant (MDR) areas with a 
prevalence of mefloquine and sulfadoxine-pyrimethamine resistant falciparum 
parasites (566).  Today, drug resistance has emerged to all classes of antimalarial 
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drugs, including evidence of the recent emergence of resistance to artemisinin 
derivatives in Southeast Asia (143, 348) (Table 1.1). 
 
Table 1.1 Dates of introduction and first reports of antimalarial drug 
resistance.  [Table modified from data presented in Wongsrichanalai et al, (566)] 
Antimalarial drug Introduced  
(genuine clinical use) 
First reported 
resistance 
Difference 
(years) 
Refs 
Quinine 1632 1910 278 (376) 
Chloroquine 1945 1957 12 (547) 
Proguanil 1948 1949 1 (57, 376) 
Sulfadoxine-
pyrimethamine 
1967 1967 0 (57, 376) 
Mefloquine 1977 1982 5 (567) 
Atovaquone 1996 1996 0 (291) 
Artemisinins 1980 2008 28 (143, 
348) 
 
Antimalarial resistance is defined as “the ability of a parasite to survive in the 
presence of concentrations of drug that normally destroy parasites of the same 
species or prevent their multiplication” (540).   Drug resistance in malaria depends 
on the ability of the parasite to respond, through innate genetic diversity, to 
adverse conditions (540, 557).  It is acknowledge that the problem of antimalarial 
resistance has emerged as a result of the indiscriminate use of antimalarials leading 
to the development of high levels of resistance in parasites through selective 
pressure (574).   The goal of malaria chemotherapy is therefore to use the 
antimalarial drugs in such a way that the selection process is minimized, thus 
extending the therapeutic life of the drug (540, 551).   
 
Many factors contribute to the development and spread of drug resistance 
including characteristics of the drug itself (dosing, drug pressure, pharmacokinetics, 
cross-resistance), human host factors (host immunity, maintenance of resistant 
parasite reservoir), parasite characteristics (genetic mutations, transmission level) 
and vector and environmental factors (vector affinity of parasites) (59, 234, 361, 
372, 376, 551, 562, 566).  Characteristics of the drug may be perhaps the most 
important determinants for drug resistance, particularly the drug elimination half-
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life (208).  Drugs with long elimination half-lives, such as mefloquine and 
piperaquine, may exert substantial residual selection on new infections contracted 
after treatment of the primary infection when the drug persists at subtherapeutic 
concentrations in the plasma (566).  Subtherapeutic dosing also results in an 
increased risk of the emergence of resistant forms because any residual parasites 
may proliferate (44).  As a result the therapeutic index may increase beyond the 
maximum dose tolerated, with a manifestation in the occurrence of drug resistance 
(566).   
 
The assessment of P. falciparum susceptibility to antimalarial drugs is commonly 
assessed through the use of an in vivo therapeutic response test (465, 572), 
although in vitro assays measuring the intrinsic sensitivity of P. falciparum from the 
inhibition of growth or schizont maturation are also used (59, 547, 566).   Whilst 
both testing methods have their place in clinical assessment of parasite resistance, 
it is often observed that results obtained from in vitro and in vivo testing methods 
are not always comparable (415).   An advantage that an in vivo assessment method 
has over in vitro testing is that it takes into account host factors such as 
immunological regulation of infection.  Furthermore, pharmacokinetic data may be 
warranted to differentiate between true resistance and failure to achieve adequate 
drug concentrations, an observation that is limited to in vivo models (551, 566).  
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1.2  MURINE MODELS FOR CHEMOTHERAPY 
1.2.1 Murine malaria models 
1.2.1.1 Isolation of murine parasites and their implementation into the research 
laboratory 
A notable contribution to malaria chemotherapy research occurred in 1948 when 
the Belgian parasitologist Ignace Vincke reported the presence of a Plasmodium 
species in African thicket rats in the Belgian Congo (now Zaire) (241, 382, 527).  The 
isolated parasite, later named Plasmodium berghei, was found to be infective not 
only in the natural host but also in laboratory rats, mice and hamsters (382) and as a 
result soon became an integral component of antimalarial drug discovery and drug 
development (33, 368, 382, 502).   
 
Three other rodent specific species, P. vinckei, P. yoelii and P. chabaudi, along with 
their subspecies (Table 1.2), were subsequently identified (261, 267, 416), with the 
majority of these parasites now used for chemotherapy research (241, 382, 433).  
The rodent malaria parasites were found to be analogous to the malaria parasites 
infecting humans and primates in the most essential aspects of structure, 
physiology and life cycle and as a consequence have proved to be valuable in 
studies on the activity and stage specificity of drugs, and the molecular biology and 
genetics of drug-resistance (241, 243, 382).    
 
Historically, the main contribution of the murine model has been in the screening of 
new antimalarial compounds, which can be clearly seen by comparing statistics of 
drug discovery both before and after the introduction of the murine malaria model 
(382).  During World War II (1939–1945) the only antimalarial drug screening model 
was the avian model, which in itself was problematic due to the vast differences in 
parasite life cycle compared to human malarias (382).  However, the P. gallinaceium 
(avian) model was soon superceeded by the introduction of the rodent model which 
proved to be a far superior drug screening model.  This was demonstrated as 
between 1963 and 1990 over 300,000 compounds were screened in rodent models 
in comparison to only 4,000 compounds using avian models (372, 382).   
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Table 1.2 Murine Plasmodium species used for chemotherapy research 
(adapted from (241, 382)) 
 
Species Subspecies Isolate  strain Place of origin Extent 
of use 
P. berghei 
(Vincke and 
Lips, 1948) 
 Keyberg 173 
NH65 
ANKA 
RLL 
SP11 
Zaire (Katanga) 
Zaire (Katanga) 
Zaire (Katanga) 
Zaire (Katanga) 
Zaire (Katanga) 
+++++ 
++ 
++ 
- 
+ 
P. yoelii P.y.yoelii 
(Landau and 
Killick-Kendrick, 
1966) 
P.y. killicki 
(Landau et al. 1968) 
P.y. nigeriensis 
(Killick-Kendrick, 1973) 
P. yoelii ssp. NS 
17X 
 
 
 
 
N67 
Central African Republic 
 
Brazzaville 
 
S.W. Nigeria 
 
Zaire (Katanga)* 
++ 
 
 
- 
 
+++ 
 
++++ 
P. vinckei P.v. vinckei 
(Rodhain, 1952) 
P.v. brucechwatti 
(Killick-Kendrick, 1975) 
P.v. lentum 
(Landau et al. 1970) 
P.v. petteri 
(Carter and Walliker, 
1977) 
P. vinckei ssp. 
 Zaire (Katanga)* 
 
S.W. Nigeria 
 
Brazzaville 
 
Central African Republic 
E. Camaroon 
+ 
 
- 
 
- 
 
+ 
 
- 
P. chabaudi P.c. chabaudi 
(Landau, 1965) 
P.c. adami 
(Carter and Walliker, 
1977)  
AS Central African Republic 
Brazzaville 
++ 
 
- 
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1.2.1.2 Life cycle  
The parsite life cycle of rodent and human malarias are remarkably similar, a 
feature not shared with all species of malaria (82).  The main difference in life cycle 
between the rodent and human forms is the time taken to complete asexual 
schizogony which takes 18-24 hours in the rodent malarias and 48-72 hours in the 
human species (82, 241, 382). There are also slight differences in the timing of each 
stage of life cycle of the rodent malaria strains, with the main differences seen in 
the chronobiological characteristics of length of schizogonic cycle, rhythm and time 
of schizogony, degree of synchronicity, the age of erythrocyte invaded and the 
pathogenicity (268, 382).  Table 1.3 provides a summary of the major features of 
the life cycle of each of the four rodent Plasmodium species compared to human 
malarias in general.  
 
Table 1.3  Different characteristics of the four rodent malaria parasites 
compared to human parasites (241, 382) 
 
 P. berghei P. yoelii P. chabaudi P. vinckei Human 
parasites 
Merozoites per schizont 12–18 12–18 6–8 6–12 8–16 
Reticulocyte preference Yes No Yes Yes Yes/No 
Synchronous infection No No Yes Yes Yes/No 
Optimum temperature 
range for sporogony (oC) 
19–21  23–26 24–26 24–26 >26 
Sporozoite infection time 
(days) 
13–14  9–11 11–13 10–13 Temperature 
dependant 
Duration of pre-
erythrocytic schizogony (h) 
48–52  43–48 50–58 60–72 6–15 days 
Duration of asexual blood 
stage (h) 
22–24  18 24 24 48–72 
Developmental time of 
gametocytes (h) 
26–30  27 36 27 48 h–12 days 
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1.2.1.3 Scientific contribution of murine malaria models 
Despite the advantages of studying human malaria parasites for determining the 
clinical applicability of new antimalarial treatment regimens or drug candidates, 
experimental models of murine plasmodia are increasingly employed in an attempt 
to understand the developmental biology of malaria parasites, parasite-host 
interactions and the pathology of human malarias (13, 269, 278).  These models 
have also proved to be an important investigational tool in the discovery and 
development of vaccines, antimalarial compounds and their therapeutic regimens 
(81, 82, 222, 241, 268, 423).  Furthermore, it has been suggested that the selection 
and use of a suitable animal model will generally reduce the time required for the 
development of the drug/vaccine prior to its evaluation in humans (401, 539).   
 
Areas where the study of murine models has contributed to the overall 
understanding of Plasmodium parasites include; 
• (Ultra-structural) morphology of the different life cycle stages (12, 294, 445) 
• Genetics of malaria parasites (81, 530, 531) 
• Function of malaria specific proteins, including candidate antigens for drug 
targets (315, 473, 523) 
• Parasite-host interactions in the mosquito (141, 204, 340, 411) 
• Immunity to malaria (269, 392, 466) 
• Vaccine development (222, 353, 391) 
• Drug development and resistance (371, 372, 423) 
 
Although simian malaria is most comparable to human parasite strains, the study of 
murine malaria parasites has several advantages over the more complex simian 
models.  Generally, murine models are inexpensive and easy to develop and 
maintain (268).  Large-scale dissective and interventional studies may also be 
performed in murine models while such techniques are not ethical nor practical in 
humans or non-human primates (486).  It is also well recognized that the use of 
simian models for the general screening of antimalarial therapies requires 
specialized skills and financial resources that are adequate to cover the high cost of 
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animals and drugs.  More importantly, the ethical considerations in such cases 
demand that the use of high order experimental animals should be restricted (382).  
 
When using murine models, selection of rodent malaria species and mouse strain is 
an important variable to be considered during experimental design and 
interpretation (162).  The individual species and strains of plasmodia have been well 
characterised and all differ significantly in their degree of infection, lethality and 
synchronicity, which can affect experimental results.  For example, P. berghei and P. 
vinckei produce lethal infections whilst P. yoelii, P. chabaudi adami, P. chabaudi 
chabaudi and P. vinckei petteri all produce self-resolving infections (162, 487).  
Furthermore, the course of infection may also vary depending on the selected 
mouse strain (162).   
 
1.2.2 Plasmodium berghei 
Experimental murine malaria models exploit all four rodent parasites, although P. 
berghei is the most comprehensively studied and manipulated parasite (162, 268, 
487, 539).    As a laboratory model, 37 animal species have been found to be 
susceptible to P. berghei after artificial inoculation with infected blood (590).  The 
majority of these species belong to the rodent family, however, African fruit bats 
and new-born rabbits have also been found to be susceptible (502, 590). In 1965, 
Meir Yoeli presented a paper at the Royal Society of Tropical Medicine and Hygiene 
meeting (590) describing the segregation of each animal species into a number of 
‘groups’ based on the course and outcome of the P. berghei infection in the 
inoculated host.  These are described below as presented in the original paper.   
a)  A fulminating and fatal course terminating in death within 7 to 14 days, 
accompanied by high and rising parasitaemia.  The white mouse and the baby 
albino rat fall into this category. 
b)    A more prolonged clinical course, terminating in the death of the host within 2-
3 weeks and accompanied by a rising parasitaemia.  The golden hamster 
(Mesocricetus auratus) belongs to this category. 
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c)  Chronic and latent course with spontaneous recovery.  Rarely, death from the 
infection and fluctuation in parasitaemia.  The adult albino rat is typical of this 
group. 
d)  Mild and transient P. berghei infection with low parasitaemia and complete 
recovery. 
e) Short-lived survival of inoculated parasites in an alien host, without power of 
multiplication.  Detection of ‘static’ infection by blood sub-inoculation into 
susceptible hosts.  
 
Within the laboratory, P. berghei is used to infect hamsters, rats and mice (502).  
When involvement of sporogonic and/or the exo-erythrocytic stages are sought, the 
susceptible mosquito vector Anopheles stephensi, is widely employed (400, 526).  As 
a laboratory model, P. berghei is largely selected for studies relating to 
developmental biology of parasites, molecular genetics studies and most 
importantly for investigation into new and innovative drug therapies (241, 268, 
502).  Specific characteristics that differentiates P. berghei from the other rodent 
malarias include: 
• Preferentially invades reticulocytes (119, 502, 539). 
• Largely asynchronous in laboratory rodents (241). 
• Results in a lethal infection within 1 to 3 weeks in most laboratory models; 
although a large number of environmental factors influence the virulence 
and pathology of infection (384, 406, 430, 448, 502). 
• Cerebral effects may be observed in selected rodent species (216, 486). 
 
The morphology of asexual P. berghei parasites have been described as very similar 
in characteristics to those of the human malaria P. vivax (501) (Fig. 1.4).  The ring 
stage is usually uni-nucleate and contains a large food vacuole (241, 501, 502).  As 
the parasite matures to the trophozoite stage the food vacuole is seen to 
significantly reduce in size resulting in a parasite that is non-vacuolate, slightly 
amoeboid and containing fine granules of black pigment (241, 501, 502, 527).  
Further maturation sees the trophozoite develop a number of merozoites (6 to 20).  
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In heavy infections, the presence of multiple parasitised cells is not uncommon 
(241, 502).   
 
 
Figure 1.4 Morphology of erythrocytic stages of P. berghei (241, 322) 
 
1.2.2.1 In vivo models 
For the majority of murine malaria research albino laboratory mouse strains have 
generally been used (382).  Although some areas of murine research, including 
those studies observing immunological responses of murine malaria, use specific 
inbred strains of mouse such as BALB/c or C56BL/6 (17, 99), random outbred Swiss 
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mice are suggested to be acceptable for the majority of murine malaria research 
providing the mice are appropriately housed, nourished and kept free of 
concomitant pathogens (372, 382).  The gender and age of laboratory mice is also 
thought to be an important consideration for chemotherapy studies (192, 372, 596).  
It is suggested that male mice weighing between 18 and 20 g are ideal for routine 
studies as female mice may demonstrate variable responses to chemotherapy 
depending on their time of oestrus cycle (372). Mice also tend to become less 
susceptible to P. berghei infections with advancing age whilst young mice that 
weigh under 18 g are hard to handle compared to slightly older and heavier animals 
(192, 372, 596).   
 
Within the laboratory, mice can be infected with rodent parasites through a number 
of techniques, as infection via mosquito transmission and artificial inoculation with 
infected blood are both successful inoculation methods (502).  When infection via 
mosquito transmission is desired, the laboratory mice are placed within a restricted 
area with mosquitoes burdened with infective sporozoites (have fed on infectious 
blood at least 14 days prior).  The mosquito bite is expected to transfer 20 to 50 
sporozoites into the host (large variability between parasite species and strain) 
resulting in a model including both liver and blood stage infection as well as 
maintaining gametocyte production (241, 382, 502, 526).  
 
In comparison, mice can be inoculated by direct blood passage from infected mice 
with high parasitaemia either through intravenous (i.v.) or intraperitoneal (i.p.) 
injection, with an inoculum of blood containing all asexual blood stages (schizonts, 
trophozoites and ring-forms) (502).  Early inoculation studies comparing these two 
routes of infection suggested that i.p. injection was as suitable as i.v. injections as 
an inoculation technique (498, 502), with the majority of  parasites injected 
penetrating the peritoneal wall and entering the blood stream within one minute of 
i.p. injection (58).  Whilst more recent studies have suggested that i.v. injection may 
be a more accurate route of inoculation (as when using i.p procedures it is 
estimated that only 10% of injected parasites will survive and enter the 
bloodstream)(241), other inoculum factors must be considered with inoculum size 
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being one of the most important (207). In order to prevent fluid overload in the 
mouse, which may lead to severe illness or death of the animal, injection of fluid 
volumes must be carefully considered.  Although a more direct method of fluid 
delivery, i.v. inoculation is hindered as no more than 0.2 mL should be injected into 
the adult mouse (> 12 weeks of age) (207).  As the majority of mice used for 
experimental research are usually between the age of 5–9 weeks, the maximum 
injectable fluid volume would be smaller.  Therefore, i.p. injections are commonly 
used in mice as fluid volumes up to 2 mL can be injected into the abdominal cavity, 
with a low risk of detrimental effects to the animal (207).  Therefore, if using 
artificial inoculation methods the route of infection must be carefully considered, 
depending on inoculum size and dilution volume (502).  
 
1.2.2.1.1 Chemotherapy testing procedures  
Since the introduction of P. berghei parasites into laboratory animals, several 
methods have been used for testing the response of erythrocytic infections of P. 
berghei to antimalarial drugs  (372).  In 1950, Thurston (498) established the first of 
the standard methods for testing antimalarial activity against blood stage P. 
berghei.  This initial method was then further modified by a number of researchers 
resulting in the development of five additional drug screening methods, of which 
the “Rane test” and “Peters 4-day test” are the most commonly used (49, 86, 89, 
132, 176, 198, 360, 378, 381, 387) .  
 
1.2.2.1.1.1 Thurston test for activity against blood forms 
The Thurston test is based on the studies by Curd et al (120) and Tonkin and 
Hawking (505) for antimalarial activity in the avian P. gallinaceum malaria model.  
Albino mice, weighing between 15 and 20 g, were inoculated, by i.p. injection, with 
P. berghei infected blood containing between 5-15 million parasites on Day 0.  All 
mice received the same parasite inoculum.  Test drugs, of which doses were weight 
adjusted, were given orally once daily for four days, commencing three to four 
hours after parasite inoculation.  Parasitaemia was monitored on the fifth and 
seventh day by Giemsa stained thin blood films.  Parasitaemia was determined by 
the percentage of parasitised erythrocytes and the geometric mean was taken for 
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each group of mice.  The minimum effective dose was defined as the smallest dose 
that gave a mean infection level of <1% on the fifth day (120, 498, 505).   
 
In 1953, Thurston published a modification of her initial method (499) in which the 
mice were given a smaller initial parasite inoculum of approximately 1 million 
parasitised erythrocytes, resulting in a parasitaemia that ranged between 1-5% on 
the fifth day.  The minimum effective drug dose was defined as the smallest dose 
that reduced the parasitaemia to 2% of that of the control mice (372, 499).    
 
Although the Thurston test provided a good model for determining drug activity 
against P. berghei (498-501), certain limitations were identified.  The first of these 
was the measurement of drug activity which, when described by Thurston was the 
minimum effective dose that gave <1% infection on the fifth day and later the 
smallest dose that reduced parasitaemia to 2% of that of the control mice. This 
form of measurement was deemed to be ineffective for comparison of the activity 
of different drugs hence the development and adaptation of the ED50 (Effective 
Dose 50%: 50% suppression of parasitaemia when compared to untreated controls) 
by Rollo in 1952 (418).   The use of an ED50 and later ED90 (373) as a measurement 
and determinant of drug efficacy remain in use for drug activity studies (162).  A 
second limitation identified by Peters (373) in 1965 was that the Thurston test 
monitored parasite suppression and was not a true therapeutic test.  Therefore, 
further modifications took place (498) so that drug therapy was not initiated until 
parasitaemia reached 10% (373).  However, perhaps the main disadvantage of the 
modified Thurston method was the increased time required for the operator to 
count blood films as inoculation methods often resulted in a chronically low 
infection for prolonged periods of time (499, 501). 
 
1.2.2.1.1.2 Warhurst bio-assay techniques 
In an attempt to overcome the interpretation problems caused by host immunity 
associated with the Thurston test, Warhurst (536) and Warhurst and Folwell (537) 
described a bio-assay technique which overcame previously noted problems of host 
immunity and copious numbers of thin blood films.  In this test, a group of 10 mice 
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were infected with a standard 107 parasitised erythrocyte suspension (erythrocytes 
suspended in ice-cold 50% calf serum and Ringer solution) and then divided into 
two groups of five after infection.  One to 3 h after infection one group of mice 
receive a single dose of drug whilst a placebo injection was given to the other group 
of 5 mice.  A second group of 10 animals were treated identically except that at the 
time of infection, the mice received an inoculum that was one-tenth that received 
by the first 10 animals.  The mean period of time required to reach a 2% 
parasitaemia for each group of mice was plotted on a logarithmic scale and the 
mean growth rate was determined through comparison of the two inoculum sizes 
(537).   
 
1.2.2.1.1.3  Thompson test for suppressive curative activity  
In the early 1960s, Schneider became interested in developing a compound that 
would give a human long lasting protection against malaria, after oral 
administration (372).  In an attempt to test the suppressive activity of the new 
compounds, a 21-day parasite free test was designed (372).  The purpose of this 
testing procedure was to treat all experimental animals on Day 0 with the test 
compound, and then infect groups of animals at Day 7, 14 and 28.  Daily blood films 
were prepared and mice were monitored for a period of 21 days after parasite 
inoculation.    At Days 7 and 21 blood was drawn from the donor mouse and 
injected into 2 naive mice to test for parasite presence and/or viability (372).  This 
testing procedure was reported to be extremely sensitive and enabled the 
differentiation between a true schizogonic drug and one that simply inhibited 
parasitaemia (372).   
 
A modified version of Schneider’s 21-day parasite free test was used with success in 
the development of cycloguanil pamoate by Thompson et al. (495, 496)  which was 
moved to human volunteer studies and demonstrated antimalarial protection for 
more than one year with sensitive P. vivax and P. falciparum strains (106, 107).  
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1.2.2.1.1.4 Rane in vivo screening system  
The Rane in vivo screening system was developed by Leo Rane at the Walter Reed 
Army Institute of Research (WRAIR) as a tool to assess the efficacy of antimalarial 
compounds that entered their research and development program (372, 382).   
 
This testing system used albino mice that were infected with a standard 106 
inoculum of P. berghei parasites by i.p. injection.  Three days after infection, mice 
were treated with a single dose of drug and animals observed daily for survival or 
death (372, 382).  Untreated control mice usually died 6 to 7 days after inoculation.  
The drug was considered to be active, and underwent further investigation, if the 
treated animals survived for at least twice as long as the untreated control mice.  
Any mice that survived longer than 60 days without exhibiting symptoms were said 
to be cured, whilst animals that died between day 2-5 of drug administration were 
said to have died from drug toxicity (372).  The minimum effective dose was 
compared to the maximum tolerated dose (i.e. the dose that produced no more 
than 1 in 5 toxic deaths) with dose levels titrated downwards to give an indication 
of the therapeutic index of the drug (382).  This simple test system allowed over 
25,000 compounds to be examined per year with all promising drugs further 
investigated using methods such as the ‘4-day test’ to obtain more accurate 
information on their activity  (365, 382, 503).   
 
An advantage of the Rane method is that as it monitors animal survival and death as 
an indicator of drug activity, an increased number of compounds may be studied in 
a short period of time (382). However, a general limitation of this method is that 
the drug efficacy of certain antimalarial compounds, such as proguanil, may have an 
immediate effect on parasitaemia but does not affect animal survival (372).  
Therefore, if drug success is dependent on animal survival time, some active 
antimalarial compounds may be overlooked.   
 
 
 
 
- 52 - 
 
1.2.2.1.1.1 Peters “4-day test”  
The ‘4-day test’ , as described by Peters (379), comprises two distinct parts: (a) a 
preliminary ‘4-day test’ for the detection of suppressive activity and (b)  the ‘4-day 
test’ for quantitative assessment of blood schizontocidal activity (382). 
a) Preliminary ‘4-day test’ for detection of suppressive activity: Groups of male 
albino mice are inoculated with either 2 x 106 P. berghei N parasites or a 
similar inoculum of  P. chabaudi AS.  All mice are then given a fixed dose of 
30 mg/kg [once daily for 4 consecutive days beginning on the day of 
infection].  For each parasite species one group of mice receive drug 
administration via subcutaneous (s.c.) injection whilst the other group 
receives drug through oral administration.  Parasitaemia is determined 
through preparation of peripheral blood film on the fifth day (first day after 
conclusion of treatment), to determine qualitatively the presence and 
degree of activity of the screening dose (379).   
b) ‘4-day test’ for quantitative assessment of blood schizontocidal activity: 
Male albino mice are inoculated with 106 parasitised erythrocytes (of either 
P. berghei or P. chabaudi strain) by i.v. administration. Following inoculation, 
all mice are dosed once daily for 4 consecutive days using the dosing range 
determined in the preliminary test (as described above).  Each tested 
compound may be administered s.c., i.p. or by any other desired route.  The 
parasitaemia is determined on the fifth day after inoculation and the ED50 
and ED90 values are determined from a semi-logarithmic time-density plot.  
The degree of cross-resistance (I50 or I90) is determined by comparing the 
drug activity in sensitive and resistant parasite strains using the following 
formula: 
 
 
 
 
 
 
         ED50/ED90 of resistant line 
 
ED50/ED90 of sensitive parent strain 
Index of cross resistance   = 
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Compounds shown to possess suppressive activity can be further tested at the dose 
ranges determined in the preliminary ‘4-day test’ for detection of suppressive 
activity  and including one dose step further than the minimum fully suppressive 
dose, for suppressive curative activity and influence on survival times as outlined in 
the Thompson test (1.2.2.1.1.3 ) (378-380, 382, 384).  
 
1.2.2.2 In vitro studies 
In vitro interactions between antiplasmodials, as represented by isobolograms, 
provide useful activity data for clinical studies. However, they do not necessarily 
determine the efficacy of a combination in the host, since this also depends on 
pharmacokinetic characteristics. Synergy, indifference (addition), and antagonism 
are the expected outcomes of drug-drug interactions (164).   
 
In 1976, Trager  and Jensen (508) described an in vitro culture method in which 
human malaria parasites could be maintained in continuous culture, whilst still 
remaining infective to Aotus monkeys. Today, parasites from both human malaria 
and experimental animals are used successfully in continuous culture for a wide 
variety of malaria research facets, in particular drug development, assessment of 
drug combinations and parasite sensitivity studies (46, 54, 63, 79, 88, 126, 224, 242, 
243, 288, 349, 405, 417, 459, 516, 568).     
 
1.2.2.2.1 Methods for evaluation of drug combinations 
Among the techniques employed in the evaluation of the combination of two 
antimicrobials potentially exhibiting synergy, are the checkerboard technique and 
the time-killing curve method (235, 302).  The checkerboard or fractional inhibitory 
concentration (FIC) technique employed a methodology similar to that utilized for 
the determination of the minimum inhibitory concentration (MIC), the lowest 
concentration of drug inhibiting growth after 24 h of incubation.  The combination 
is said to have a synergistic effect if there is a 4 fold reduction in the MIC of each of 
the agents tested alone (358). In the time-killing curve method, the reduction of a 
fixed inoculum over 24 h exposure of combination antimicrobials is compared with 
the effect of each agent used alone (235).  In this method the measure of success is 
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determined by calculating the IC50, which is the concentration of drug required to 
inhibit growth of the parasite by 50% compared to untreated controls (349, 488).  
 
1.2.2.2.2 Isobolograms 
The study of the presence, type, and degree of interaction between biologically 
active agents is highly relevant to many research areas including pharmacology, 
immunology and toxicology (302). The construction of isoboles (Fig. 1.5) is a classic 
procedure of the analysis of interactions between agents (164, 302).   The isobole 
method has been used for the evaluation of synergy and antagonism in many fields 
and requires experimental data for agents used alone and in different dose 
combinations at equi-effective levels (126, 164, 302, 475). The construction of 
isobolograms has several disadvantages.  Finding a combination of drugs that would 
produce a given effect is a time-consuming task.  In addition, isobolograms can only 
be used to evaluate interactions at this effect level (302).  
 
Figure 1.5.  Isobolograms demonstrating antagonistic (a) and synergistic (b) drug 
combinations in the rodent P. berghei model.  (Taken from (459)) 
 
However, isobolograms have also proven to be a useful method of evaluating 
antimalarial drug combinations in in vivo models such as the P. berghei murine 
malaria model.  Whilst discrepancies in isoboles prepared from in vitro and in vivo 
data may occur, this is not of major concern as in vivo parasites are exposed to 
variable levels of drugs and metabolites, compared to the direct antiparasitic 
activity observed with in vitro parasite cultures (459). This method of antimalarial 
(a) (b) 
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compound assessment has been successful in several P. berghei murine models (89, 
459). 
 
1.2.2.3 In vivo versus in vitro studies 
The majority of primary drug screening in vitro methods, as well as investigation 
into their modes of action, are performed using P. falciparum parasites in culture.  
Nevertheless, the study of the action of drugs in rodent Plasmodium models 
remains an important step for in vivo studies of the activity of new molecules, drug 
associations and the setting up of new therapeutic strategies (268).    
 
Rodent malaria models are widely used for screening new drugs for their 
antimalarial activity in vivo (243, 378).  The study of drugs in rodent-malaria models 
can provide valuable information about stage specificity of the drugs, routes of 
administration and development of resistance  (243).   The P. berghei rodent model 
has been developed to allow the determination of the effect of drugs on the 
erythrocytic schizogony both in vivo and in vitro cultures (242, 323, 379, 384, 417, 
430, 500-502, 525).  Synchronized short-term cultures of blood stages are easily 
established (242) in which antimalarial efficacy and stage specific activity of drugs 
can be accurately assessed and compared with the in vivo antimalarial activity 
(243). 
   
Comparisons of the antimalarial activities from different studies are hampered 
when different Plasmodium species and different methods are used.  In vitro and in 
vivo studies using the same species are therefore valuable in determination and 
comparison of the antimalarial activity of drugs (243, 324).  For example, studies 
with a number of dihydroartemisinin (DHA) derivatives showed good activity 
against P. falciparum in cultures, but were ineffective against P. berghei in rodents 
(281).  It is unknown whether variation in susceptibility of various parasite species, 
differences in stability of drugs between culture and host or other factors in the 
host are responsible for the observed difference in antimalarial activity (281).  
Variation in the antimalarial activity of a drug between studies can also be 
influenced by differences in culture methods, routes of administration and solvents, 
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which hamper comparison of results from laboratories using different techniques 
(243).  Standardized experiments and combination in vitro and in vivo studies with 
the same species are therefore essential for the accurate comparison of the 
antimalarial efficacies of different drugs (243).  This can be observed in a series of 
experiments conducted by Janse et al. (243), who demonstrated a good comparison 
of the in vitro and in vivo antimalarial activity of artemisinin in a P. berghei model.  
 
Traditional in vitro measurements such as the MIC are used to predict outcome of 
antimicrobial therapy.  While these measurements are a good indication of the 
potency of an antimicrobial, they do not provide the type of information necessary 
to determine the optimal drug dose or dosing interval (18).   The MIC test provides 
information about a drug concentration at a single time point.  However, the MIC 
does not elucidate the effect of varying drug concentrations over time or whether 
there may be effects that persist after drug exposure.  Both in vitro and animals 
studies have been used to determine the impact of drug concentration on the rate 
and extent of antimicrobial killing (18). Both in vitro and animal studies can also 
determine the impact of drug exposure on organism growth after drug exposure.  
However, only in vivo animal models are able to determine the time course of 
activity at the site of infection and the potential impact of host immune factors on 
drug activity (18, 278).   
 
Animal model studies have a distinct advantage over both in vitro models and 
clinical trials in the ability to discern which pharmacokinetic/pharmacodynamic 
dosing index is most closely associated with efficacy (18).  Furthermore, whilst 
studies with bacteria, tissue culture, and computer simulation have been found to 
provide useful information for therapeutic studies, testing on animals is required in 
order to attain results influenced by the complexities of a living organism (407).     
 
1.2.3 Murine malaria as a model for human infections 
There are a large number of animal models that provide investigators with the 
ability to characterise the pharmacokinetics and pharmacodynamics of antimalarial 
drugs (268, 382, 407).  However, murine models are the most versatile of the 
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animal models in which to study the interactions between host and the erythrocyte 
stage of parasite, the analysis of molecular interactions and precise pathological 
changes (134, 278, 433).  Attractive characteristics of the murine model include the 
fact that it is (i) inexpensive and easy to maintain, (ii) the mouse immune system is 
well characterised and (iii) large scale intervention studies of a nature not 
permissible in humans, may be performed (487).  While there may be 
pharmacokinetic and immune state differences between different animal models, 
appropriate pharmacodynamic analyses most often account for these differences 
and allow comparison of data among studies possible (18).  
 
Although mouse models may contribute to the understanding of the pathogenesis 
of complications of malaria, the human disease is not replicated in full (269).  This 
may be seen in particular in the study of cerebral malaria, in which several murine 
models have been developed (83, 121, 134, 486).  Whilst many similarities between 
human and murine cerebral malaria can be identified, particularly in regard to 
pathological lesions (such as sequestration, cerebral hemorrhage or infarction) and 
clinical symptoms (such as ataxia, fitting and coma) (134, 293), there are also 
distinct differences in the disease progression.  A criticism of several of the current 
cerebral models (such as P. berghei ANKA in C57BL/6 mice) is that these murine 
models are characterised by monocyte adherence to blood vessels (23, 486) 
although more recent models have found the presence of parasite sequestration in 
the brain which more closely mimics P. falciparum infection (23, 214).  However, 
recent studies in African children have also identified that those who have died 
from cerebral malaria also show the adherence of mononuclear cells in the brain 
(278, 394).  Therefore, for future studies the use of P. berghei ANKA in BALB/c mice 
may be a more appropriate clinical model given that both infected erythrocytes and 
mononuclear cells were found to sequester in the brain, thus more closely 
resembling the human disease (214, 278).  Furthermore, one of the major 
differences in the pharmacokinetics between animals and humans is that the rate of 
drug elimination is faster in animals. This is especially true in small rodents, which 
are commonly used in animal infection models.  In general, the half-life of 
antimicrobial drugs is 6 to 9 fold longer in humans than in mice (18).   
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Whilst mouse models are not exact replicas of the human infection and disease, 
they do provide a useful insight into disease pathogenesis, complications of 
infection, interaction of the host immune system and treatment therapies (269, 
278).   Whilst direct extrapolation from rodent biology to human malarias should be 
done with caution, and might not be applicable in all situations, each of the four 
rodent malaria species has similar characteristics to the human malarias and which 
makes them suitable for parallel study (75, 80, 269).   Therefore, a suitable murine 
model may contribute valuable data, and a greater understanding, of specific 
disease processes, therapeutic responses and the identification of potential targets 
for therapeutic intervention, all important characteristics for drug development and 
drug efficacy studies (1, 269, 278, 433).   
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1.3 ANTIMALARIAL DRUGS 
1.3.1 Introduction 
In the current clinical setting there are at least 10 defined classes of antimalarial 
drugs which are used for the prophylaxis and chemotherapy of malaria including 
arylaminoalcohols, 4-aminoquinolines, dihydrofolate reductase inhibitors, 8-
aminoquinolines, antibiotics, sesquiterpene lactones and naphthoquinones (42, 
250, 300, 423, 535, 540, 555).   Prophylactic drugs are used to prevent the 
establishment of the Plasmodium parasite either in the liver (primaquine) or blood 
(mefloquine), whilst malaria chemotherapies are used to suppress and clear 
parasitaemia and achieve clinical cure for current infections (540).   
 
1.3.1.1 Classification of antimalarial drugs 
Conventional antimalarial drugs are generally classified based on either the stage of 
parasite that they target or on chemotherapeutic actions (236).  In consideration of 
these factors, antimalarials are classified as blood schizontocides, tissue 
schizontocides, gametocytocides or sporontocides.   
 
1. Blood schizontocides – this class of drug act on the asexual erythrocytic 
forms of all Plasmodium species are used to achieve clinical or suppressive 
cure.  The majority of all commonly used antimalarials fall into this category 
eg.  chloroquine, quinine, mefloquine, pyrimethamine, amodiaquine, 
proguanil, sulfadoxine, tetracyclines, artemisinin derivatives (39, 236, 266, 
539) (Fig. 1.6).  
 
2. Tissue schizontocides – this class of antimalarials is used either for 
prophylaxis or for the prevention of relapse of P. vivax or P. ovalae by 
eliminating developing tissue schizonts (primary tissue forms) or latent 
hypnozoites (secondary exoerythrocyic forms).  Examples of tissue 
schizontocides include primaquine, pyrimethamine and proguanil (39, 236, 
266, 539) (Fig. 1.6).   
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3. Gametocytocides – These antimalarials act by destroying the sexual forms of 
the parasite in the blood thereby preventing transmission of infection to the 
mosquito.  Chloroquine and quinine have gametocytocidal activity against P. 
vivax and P. malariae, but not against P. falciparum.  Primaquine is a 
commonly used gametocyctocide for P. falciparum infections (39, 236, 266, 
539). Recent investigations have also provided evidence that the artemisinin 
drugs also demonstrate gametocytocidal activity against P. falciparum (213, 
398, 574) (Fig. 1.6). 
 
4. Sporontocides – This class of antimalarials acts by preventing development 
of oocysts and sporozoites in the infected mosquito, thus preventing further 
transmission of infection.  Primaquine, pyrimethamine and proguanil are all 
classed as sporonticides  (236, 266, 539) (Fig. 1.6). 
 
 
 
Figure 1.6.  Action of antimalarial compounds at different stages of the 
development of the malaria parasites in Anopheles mosquitoes and in the human 
host (540). 
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1.3.1.2 Determinants of drug effectiveness 
When selecting an antimalarial drug for clinical therapy, a number of factors much 
be considered.  These include assessment of the patient’s age, the degree of 
immunity (if any), the likely pattern of susceptibility to antimalarial drugs, drug 
pharmacokinetics, parasite burden, and the cost and availability of those drugs (39, 
555).  All of these factors prove to be important determinants in the selection of a 
suitable treatment option.  The main issues related to drug selection are 
predominantly related to drug availability, adherence to therapy and drug 
resistance patterns (39, 44, 186, 555). 
 
1.3.2 Artemisinins  
Artemisinin, more traditionally known as qinghaosu, is isolated from the leaves of 
the Chinese herb sweet wormwood Artemisia annua L and is the only natural 
antimalarial agent since the discovery of quinine (272).   Historical accounts report 
the antipyretic properties of artemisinin from Chinese scripture dating back over 
2000 years with the first accounts of the specific effect of malarial fever 
documented in the 16th century (128, 228, 238, 570, 574).  In 1972, Chinese 
scientists characterised the structure of artemisinin as a sesquiterpene lactone with 
an internal peroxide linkage and within 10 years the drug was introduced into 
clinical practice (128, 238, 520). The semi-synthetic artemisinin derivatives 
dihydroartemisinin (DHA), artesunate, artemether and arteether (Fig. 1.7) were 
subsequently developed and introduced into clinical practice where they have 
become renowned as the most potent and rapidly acting of the antimalarial drugs 
available on the market today, with clearance of parasites noted within 48 h in most 
cases (212, 238, 521).   
 
Although artemisinins are an exciting class of antimalarial drugs with their short 
elimination half-life, rapid onset of action and no major side-effects, a major 
drawback of these drugs is the high parasite recrudescence rates within 2 to 3 
weeks of monotherapy (187).  In view of this high recrudescence rate, it has been 
concluded that to prevent the formation of artemisinin resistant parasites, 
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artemisinins should only be used in combination therapies rather than in 
monotherapy (77, 521, 552, 570).  
 
 
Figure 1.7. Chemical structure of 1. Artemisinin; and derivatives 2. 
Dihydroartemisinin (DHA); 3. Artemeter; 4. Arteether; 5.  Artesunic acid 
(artesunate) and 6.  Artelinate  (570). 
 
1.3.2.1 Mode of action 
For decades after their discovery, the antimalarial action of artemisinin and its 
derivatives was based on their unusual chemical structure incorporating a peroxide 
bridge and was attributed to their chemical capability to generate free radicals (213, 
570).  It was thought that the endoperoxide bridge underwent ring-opening via 
protonation or formation of a complex with metal iron causing destructive, free-
radical generation with the parasite altering the function of key parasite proteins, 
including membrane transporters (128, 152, 363).  Early studies indicated that the 
modulation of oxidative stress may be important for antimalarial activity as those 
artemisinin compounds lacking the peroxide oxygen atom, were without activity 
(213, 363).   
 
More recently an alternative mechanism of action for artemisinins was proposed 
which is based on the inhibition of the malaria parasite’s calcium ATPase 6, 
sarcoplasmic endoplasmic reticulum calcium ATPase (SERCA) (152, 213, 570).  
SERCAs act to reduce cytosolic free calcium concentration by actively concentrating 
Ca2+ into membrane-bound stores with this activity is critical to cellular survival 
(213).  Eckstein-Ledwig et al. (152) demonstrated that artemisinins inhibited the 
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SERCA ortholog of P. falciparum (PFATP6) with marked specificity, ultimately 
resulting in the death of the parasite (152, 263, 515).  However, SERCA inhibition as 
a mechanism of action for artemisinins remains contentious (355, 569). Whilst 
recent publications have offered further possible mechanisms for artemisinin’s 
antimalarial action (136, 532), the drugs’ biological targets still remain ambiguous 
(355).  
 
1.3.2.2  Antiparasitic activity 
Artemisinin derivatives are active against all human malaria parasites, including 
multidrug-resistant P. falciparum and have a broad activity against the 
intraerythrocytic stages of the parasite, ranging from young ring-forms to schizonts 
(128, 212, 213, 238, 574).  In falciparum malaria, it has been shown that artemisinin 
also kills gametocytes, including stage 4 gametocytes which are otherwise only 
sensitive to primaquine (213, 574).  This gametocytocidal activity of artemisinin 
derivatives was also shown in clinical studies in Thailand which showed that 
artemisinin derivatives (artesunate and artemether) reduced the transmission 
potential of falciparum malaria (398).    
 
1.3.2.3 Pharmacokinetics  
Pharmacokinetic studies of artemisinins have been limited by difficulties of assays 
with several different techniques employed by various groups giving ranging 
accuracies (344, 570).  Whilst high performance liquid chromatography (HPLC) with 
electrochemical detection was originally deemed the method of choice for 
measurement of artemisinin and its derivatives, with a sensitivity of 1–5 ng/mL 
(520, 521), more recently LC-MS methods have shown to have equal sensitivity with 
the additional quality of measurement of drug concentrations from small sample 
volumes (480, 524, 533).  Although the pharmacokinetic parameters of artemisinin 
and its derivatives have been determined, unfortunately very few pharmacokinetic 
studies have focused on the variation of artemisinin profiles in different populations 
of patients, particularly children and pregnant women (570).   
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1.3.2.3.1  Artemisinin 
After oral or rectal administration of artemisinin the peak plasma concentrations 
occur 3 h and 11 h later, respectively (344, 574).  Artemisinin is a potent inducer of 
its own metabolism with an estimated elimination half life of 1-3 h (32, 128, 238).    
 
1.3.2.3.2 Dihydroartemisinin (DHA) 
DHA is the main active metabolite of the artemisinin derivatives, but can also be 
administered orally and rectally as a drug in its own right.  DHA is rapidly absorbed 
following oral administration reaching peak plasma concentrations approximately 
2.5 h after dosing.  After rectal dosing, peak plasma concentrations occur 
approximately 4 h later.  The elimination half-life of DHA is estimated to be 40-60 
min and it is metabolised to an inactive glucuronide (128, 238, 347, 574).    
 
1.3.2.3.3  Artesunate  
Artesunate is rapidly absorbed after dosing and is almost entirely converted to DHA, 
the active metabolite through which the antimalarial activity of artesunate is 
determined (344).  Artesunate peak plasma concentrations occur 0.2–1.6 h (53, 
337, 345, 347), 1.4–3.1 h (255, 343) and 0.2–0.6 h (237) after oral, rectal and i.m. 
administration, respectively (344, 574).  The elimination half-life of artesunate is 
estimated to be between 2-5 min before conversion to DHA (elimination half-life 
40-60 minutes) (128, 238, 344).   
 
1.3.2.3.4  Artemether 
Artemether is the methyl ester of DHA and is metabolized to DHA.  Artemether can 
be administered orally or intramuscularly with peak plasma concentrations 
occurring 2-3 h after oral dosing or approximately 6 hours after i.m. injection.  
However, following i.m. injection absorption is variable and slow and although the 
mean absorption time is approximately 6 h, peak plasma concentration can occur as 
long as 18 h after dosing (574).  The elimination half-life of artemether ranges 
between 2-11 h (128, 238).   
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1.3.2.3.5  Artemotil (previously arteether) 
There are limited data on the pharmacokinetics of artemotil, however, absorption is 
said to be slower and more erratic than the other artemisinin derivatives, with 
some patients having peak plasma concentrations more than 245 h after 
administration (574).  A limited study in healthy volunteers suggested that the 
absorption half-life of artemotil varied from 0.6 to 1.7 h with a long elimination half-
life of 25-72 h (249).   
 
1.3.2.4  Clinical applications 
Artemisinin derivatives can be used for the treatment of both uncomplicated and 
severe malaria in both adults and children (570).  Since their introduction into the 
clinical setting as a chemotherapeutic agent artemisinins have been used 
extensively, predominantly in combination therapies, with impressive results (27-
29, 31, 165, 180, 209, 217, 227, 230, 244, 256, 310, 521, 522, 571).  The most 
rapidly acting of all antimalarials, artemisinins are effective against all Plasmodium 
species and are active by parenteral, oral or rectal administration (77, 552, 570).  To 
date, there has been no significant toxicity reported in humans (218, 318, 552, 570).   
 
1.3.2.5  Adverse Effects 
In the clinical setting artemisinin and its derivatives have been found to be safe and 
remarkably well tolerated.  However, occasional reports of mild gastrointestinal 
disturbances, dizziness, tinnitus, reticulocytopenia, neutropenia, elevated liver 
enzymes and electrocardiographic abnormalities including bradycardia and 
prolongation of the QT interval have been reported (238, 520, 574) . 
 
Animal toxicology studies have reported neurotoxicity, particularly when using very 
high doses of i.m. artemotil and artemether, however, these results have not been 
substantiated in humans (218, 574).  In the animal studies, administration of high 
doses of artemether and artemotil resulted in selective damage to the brain stem 
centres involved predominantly in auditory processing and vestibular reflexes (68, 
350, 436, 506).  However, although neurotoxic and cardiotoxic effects have been 
observed in experimental animals, these all occurred after high dosing regimens 
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and therefore the probability of adverse effects in humans using the clinical dosing 
regimens is minimal (42). 
 
Animal studies have also provided evidence of morphological abnormalities and 
embryo death after artemisinin derivatives were administered during early 
pregnancy (582). A comprehensive review by Clark (104), on the embryotoxic 
effects of artemisinin derivatives in animal models, suggested that malformations of 
the cardiovascular and skeletal systems occurred when embryolethal doses were 
administered in the early gestational period, but not in late gestation. Furthermore, 
such adverse effects were reported in the absence of maternal toxicity (104).  The 
effect of artemisinin and its derivatives have not been thoroughly evaluated in the 
first trimester of pregnancy in Humans (534).  Therefore,  the WHO recommends 
that use of artemisinin derivatives during the first trimester of pregnancy should be 
avoided until further investigation has taken place (582).   
 
1.3.2.6  Resistance  
It was generally regarded that through the tight control of artemisinin therapies, 
and having their use limited to combination therapies, resistance towards this 
highly efficacious drug could be prevented (149, 551, 563).  In 2000, a report was 
published which described the reduced parasite clearance noted in 4 patients in 
Sierra Leone after treatment with artesunate (431).  Whilst the authors concluded 
that this was evidence that resistance towards artesunate was developing on the 
African continent, no other non-responsive or confirmed cases of parasite 
resistance were published and it was still generally acknowledged that there was no 
resistance towards artemisinin drugs (31, 550).  However, further cases of 
artesunate resistance in P. falciparum infection were published in 2009 (143), 
where it was clearly demonstrated that there was a prolongation of parasite 
clearance time after artesunate therapy in clinical cases in Western Cambodia 
compared to north-western Thailand (143).  The described prolonged period to 
parasite clearance could not be explained by drug pharmacokinetics or other host 
factors and was therefore concluded to be artesunate resistance (143). 
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1.3.3 Piperaquine 
Piperaquine (PQ) is a bisquinoline antimalarial which was first synthesized in the 
1960s by both the Shanghi Pharmaceutical Research Institute in China and Rhone 
Poulenc in France (92, 127).  During the next 20 years PQ was used extensively as 
both a prophylactic agent as well as for malarial chemotherapy in China and 
Indochina.  Once the Chinese National Malaria Control Programme recommended 
PQ over CQ for the treatment of malaria, over 140 million adult treatment doses 
were distributed (127, 217).  However, with the emergence of PQ-resistant P. 
falciparum strains as well as the emergence of the artemisinin derivative drugs, the 
use of PQ in the clinical setting declined (127).   
 
In the quest for the development of new antimalarial combination therapies, PQ 
was ‘rediscovered’ by Chinese scientists as a suitable drug partner for combination 
with an artemisinin drug (127).   PQ was found to be a useful partner drug for 
artemisinin derivatives as early clinical studies demonstrated that PQ had good 
tolerance, mild side-effects, high-level prophylactic efficacy for 3 weeks after a 
single oral administration and rapid blood schizontocidal action against P. 
falciparum (46).  Subsequently, several artemisinin combination therapies including 
PQ as the partner drug have emerged in the clinical setting, with results to date 
demonstrating good tolerability and efficacy (10, 27, 29, 139, 178, 189, 209, 217, 
252, 253, 305, 456, 480). 
 
1.3.3.1  Mode of action 
PQ is a member of the 4-aminoquinoline class of antimalarial drugs and contains the 
7-chloro-4-aminoquinoline structure found in every member of this drug class (127) 
(Fig. 1.8).  As a result, it is likely that PQ has a similar mode of action as other 4-
aminoquinolines such as CQ.  Evidence suggests that the mode of action of PQ is the 
inhibition of the haem-digestion pathway in the parasite food vacuole (127, 356).  It 
is suggested that PQ accumulated in the malaria parasite by iron trapping, resulting 
in high drug concentrations in the food vacuole, which leads to an inhibition in the 
formation of the haemozoin polymer (356). 
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  Figure 1.8. Chemical structure of piperaquine phosphate (127)  
 
1.3.3.2  Antiparasitic activity 
The parasite maturation stage predominantly affected by PQ administration is the 
trophozoite, as this is the only asexual stage which contains a functional food 
vacuole (91, 127).  Microscopic studies on the effect of PQ on the structure of 
erythrocytic stages of P. berghei ANKA, of which all asexual parasite stages are 
observed within the peripheral circulation, supports the proposed mechanism of 
action of PQ as after treatment the ultrastructure of trophozoites are 
predominantly affected whilst ring-form, schizonts and gametocytes showed few 
morphological changes (93, 94).   Changes to the structure of trophozoites was first 
identified as the progressive swelling of the food vacuole membrane with eventual 
autophagocytosis of the parasite, 12-24 h after drug administration (93).  It is 
therefore highly likely that the target of PQ efficacy is the food vacuole of the 
trophozoite (90, 93).   
 
1.3.3.3  Pharmacokinetics 
Despite use as an antimalarial agent in clinical practice since the early 1960s, 
pharmacokinetic data of PQ in humans has only recently become available (10, 232, 
286, 425, 443, 480).  The first clinical study describing the pharmacokinetics of PQ 
was published by Hung et al, (232) who described the population pharmacokinetics 
of PQ in Cambodian children and adults with uncomplicated P. falciparum and P. 
vivax malaria. All patients received the artemisinin combination therapy Artekin 2® 
(each tablet containing 40 mg of DHA and 320 mg of PQ phosphate (PQP)).  It was 
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shown that PQ had a slow absorption and a long terminal elimination half-life (t½) of 
22.6 days (543 h) in adults and 13.5 days (324 h) in children (232).    
 
With the increasing popularity of PQ as a partner drug to the artesmisinins for 
combination therapy, this initial report was rapidly followed by a succession of 
studies investigating the pharmacokinetics of PQ in healthy and malaria-infected 
populations, across a variety of ethnicities, age groups and infecting parasite species 
(254, 286, 425, 480).   Despite a general consensus that PQ has an extremely long 
elimination half-life, designating a consistent value to this parameter has proven to 
be a contentious issue (127, 483).   The accuracy of the published and generally 
accepted half-life of 23 days (231) was challenged by Tarning et al. (483) who 
suggested that the previously published value was likely to be an underestimation 
as a result of insufficient assay sensitivity,  short duration of sampling and 
oversimplified fitting of two-compartment models.  In their study, the duration of 
sampling was increased from 35 days (previous published report (231)) to 93 days 
(483).  As a result of the extended period of monitoring of plasma PQ 
concentrations, the terminal elimination half-life was suggested to be in the order 
of 36 days although if based on the last measurements, could be as long as 80 days 
(483).   However, since these early pharmacokinetic data, further studies in healthy 
volunteers have reported PQ half-life in the range of 11.7 to 20.3 days after a single 
dose (286, 425, 443), and as 12.5 days after multiple doses (286).  In patients with 
uncomplicated malaria the mean elimination half life (t½) was suggested to range 
between 13.5 and 28 days (232, 254, 480).  The aforementioned studies 
demonstrate the issues involved in accurately measuring and defining 
pharmacokinetic parameters for long half-life drugs, such as PQ.  Reported half-lives 
appear to be strongly dependent on sample numbers, assay sensitivity and the 
duration of follow-up after drug administration.    Such issues are best illustrated in 
Fig. 1.9 (483), which shows the relationship between follow-up duration and assay 
sensitivity and the potential problems associated with the estimation of terminal 
elimination half-life for drugs, like PQ, that have multiphasic elimination kinetics 
and a long terminal half-life.   
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Figure 1.9 Pharmacokinetic elimination of piperaquine.  The diagram  
illustrates the different estimates of the terminal elimination half-life as a function 
of follow-up duration and assay sensitivity (483) 
 
 
1.3.3.4 Clinical Efficacy 
Published preclinical studies, although limited, have concluded that PQ is a 
relatively safe and well tolerated drug, with a good toxicity profile (50, 92, 127).  It is 
effective against all Plasmodium strains, including those strains of P. falciparum 
which are resistant to CQ, with few patients reporting adverse affects.    Despite the 
rapid acquisition of parasite resistance towards PQ after extensive monotherapeutic 
use,  the excellent tolerability, effectiveness, long half-life and low cost of PQ make 
it a promising partner drug for short-course antimalarial combination therapies 
(127).   
 
Even with the successful implementation of the artesunate-mefloquine and 
artemether-lumefantrine combinations in malaria endemic countries, the quest for 
a more desirable Artemisinin Combination Therapy (ACT), with a partner drug that 
fulfils more of the WHO recommendations, continues.  Whilst searching for new 
partner drugs for ACTs, PQ underwent a renaissance and as a result a number of 
ACTs including PQ as the partner drug have been successfully formulated and 
implemented in the clinical setting (Table 1.4)(456).  The first PQ combination 
therapy combined the artemisinin derivative DHA with PQP in a co-formulation with 
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Table 1.4  Combination therapies including PQP currently used in the clinical 
setting.  Abbreviations: Dihydroartemisinin (DHA); Artemisinin (AR); Piperaquine 
phosphate (PQP); Trimethoprim (TMP); Primaquine (PRIM); days (d); hours (h). 
 
Commercial 
name 
DHA 
(mg) 
AR 
(mg) 
PQP  
(mg) 
TMP 
(mg) 
PM 
(mg) 
Dosing schedule      
(adult) 
Cure rate Ref 
CV-8® 32 0 320 90 5 2 tablets at 
t = 0, 24 and 48 h 
28 d: 94% (178) 
Artecom® 32 0 320 90 0 2 tablets at 
t = 0, 6, 24 and 48 h 
28 d: 96.9% 
56 d: 97.4% 
(560) 
(217) 
Duo-
Cotexcin® 
40 0 320 0 0 3 tablets at  
t = 0 and 24 h,  
2 tablets at t = 48 h 
 
2.1 mg/kg/day DHA 
17.1 mg/kg/day PQP 
t = 0, 24 and 48 h 
28 d : 97.8% 
 
 
 
42 d: 98% 
(595) 
 
 
 
(589) 
Artekin® 40 0 320 0 0 2 tablets at 
t = 0, 6-8, 24 and 48 h 
 
 
 
1.6 mg/kg/day DHA 
12.8 mg/kg/day PQP 
t = 0, 8, 24 and 48 h 
 
1.6 mg/kg/day DHA 
12.8 mg/kg/day PQP 
t = 0, 24 and 48 h 
 
 
2.1 mg/kg/day DHA 
16.8 mg/kg/day PQP 
t = 0, 24 and 48 h 
 
2.25 mg/kg/day DHA 
18 mg/kg/day PQP 
t = 0, 24 and 48 h 
 
28 d: 92.3–
100% 
56 d: 98.7% 
63 d: 97.5% 
 
63 d: 100% 
63 d: 96.1% 
 
 
28 d: 95.2–
99% 
63 d: 99.4% 
 
 
28 d: 99% 
42 d: 100% 
63 d: 98.4% 
 
42 d: 87–
89.9% 
63 d: 92.2% 
(27, 139, 
253) 
(217) 
(244) 
 
(29) 
(27) 
 
 
(252, 
477) 
(29) 
 
 
(456) 
(305) 
(189) 
 
(209, 
397) 
(413) 
Artequick® 0 80 400 0 4 3.2 mg/kg/day AR 
16 mg/kg/day PQP 
0.16 mg/kg/day PRIM 
t = 0, 24 and 48 h 
28 d: 98.5% (265, 
476) 
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trimethoprim and primaquine called CV-8® (127, 178).  This combination was 
implemented as national policy for first-line treatment of uncomplicated malaria in 
Vietnam in 2000, with a 3-day regimen giving 28-day cure rates of 96%, a similar 
outcome to the combination atovaquone-proguanil (Malarone) (178). After slight 
modification of the original CV-8® formulation, Artecom® was registered in both 
Vietnam and China, however, its use in the clinical practice appears to have been 
limited  (127, 217).   The most recent PQ formulations Artekin® (PQ-DHA) and 
Artequick® (PQ-artemisinin) have been more successfully implemented into the 
clinical setting, particularly in Southeast Asia, with both drugs being shown to be 
highly efficacious   (27, 29, 139, 189, 209, 217, 244, 252, 253, 265, 305, 336, 397, 
413, 456, 476, 477, 589, 595).  
 
Benefits of DHA-PQ over artemether-lumefantrine were that DHA-PQ offered better 
post-treatment prophylactic effect, a significantly lower risk of recurrent 
parasitaemia after treatment, simple dosing schedule, more consistent intestinal 
absorption, relatively low cost, a lower risk of gametocytaemia after therapy and 
better haemoglobin recovery (336, 589).   Several advantages that DHA-PQ has over 
artesunate-mefloquine are that the treatment course is cheaper (approximately 
US$1.50 per adult treatment), better tolerated (217) and available as a co-
formulation which means the treatment course is easier to take and should result in 
an increase in adherence thus limiting the chance of the emergence of resistant 
parasites to either the DHA or PQ (456).  
 
Studies comparing the combinations artesunate-mefloquine and DHA-PQ have 
demonstrated that both treatment regimens were highly efficacious and well 
tolerated treatments (27, 29, 217, 253, 305, 456) with reported cure rates of 95 to 
99% with 3-day dosage regimens in uncomplicated falciparum malaria (27, 139, 217, 
252, 456, 477).  Therefore, with the successful implementation of PQ based ACTs in 
the clinical setting, it is important to further understand the relationship between 
PQ plasma concentrations and toxicity or efficacy (253) as well as determining the 
therapeutic index for PQ, which, remains poorly defined.  
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1.3.3.5  Adverse effects 
Overall, studies have shown that when taken in monotherapy or as an ACT, PQ is a 
well tolerated drug with few patients reporting adverse effects (127, 139, 178, 217).  
Minor complains that have been reported include mild headache, dizziness, nausea, 
abdominal pain and vomiting   (27, 29, 92, 127, 139, 209, 217, 232, 456, 477) 
although these symptoms are often difficult to distinguish from the symptoms 
resulting from the malaria infection.  However, in a healthy volunteer study it was 
found that mild nausea, abdominal pains, dizziness and fatigue occurred transiently 
after PQ administration (443) suggesting that the mild adverse effects noted in 
clinical studies were in fact due to either a combination of symptoms of malaria and 
drug administration or simply due to PQ administration.   
 
To date there are limited data available relating to the safety of PQ use during 
pregnancy, lactation or in children younger than 12 months of age (127, 139, 232, 
252, 253, 413). 
 
1.3.3.6 Resistance 
After the extensive and unregulated use of PQ as a monotherapy for antimalarial 
prophylaxis and chemotherapy in China, PQ resistance soon emerged with IC50s 
significantly increasing in areas of southern China where PQ use was widespread 
(127).  As a result, the use of PQ for either prophylaxis or chemotherapy was 
stopped and its use has only recently resumed, albeit in combination therapies 
under much stricter regulation.      
 
There are conflicting views in the literature to whether any cross-resistance 
between PQ and other antimalarial drugs (particularly other 4-aminoquinolines and 
artemisinins) exist (89, 90, 127, 279, 280, 356).  In two PQ resistant mouse strains, 
P. berghei ANKA and K173 PR strains, cross-resistance was found between PQ, 
hydroxy-PQ, artesunate, artemisinin and mefloquine (279, 280). However, studies 
looking at the cross-resistance of PQ in CQ-sensitive and CQ-resistant isolates of P. 
falciparum from Cameroon suggested that with IC50s of <100 nmol/L there was only 
a slight correlation between the two drugs therefore minimizing the risk of in vitro 
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cross-resistance (46).  More recently in vitro studies observing the interactions 
between PQ, DHA, mefloquine, quinine, CQ, pyronaridine and naphthoquine 
demonstrated that PQ had no interaction with DHA, CQ, pyronaridine and 
naphthoquine but antagonism with mefloquine (126).  This suggests that there 
should be little clinical interaction of PQ with any of the drugs studies except 
mefloquine which, according to these results should be limited (126).   
 
1.3.4 Chloroquine 
The antimalarial CQ (originally named Reochin) was discovered in 1934 by Hans 
Andersag at Bayer I.G. Farbenindustrie A.G. laboratories in Germany (39, 105, 111).  
However, it wasn’t until during World War II that British and U.S. scientists 
recognized CQ as an effective and safe antimalarial drug (39, 341).   Therefore, CQ 
became the first-line treatment for uncomplicated and severe malaria as well as the 
principal drug for malaria prophylaxis (105).  In the late 1950s the first cases of CQ-
resistant P. falciparum were documented in Thailand and Columbia which was soon 
after followed by the spread of CQ-resistant strains worldwide (39, 63, 326).   
 
Despite the extensive spread of CQ-resistant strains of P. falciparum and more 
recently the emergence of chloroquine-resistant P. vivax strains in New Guinea and 
Indonesia (38, 40, 110, 412), CQ remains by far the most widely used antimalarial 
drug worldwide (450, 540, 562).   
 
1.3.4.1  Mode of action 
Whilst the precise mechanism of action of CQ is not fully elucidated, it is generally 
considered that the antimalarial action of CQ is attributed to the drug’s 
accumulation within the haem-rich lysosomes of the food vacuole of malaria 
parasites.  This accumulation results in an increase in the intralysosomal pH of the 
parasite which directly inhibits the lysosomal hydrolysis of haemoglobin.  As a 
consequence, toxic metabolites accumulate within the parasites leading to the 
arrested growth of the parasite (219, 297, 356, 409, 562).   
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1.3.4.2  Antiparasitic action 
CQ only acts on those stages of the parasite life cycle that can actively digest 
haemoglobin within the erythrocyte, thus trophozoite stage parasites (540).  This 
has been confirmed by ultrasturctural studies which have shown that the parasite’s 
food vacuole is the target of the activity of CQ (424, 540).   
 
1.3.4.3  Pharmacokinetics  
 CQ has a long terminal elimination half-life ranging from 3 h to 1500 h (490) 
although most recent studies suggest a longer terminal elimination half-life of 1–2 
months (148, 264, 504, 540, 562).  In healthy patients and those with 
uncomplicated malaria, oral chloroquine is rapidly absorbed with peak plasma 
concentrations of approximately 250 µg/L reached within 2 h of dosing.  After i.m. 
or s.c. injection, absorption is so rapid that dangerously high peak plasma 
concentrations (500–3500 µg/L) may be reached within 5–20 min after 
administration of a 5 mg base/kg dose (540).    
 
CQ is extensively bound to tissues, particularly the liver, connective tissue and 
pigmented tissues such as the skin and retina resulting in a very large total volume 
of distribution.  CQ is also concentrated in erythrocytes, granulocytes and platelets 
with approximately 55–60% bound in plasma (148, 540).  Following administration, 
the drug is rapidly dealkylated  in the liver via cytochrome P450 enzymes into the 
pharmacologically active desethylchloroquine (DECQ) and bisdesethylchloroquine 
(148, 264).   
 
1.3.4.4 Clinical efficacy  
Whilst CQ-resistant P. falciparum is present worldwide, with high grade resistance 
in many areas, CQ remains the drug of choice for combating CQ-sensitive parasites 
in Africa (59, 551, 561).  However, clinical failure after a course of CQ now exceeds 
25% in much of Africa but as the drug is cheap and readily available, it remains the 
first-line therapy throughout much of Africa and parts of Southeast Asia (562).   
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In the clinical setting CQ is most commonly used for the oral treatment of 
uncomplicated malaria and is effective against all CQ-sensitive parasite species 
(111, 562). Recent efficacy studies of CQ in Burkina Faso, a region which has had 
high grade CQ-resistant P. falciparum since 1983, demonstrated that after 
administrating a standard course of CQ to children, parasitological and clinical 
failure rates were reported to be 27% and 10%, respectively (330). These results 
were surprising as clinical failure rates in the same region in 1988 were estimated to 
be closer to 70% (437). Therefore, this efficacy study suggested that since replacing 
CQ as a first-line drug, the incidence of CQ resistance has decreased.  Such 
observations appear to correspond to a general trend seen across areas of 
Southeast Asia.  Furthermore, data collected in 1994 in Gabon showed a decrease in 
CQ resistance isolates (385) and further data in 1996 (67) showed a significant 
increase in P. falciparum sensitivity to CQ.   These data imply that if CQ 
monotherapy is replaced in a region for a period of time, there is the capacity for 
the parasites to become more sensitive to the drug.  Therefore, CQ should not be 
disregarded as an antimalarial therapy and, with better understanding of the 
mechanisms of resistance, there is a potential for CQ to be restored to clinical utility 
(111, 183).  For example, it has been suggested that sequential treatment with CQ 
and a glutathiamine-depleting drug, may increase the efficacy of CQ in the clinical 
setting (183).  Furthermore, it has been demonstrated that combination of CQ with 
a sensitising drug, such as antihistamines or antidepressants, may increase the 
clinical efficacy of the drug particularly against CQ-resistant parasites (56).   Studies 
reported that addition of the antihistaminic drugs cyproheptadine (377), azatadine 
(47), or chlorpheniramine (462) potentiated the activity of CQ against mild to 
moderately CQ-resistant parasites (56).  
 
1.3.4.5  Adverse effects  
CQ is generally well tolerated, however, when plasma concentrations exceed 250 
µg/mL, unpleasant side-effects such as dizziness, headache, diplopia, disturbed 
visual accommodation, dysphagia, nausea and malaise may develop.  Therefore, the 
adverse effects of CQ are usually limited to patients receiving intravenous infusions 
(364, 540).  In Africans, Haitians and dark-skinned Asians pruritus of the palms, soles 
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and scalp may also be a problem and is particularly seen in cases of therapeutic 
noncompliance (364, 540, 562).  Pruritus is suggested to occur in up to 70% of adult 
Africans taking CQ (364).  Serious adverse effects such as hypotension, 
electrocardiograph abnormalities, leucopenia and aplastic anaemia are rare but can 
occur at high drug concentrations (562).    
 
1.3.4.6 Resistance 
The first case of CQ-resistant P. falciparum malaria was described in Colombia in 
1960 and within a short period, had spread to most of the malaria endemic regions 
of the world (326, 461).  So rapid was the progression of resistance that within 10 
years of the first case, CQ-resistant P. falciparum had spread across the entire 
African continent (547).  Today, CQ remains effective for P. vivax, P. ovalae and P. 
malariae infections worldwide and for falciparum malaria in restricted areas such as 
central America northwest of the Panama Canal, Haiti, the Dominican Republic and 
parts of the middle east (540).  However, caution must be taken before treating any 
cases of malaria with CQ as reports of chloroquine-resistant P. vivax have also 
started to emerge (461, 540). 
 
1.3.5 Antimalarial combination therapies 
In light of the ever increasing pressure of the emergence of drug resistance, 
antimalarial combination therapies are now thought to be the way forward in the 
treatment of uncomplicated and severe malaria (581, 583{World Health 
Organization, 2010 #1255)}.  The concept of combination therapy is based on the 
synergistic or additive potential of two or more drugs, which have independent 
modes of action and/or different biochemical targets, so as to improve therapeutic 
efficacy and delay the development of resistance to individual components of the 
combination (127, 581).   In order to determine the merits of a proposed 
combination therapy for different epidemiological conditions, a set of criteria have 
been suggested by the WHO (581).  The major criteria include the following:  
•  Therapeutic efficacy of the combination, irrespective of the efficacy of the 
individual components. 
• Safety of the drugs in combination, especially amongst high risk groups. 
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• Potential for widespread use at all levels of heath care, including use for 
home management. 
• Potential for consumer compliance. 
• Cost effectiveness.  
• Potential for the delay or prevention of development of resistance. 
• Other factors: including product availability, production capacity and 
potential for wide-spread use at a sub-regional level.   
 
In the clinical setting, a number of drug combinations are currently available and 
used successfully to treat uncomplicated and severe malaria. The most common are 
the ACTs (150, 335, 351, 551, 555, 563, 581).  
 
1.3.5.1  Artemisinin combination therapy 
In recent times ACTs have become increasingly popular in Southeast Asia for 
malaria chemotherapy and are expected to become more frequently used in 
tropical Africa (438, 581).  Although ACT has been recommended by the WHO since 
2001 as the ‘ideal strategy’ for malaria control, overall deployment has been slow.  
This is primarily related to their high relative cost, limited public awareness of the 
concept and advantages of combination therapy, limited knowledge on the safety 
of ACTs in pregnancy and other operational issues including inappropriate drug use, 
lack of suitable formulation and the imbalance between supply and demand (335, 
562).   
 
The advantages of ACT relate to the unique properties and mode of action of the 
artemisinin compound including; its rapid reduction of the parasite biomass, rapid 
resolution of clinical symptoms, effective action against multidrug-resistant P. 
falciparum, reduction of gametocyte carriage thus possibly reducing transmission of 
resistance, little documented resistance to artemisinin or its derivatives in most 
regions and few reported adverse clinical effects (335, 581).  Ideally, in ACT the 
partner drug should have a half-life exceeding 4 days (eg. mefloquine or PQ) which 
both protects the artemisinin derivatives against resistance and offers an extended 
period of malaria prophylaxis whilst enhancing efficacy  (46, 232, 252, 351, 581).  
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With the increasing emergence of drug-resistant P. falciparum, the use of ACTs in 
the clincal setting has also grown, resulting in the WHO recently recommending 
ACTs as the treatment of choice for uncomplicated malaria (253, 574, 581)}.   In 
order to provide efficacious antimalarial therapy, without the risk of drug 
resistance,  the WHO has stipulated that when devising new ACTs the following 
factors must be considered    (128, 351):  
• Components have different modes of action. 
• No interactions. 
• Short course regimens (3 days at most). 
• At least one drug which clears asexual forms rapidly. 
• At least one drug with a long half-life. 
• Well tolerated, low toxicity. 
• Broad spectrum of action (including against gametocytes). 
• Co-formulation, if possible. 
 
It is currently estimated that more than 60 malaria endemic countries are 
advocating the change of antimalarial policy to ACTs, however, there is still much 
debate over which are the most suitable combinations for first-line treatment of 
uncomplicated malaria (408).  To date, artemether-lumefantrine (Coartem®) is the 
only co-formulated ACT which has international registration (28, 408).  However, 
despite not being commercially available as a co-formulation, artesunate-
mefloquine is a popular choice of ACT, particularly in Southeast Asia (28, 352, 457, 
476, 477, 522, 560). Artesunate-mefloquine is used as first-line antimalarial therapy, 
as a 3-day regimen (artesunate 12 mg/kg and mefloquine 25 mg/kg), in many 
Southeast Asian countries, demonstrating excellent efficacy and tolerability (28, 
352, 456, 457, 477, 522).  Despite the efficacy of this combination, there are a 
number of drawbacks for relying solely on this treatment regimen, particularly 
when considering the stipulations made by the WHO for ACTs.  These include:  
1. The high price of each adult treatment of artesunate-mefloquine 
(approximately US$3 per treatment) means that most people in endemic 
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areas cannot afford the treatment and thus are treated with less effective 
alternatives (eg. CQ) (456) 
2. Mefloquine has some common adverse effects, and although not serious, 
can result in poor adherence to the multiple dose therapy.  Mefloquine can 
also be associated with neurological and neuropsychiatric side-effects, 
however, these are usually mild and are not long lasting (118, 125, 456) 
3. To date, co-formulated mefloquine and artesunate are not widely available 
commercially.  Hence, if patients experience adverse effects to mefloquine 
they can stop taking this drug but continue to take the artesunate which 
thereby compromises efficacy and risks parasite resistance (456, 457).  In 
2010, a co-formulation of mefloquine and artesunate (ASMQ) was registered 
for clinical trials and several trials in Africa and Latin America are currently in 
progress.  
 
The co-formulation artemether-lumefantrine has proved to be highly effective and 
well tolerated in several studies from Africa and Southeast Asia (2, 29, 30, 160, 161, 
329, 404, 492, 522, 589, 595). Like the artesunate-mefloquine combination, 
however, artemether-lumefantrine has several drawbacks.  Disadvantages of this 
combination include; the need for twice-daily dosing, that each dose should be 
taken with a fat-rich meal or soya milk (30, 161) as well as the relatively high 
recurrence of parasitaemia within 28 days (317, 589).  
 
Alternative ACTs, which are either currently available or in the process of 
undergoing clinical investigation, include: 
1. DHA-PQP (Artekin®)  
2. Artesunate plus sulfadoxine-pyrimethamine  
3. Naphthoquine plus DHA  
4. Artesunate plus amodiaquine 
5. Artesunate plus pyronaridine 
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1.3.5.2 Non-artemisinin combination therapies  
Before the introduction of the ACTs several successful non-artemisinin combination 
therapies were used in the clinical setting, specifically quinine-tetracycline (or 
doxycycline), sulfadoxine-pyrimethamine and most recently atovaquone-proguanil 
(MalaroneTM), amodiaquone-sulfadoxine-pyrimethamine and chlorproguanil-
dapsone (LapDap) (128, 362).  However, with each of these combinations a number 
of issues have hampered their continued application in the clinical setting, 
particularly relating to side-effects (quinine-tetracycline), compliance (each dosing 
strategy usually spans 7–10 days) and declining efficacy (high-grade resistance to 
sulfadoxine-purimethamine is common).  Although atovaquone-proguanil is given 
as a short-course regimen it is one of the most expensive antimalarial therapies 
currently available and despite being only introduced in 2000, highly resistant cases 
have already been reported (128, 464).    
 
Whilst the majority of comparative efficacy studies conducted between ACTs and 
non-ACTs demonstrate that ACTs have the highest cure rates (particularly when 
referring to treatment failure) and tolerability, ACTs are not always the best or most 
feasible option for malarial chemotherapy (262, 362).  The high cost of artemisinin 
based therapies and their availability, particularly on the African continent remain 
major concerns (588).  As a result clinicians in Africa are turning to the inexpensive 
and widely available non-artemisinin combination therapies, particularly 
amodiaquone plus sulfadoxine-pyrimethamine, which may still be a feasible 
treatment option in areas where sulfadoxine-pyrimethamine resistance is not 
endemic (314, 588).   
 
The most commonly used non-artemisinin combination therapies available in the 
clinical setting, which still remain efficacious in many regions and are therefore a 
suitable option for ACT, if necessary, include the following (581): 
1. Amodiaquine plus sulfadoxine-pyrimethamine 
2. Atovaquone-proguanil (MalaroneTM) 
3. Quinine plus tetracycline (or doxycycline) 
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1.4 AIMS OF THE THESIS  
 
Although the rodent P. berghei model has been the primary animal model for in 
vivo screening of new antimalarial compounds, its application has been limited to 
efficacy assessment.  The potential of this model to provide pharmacokinetic and 
additional pharmacodynamics data, has therefore not been fully explored. Whilst 
the overall aim of this thesis was to further investigate and develop the P. berghei 
murine malaria model as a tool for the assessment of the pharmacokinetic and 
pharmacodynamic properties of antimalarial drugs, the specific objectives included: 
 
1. To evaluate the efficacy of dihydroartemisinin (DHA) in an asplenic murine 
malaria model. 
The pharmacodynamic properties of DHA were investigated through a 
single dose ranging study conducted in both P. berghei infected and 
uninfected asplenic and intact mice.  Given published clinical findings, it was 
hypothesised that the efficacy of DHA would be compromised in the 
asplenic mice. (Chapter 3; Paper I) 
 
2.  To obtain robust pharmacokinetic and pharmacodynamic data following 
the single dose administration of piperaquine (PQ) to mice 
The pharmacokinetic and pharmacodynamic properties of PQ were 
investigated in P. berghei infected and uninfected mice after administration 
of single doses of PQ phosphate (PQP).  Similarly to human pharmacokinetic 
studies it was hypothesised that in the murine malaria model, PQ would 
demonstrate a long elimination half-life, with little difference in drug 
plasma concentrations between P. berghei infected and uninfected mice. 
(Chapter 4; Paper II). 
 
3. To investigate drug efficacy, reinoculation outcomes, and parasite viability 
after administration of a single dose of PQ in the murine malaria model 
Previous investigations (Chapter 4) demonstrated that high dose PQP had 
an extended antimalarial efficacy, with resolution of detectable 
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parasitaemia, although for the majority of the pharmacokinetic profile, PQ 
plasma concentrations were deemed to be at less than efficacious 
concentrations.  Therefore, the aim of this study was to determine whether 
the extended antimalarial efficacy was a result of drug effects alone or a 
combination of drug efficacy and host factors. It was hypothesised that in 
combination with initial PQ efficacy, the host immune system played an 
important role in the resolution of infection. (Chapter 5; Paper III) 
 
4. To obtain robust pharmacokinetic data for chloroquine (CQ) and its major 
metabolite desethylchloroquine (DECQ) after single and multiple dose 
administration in the murine malaria model. 
Despite CQ being used extensively throughout the clinical setting, the 
pharmacokinetic parameters of this drug in preclinical models is not well 
defined.  Furthermore, there are limited data on the pharmacokinetics of 
multiple dose CQ administration or single and /or multiple dose DECQ 
administration in mice.  It was hypothesised that in the murine malaria 
model, CQ would have a long elimination half-life in both malaria-infected 
and uninfected mice. (Chapter 6; Paper IV). 
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CHAPTER TWO 
 
METHODS 
 
2.1 MATERIALS 
2.1.1 Animals and animal welfare 
2.1.1.1 Mice 
2.1.1.1.1 Experimental mice 
All experimental work was performed using 5-6 week old male outbred albino male 
Swiss Arc:Arc(S) mice which were obtained from the Animal Resource Centre (ARC; 
Murdoch, Australia).  The ARC reports that the original breeding stock of Arc:Arc(S) 
mice was received from the Charles River Breeding Laboratories (Kingston, NY) in 
1991 as a SPF CD1 animal stock (22).  This particular mouse strain was then re-
imported from the Charles River Laboratory in 2006 (22).  Whilst genetically stable 
inbred mouse strains are often used in animal studies involving specific disease 
processes or immunological responses, outbred mouse strains are more commonly 
associated with drug development or efficacy studies (18, 122, 268, 378, 379, 381).  
The outbred Swiss mouse model was therefore used for all studies as it provided a 
robust and economical mouse model.  Male mice were selected for use in these 
studies which eliminated the chance of variable biochemical parameters as result of 
fluctuating hormone levels which can be linked to females (268).   
 
The experimental design of each animal investigation was based on a modified Rane 
in vivo screen system (Refer to 1.2.2.1.1.4).  The number of animals used in each 
drug treatment group throughout the thesis investigations was selected based on a 
statistical power calculation. For the pharmacodynamic studies, it was determined 
that statistically significant results could be achieved in this biological system with 
at least 8 mice per treatment group (>25% difference in outcomes; power = 80%; 
α=0.05). 
 
2.1.1.1.2 Mice for P. berghei passage 
Inbred albino male BALB/cArc mice (ARC; 7-8 weeks of age) were used for the 
weekly passage of P. berghei infection.  The BALB/c mice were originally sourced by 
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the ARC from the Animal Breeding Unit, University of Western Australia (Crawley, 
Australia) in 1981 (21).  In order to obtain specific pathogen free status in this 
strain, the first litters were derived by  caesarean (21).  The genetic make-up of the 
BALB/c mice used in all investigations were the inbred albino Tyrc, Tyrp1b, A, H-2d 
strains (21).  As the experimental procedures involving BALB/c mice required a 
stable infection for weekly passage, this inbred strain was chosen as it is the most 
established method of passage and it reduces immunological responses when 
transferring the infection between mice.   
 
2.1.1.1.3 Sentinel mice 
Male Swiss mice (ARC; 5-6 weeks of age) were used as sentinel mice for the animal 
holding room.  At quarterly intervals, 6 mice (of similar age to experimental mice) 
were obtained and separated into 3 open-top cages (n=2 per cage) with the cages 
then distributed around the animal room (1 cage close to the entry door, 2 cages 
dispersed within the experimental cages).  These mice received the same food, 
water and bedding as the experimental mice.  Additionally, when changing dirty 
bedding in the experimental cages, a small amount of dirty bedding was randomly 
selected and placed in the sentinel cages.  At the conclusion of the interval, blood 
was harvested from the mice and sent for laboratory testing (Murine Virus 
Monitoring Service, Gilles Plains, South Australia) against a panel of known murine 
viral pathogens, most importantly including Mouse Hepatitis Virus (MHV), Mouse 
Parvovirus (MPV), and Pneumonia Virus of Mice (PMV) (Full testing panel outlined 
in Appendix 1).  For the duration of research undertaken for this thesis, the sentinel 
mice remained pathogen free.   
 
2.1.1.2 Animal welfare 
2.1.1.2.1 Ethical approval 
All experimental protocols described in this thesis were approved by the Curtin 
University Animal Ethics Committee.  All research was conducted in accordance 
with the NHMRC Code of Practice for the Care and Use of Animals for Scientific 
Purposes (342).   
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2.1.1.2.2 Housing facilities 
Between 2005 and 2007, all animals were housed in the School of Pharmacy animal 
laboratory in an air-conditioned room set at 22oC with a 12-h light/dark cycle.  This 
animal laboratory was decommissioned at the end of 2007 and all animal research 
was moved to the Curtin University PC2/PC3 Animal Research Laboratories.  As a 
result, the P. berghei inoculum had to be re-established in the new environment 
from frozen blood stocks.  Within the new facility, animals were housed in a PC2 
rated animal holding room, maintained at 22oC, with a 12-h light/dark cycle.   
 
2.1.1.2.3 Cages 
Non-porous, translucent plastic cages with stainless steel bar tops were used to 
house the mice.  For experiments over short periods (1-2 weeks) small cages housed 
a maximum of 4 mice whilst large cages housed up to 12 mice.  For experiments 
lasting more than 2 weeks, a maximum of 2 and 8 mice were housed in each small 
and large cage, respectively.  Stainless steel nameplates were used to hold 
identification cards on the front of each cage.  Plastic water bottles with stainless 
steel drinking teats were used for water dispensing.   
 
All cage components were autoclaved at 121oC for 15 min on a hard good cycle, 
using an accredited autoclave in the School of Pharmacy and/or Curtin University 
Animal Research Laboratories.  
 
2.1.1.2.4 Bedding 
ALPHA-dri bedding (Shepherd Specialty Papers; Able Scientific, Perth, Western 
Australia) was autoclaved at 121oC for 15 min on a hard goods cycle, using an 
accredited autoclave.  Cellulose bedding was selected for use as it ensured low dust 
accumulation and ingestion of bedding by the mice would not interfere with animal 
biochemistry parameters, which can be seen when using wood chips as a bedding 
source (251).  A number of autoclaved tissues were also placed in each cage for use 
as nesting material.   
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2.1.1.2.5 Acidified water 
Acidified water (pH2.5) was prepared by adding 400 μL of 32% w/v HCl to 1 L glass 
bottles of de-ionised water.  Before use, the prepared water solution was 
autoclaved for 20 min at 121oC on a fluid cycle in an accredited autoclave.  The 
water was acidified in order to prevent bacterial contamination whilst water was 
either in storage or in the cage water bottles (439, 469).   
 
2.1.1.2.6 Rodent food 
Rodent food cubes, purchased from Glen Forrest Stock Feeders (Perth, Western 
Australia), were used for animal feed.  The food was autoclaved on a hard goods 
cycle for 20 min at 121oC in an accredited autoclave before distribution to the 
animals.   
 
2.1.1.2.7 Environmental enrichment 
Cardboard tubes and small cardboard boxes were autoclaved at 121oC for 15 min 
on a hard goods cycle, with a selection placed in each cage to provide stimulation.  
The goal of adding environmental enrichment to the cages was to decrease fighting, 
particularly in the large cages, as part of established animal welfare 
recommendations (342).   
 
2.1.2 Parasites 
The rodent specific parasites, P. berghei ANKA parasites were used for all 
experimental work.  Originally sourced from the Australian Army Malaria Research 
Institute (Enoggera, Queensland; acquired by Prof K Ilett and Dr K Batty in 1995), 
the parasites were well established in the laboratory through weekly passage of 
infection through BALB/c mice.  The P. berghei ANKA strain was selected as it 
induced high mortality in mice, thus providing a good model to estimate 
antimalarial drug efficacy in reducing parasitaemia, and is sensitive to all currently 
used antimalarial drugs (379). Occasionally, volumes of infected blood were 
prepared as stock samples and stored at -80oC, should a new infection line require 
development at a later date.   
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2.1.3 Antimalarial drugs 
Antimalarial drugs selected for evaluation included DHA, PQ and CQ.  DHA 
(MW=284.3) was obtained from Dafra Pharma N.V. Turnhout, Belgium. PQ 
phosphate (PQP; MW=927.5) was sourced from Yick-Vic Chemicals and 
Pharmaceuticals, Kowloon, Hong Kong whilst CQ diphosphate salt (MW= 515.9) was 
obtained from Sigma-Aldrich (St. Louis, MO, USA).   
 
2.1.4 Sodium pentobarbitone 
Pentobarbitone injection is commercially available as Lethobarb® (300 mg/mL; 500 
mL) which is 5-10 times the required concentration (murine doses were 3-4 mg) and 
was unsuitable for the present studies.  Therefore, for the present studies, all 
sodium pentobarbitone for injection (sodium pentobarbitone at 30 mg/mL, 
propylene glycol at 40% [vol/vol], and ethanol at 10% [vol/vol] in water [pH 9.5]) 
was prepared in house by a registered pharmacist (Dr K Batty).  After preparation 
the sodium pentobarbitone solution was stored in 10 mL volumes in sterile glass 
bottles in a cool, dark environment.  At time of use the solution was diluted 50:50 
with 0.9% NaCl for injection.  
 
2.1.5 Reagents and chemicals 
May-Grunwald Giemsa stain was obtained from the Department of Microbiology, 
Royal Perth Hospital, Western Australia. All general laboratory chemicals and 
solvents were of analytical grade (Sigma-Aldrich Chemical Co., Milwaukee, WI; BDH 
Laboratory Supplies, Poole, England; and Merck Pty. Limited, Kilsth, Victoria, 
Australia).  
 
2.2 METHODS 
2.2.1 Mouse manipulations 
2.2.1.1 Animal identification 
As each animal cage contained at least 4 animals, and all results were mouse 
specific, it was desirable that each individual could be identified.  This was 
accomplished by marking the topside of the base of each tail with a coloured 
permanent marker.  The markings were monitored closely and renewed over the 
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period of the study should they have faded over a period of time or were 
rubbed/licked off, particularly after nesting during each night.   
 
Whilst there are a number of techniques that are commonly used for animal 
identification, including the use of either tattoos or punctures in the ear, the 
experiments used in these studies were short term and did not require such 
invasive identification methods.   
 
2.2.1.2 Restraint for manipulation 
In order to gain greater control of the mouse for i.p. injection, correct restraint had 
to take place to reduce the possibility of injury during manipulation.  The mouse 
was first removed from the cage, by lifting it at the base of the tail, and then placed 
on the cage lid.  The tail was held firmly and using the right hand, the tail pulled 
back gently, causing the mouse to pull in the opposite direction and clasp the cage 
bars with all four feet (Fig. 2.1; A).  Using a quick firm action, the thumb and 
forefinger of the left hand grasped the scruff of the neck, near the base of the head 
whilst the tail was still held by the right hand (Fig. 2.1; B).  With the tail held in the 
right hand, and the scruff in the left, the mouse was lifted and laid against the left 
palm.  The tail was then tucked under the third and fourth finger of the left hand 
resulting in the manual restraint of the animal (Fig. 2.1; C).  This position allowed 
adequate access to the abdominal region for i.p. injection and ensure little 
movement from the mouse, thus preventing injury during injection processes.   
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Figure 2.1 Manual restrain of a mouse.  A: The mouse is removed from the 
cage by lifting the base of the tail and placed on the cage lid and gently pulled 
backwards.  B: The scruff of the mouse’s neck is grasped with the thumb and 
forefingers whilst the right hand still holds the tail. C: The tail is tucked under the 
little finger of the left hand whilst the mouse’s back lies across the palm of the 
hand, manually restrained.   
 
2.2.1.3 Tail bleeding procedures 
Peripheral blood smears were prepared using a single drop of blood collected from 
one of the veins of the mouse tail. The mouse was initially removed from the cage 
by picking it up at the base of the tail and drawing it backwards into a bleeding cone 
by the tail.  The mouse tail was held firmly between the fore and middle fingers at 
the base of the cone to limit mouse movement, whilst the thumb and little finger 
held the top of the tail to prevent movement.  A small prick was then made in one 
of the tail veins using a 26Gx½ inch needle which resulted in the formation of a 
single droplet of blood.  The blood was collected in a 15 μL heparinised capillary 
tube and further blood flow from the vein was stemmed by placing a tissue over the 
needle prick and gently applying pressure until a clot formed.  The mouse was then 
returned to its cage.  
 
2.2.1.4 Intraperitoneal injection 
Intraperitoneal injections were made into the caudal left abdominal quadrant.  The 
mouse was restrained manually (Section 2.2.1.2) and the head and body tilted 
downwards.  A 26Gx½ inch needle, with the bevel facing upwards to prevent tissue 
tearing, was inserted firmly through the skin past the abdominal wall and the 
syringe contents deposited into the abdominal cavity.  During insertion, care was 
taken to note the change in tissue densities as incorrect positioning of the needle 
A B C 
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may result in the penetration of an abdominal organ and/or slow or erratic 
absorption of the injected compound (469). 
 
2.2.1.5 Cardiac puncture 
The mouse was manually restrained (Section 2.2.1.2) and injected i.p. with 200 μL of 
diluted (15 mg/mL) sodium pentobarbitone and then rested to allow the 
anaesthetic to take effect.  After 5 to 10 min mouse reflexes were tested to see if 
the anaesthetic had taken control.  Foot reflexes were tested by squeezing the back 
foot between the thumb and middle finger.  If the mouse was still conscious, this 
would result in a kicking reflex.  To test tail reflexes, the base of the tail was pressed 
firmly with the thumb.  If the mouse squeaked or flinched then anaesthetic control 
had not been obtained and the mouse was further rested.  If no response was 
observed in either reflex test, cardiac puncture procedures could continue. 
 
The mouse abdominal midpoint was determined and using surgical scissors, a small 
incision was made by lifting the skin and cutting a small hole through the fur and 
skin layers.  From this point a midline vertical incision was made to the chin.   Four 
further incisions were made, two from the primary incision radiating out to the left 
and right side of the abdominal cavity, and two incisions running left and right of 
the vertical incision at the mouse diaphragm to each forelimb, respectively (Fig. 2.2; 
A).  Using forceps, the sternum was lifted exposing the chest cavity and diaphragm.  
Using a sharp blade, a hole was made in the diaphragm resulting in the collapse of 
the lungs.  The ribs were parted by excising the sternum, exposing the heart and 
collapsed lungs (Fig. 2.2; B).  Whilst still raising the sternum with forceps, a 1 mL 
syringe with a 26Gx½ inch needle was used to harvest blood from the left cardiac 
ventricle (Fig. 2.2; C).  The vacuum within the syringe, combined with the pressure 
of the beating heart, resulted in the syringe filling with blood.   
 
A male mouse with an approximate weight of 30g has a total blood volume in the 
range of 3-5 mL.  However, for the purposes of this project, only 1-1.5 mL of blood 
was collected, preferentially in a single draw.  Once drawn, the blood was placed 
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into a paediatric citrate anticoagulant tube (Citrate 0.105M, 1 mL, BD Vacutainer) 
and mixed thoroughly. 
 
   
 
Figure 2.2 Schematic demonstrating the procedures of internal cardiac 
puncture.   A: A primary inscision was made at the abdominal mid-point,  
immediately above the external genetalia, and a vertical inscision was made to the 
mouse chin.  4 radiating cuts were made along the primary vertical incision towards 
each limb. B: The skin was pealed back revealing the abdominal organs.  To gain 
access to the heart the diaphragm was first punctured to collapse the lungs, then 
the sternum excised, revealing the cardiothorassic organs underneath.  C:  A 26Gx½ 
inch needle, connected to a 1 mL syringe, was placed in the left ventrical and the 
maximum volume of blood removed.  Organs observed in the cardiothorassic cavity 
included 1. Thyroids; 2. Esophagus; 3. Trachea; 4. Thymus; 5.  Heart; 6. Lungs.  The 
original image, sourced from (366), was modified for explanatory purposes.   
 
 
2.2.1.6 Euthanasia  
Pre-determined end points of >40% parasitaemia, >10% reduction in mouse body 
weight in less than 24 h, animal distress or the termination of the experimental 
protocol were selected and firmly adhered too in all studies.    
 
When euthanasia was required the mouse was manually restrained (Section 2.2.1.2) 
then injected with 200 μL of 15 mg/mL sodium pentobarbitone injection by i.p. 
A B C 
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administration (dose=100 mg/kg).  A further 100-200 μL of sodium pentobarbitone 
injection was administered 3-5 min later if the mouse had not expired.  Variable 
volumes of sodium pentobarbitone were administered to the mice dependant of 
age, body weight, health status and sex, all which may influence the sensitivity to 
both the desired and undesired effects of anesthetics (469).       
 
2.2.2 Parasite preparations 
2.2.2.1 Establishment of parasitaemia 
For the purpose of these investigations the murine malaria model was initiated 
from cryopreserved stock parasites.  Two BALB/c mice were initially infected with 
200 μL of thawed cryopreserved P. berghei ANKA parasites by i.p. injection (Section 
2.2.1.3). Mice were maintained and monitored daily until a significant level of 
parasitaemia had been established (>30% parasitaemia).  At this time the total 
blood volume was collected via cardiac puncture (Section 2.2.1.5).  After 
determining an accurate blood parasitaemia, the blood was diluted to a standard 
inoculum of 107 parasitised erythrocytes per 100 μL.  The standard inoculum (100 
μL) was passaged into two new BALB/c recipients to maintain constant passage of 
the infection.   
 
2.2.2.2 Parasite inoculation 
To determine parasite density within a blood sample, total red blood cell and 
parasite counts were performed.  The total number of red blood cells was 
determined using a cell count performed in a Neubauer chamber (Section 2.2.2.3) 
while parasitaemia was estimated by counting the number of parasites in tail blood 
films taken before mouse euthanasia (Section 2.2.1.6).  The volume of blood 
required for an inioculum of 107 parasites was determined using the following 
calculation.     
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* For these series of investigations a standard value of 0.004 was used, which took into 
account the counted area of the Neubauer chamber (10 squares = 0.4mm2), the chamber 
depth (0.1mm) and the dilution factor (1:100). 
 
Once calculated, the volume of blood was drawn from the anticoagulant tube into a 
positive displacement pipette and then diluted in the appropriate volume (1 mL 
blood volume) of citrate phosphate dextrose buffer (Appendix 2) and mixed 
thoroughly on a vortex.  When infecting, 100 μL of the standard inoculum was given 
to each mouse by i.p. injection. 
 
2.2.2.3 Neubauer cell counting chamber (haemacytometer) 
The Neubauer cell counting chamber has a glass-etched grid on its base to allow the 
number of cells to be accurately determined.  To determine red blood cell numbers, 
a blood suspension was prepared by diluting 10 μL of blood in 990 μL of 
formaldehyde in trisodium citrate (Appendix 2).  The blood/diluent preparation was 
vortexed then 10 μL was pipetted into the chamber and left for 5 minutes to allow 
the erythrocytes to settle.  Under x40 light microscopy, red blood cell numbers 
were counted in 10 of the inner 25 grid squares (Fig. 2.3).   
 
 
 
 
 
 
 
 
 
 
 Volume of blood  = Total RBCC 
     0.004* 
x  100  x  
% Parasites 
      100 
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Figure 2.3 Neubauer cell counting chamber.  After loading 10 μL of diluted 
blood suspension into the chamber, erythrocyte numbers were counted in 10 of the 
25 squares within the specified area (as shown by ). Using this cell total we are 
able to calculate the total number of erythrocytes per µL of blood. 
 
 
2.2.2.4 Preparation and staining of blood films 
Peripheral blood films were prepared using blood collected from one of the tail 
veins from each mouse (Section 2.2.1.3).  To prepare the blood film a single droplet 
of heparinised blood was placed at the base of a clean, labelled glass microscope 
slide.  A spreader slide was then drawn back into the blood droplet causing the 
droplet to spread across the edge of the spreader slide.  Using a smooth, 
uninterrupted movement, the spreader slide was moved away from the droplet of 
blood forming a thin blood smear.  An ideal blood smear should have an area of 
thickly stacked red blood cells at the base of the slide, and an area in which red 
blood cells are spread in a single uniform layer.   
 
All thin blood films prepared in these investigations were stained using May-
Grunwald Giemsa, a commonly used stain for the improved visualisation of malaria 
parasites.  Thin blood smears were fixed in absolute methanol for 30 sec.  The slides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 96 - 
 
were then air dried (approximately 2 min) before placing them on the HemaTek 
staining machine loaded with a 10% May-Grunwald Giemsa preparation 
(Department of Microbiology, Royal Perth Hospital, Perth, Australia).  Whilst passing 
through the staining machine each film was exposed to stain for 4 min, buffer 
solution for 3 min and a wash solution for 2 min.  The machine then dried the 
stained films by blowing air against the slide for 2 min.  Once dried, the slides were 
cover slipped using DePex as the mounting medium.    
 
2.2.2.5 Determination of parasitaemia 
Prepared blood films were stained, air dried, cover slipped with DePex then left to 
air dry for 1 to 2 days. Once dried these films were observed under light microscopy 
using a x100 oil immersion objective.  Within the eyepiece of the microscope, a 1cm 
x 1cm, 100 square graticule had been placed, allowing more accurate cell counting 
within each field of view (FOV).   
 
To determine blood parasitaemia two types of cell counting took place.  After 
selecting a section of the film that showed a uniform distribution of red blood cells, 
all red blood cells, including parasitised cells, were counted within the 100 graticule 
squares.  The total number of parasitised erythrocytes was then counted within the 
same area.  The lens was then moved upwards 1 field of view with a similar 
procedure undertaken.  This process was followed for the number of fields of view 
required (30 and 100 fields of view for parasitaemias <0.05% and >0.5%, 
respectively). Using the values obtained for total number of red blood cells and 
parasitised red blood cells in 100 squares, parasitaemia was then calculated using 
the formula below.  An accelerated method of counting was also employed when 
>30 fields of view were required to be counted.  At this time, the number of 
erythrocytes was counted in only ¼ of each FOV and multiplied by 4 to determine 
the total number of cells per FOV.  However, this accelerated method could only be 
used when the film being counted had an even distribution of red blood cells.    
 
 
 
    PRBC  
    RBCC x    100 % Parasitaemia  = 
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2.2.2.6 Parasite staging 
Studies in asplenic mice required stage-specific parasite counts (Chapter 3). 
Parasites were separated into the 4 different asexual maturation stages; ring-form, 
early trophozoite, late trophozoite and schizonts, using a pre-prepared 
identification chart (Table 2.1).  In order to numerically tally the different stages, a 
haematology differential counter was used which allowed the operator to tally each 
parasite stage separately, whilst calculating the total number of parasites counted.  
All parasite staging was performed using x100 oil immersion light microscopy.  All 
microscopy was performed by a single operator to maintain continuity and 
reproducibility of results.   
 
2.2.3 Statistical analysis 
All statistical analysis of the counting data was performed using the statistical 
computer packages SigmaStat® 2004 (SPSS Inc., Chicago) obtained from Hearne 
Scientific Software Pty, Melbourne and Microsoft Excel for Windows (Microsoft® 
Windows 2000 Professional).  From raw data the mean, standard deviation, 95% 
confidence interval and linear interpolation were determined.  Student’s t-test and 
one way analysis of variance (ANOVA) testing was also performed using the 
SigmaStat® program. A P value of <0.05 was deemed significant for all statistical 
analysis.   
 
All statistical data was plotted on a series of linear and semi-logarithmic graphs 
using the statistical program SigmaPlot® 2004 (SPSS Inc., Chicago) obtained from 
Hearne Scientific Software Pty, Melbourne.  
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Table  2.1 Asexual P. berghei parasite stages.  Examples of parasite 
morphology used for the identification and staging of P. berghei maturation stages 
(Gibbons, unpublished; based on (241)). 
 
Maturation stage Morphology Characteristics 
 
Uninfected 
erythrocytes 
 
    
Erythrocyte containing 
no intracellular parasite. 
 
Ring-form 
       
Substantial nucleus with 
a thin chromatin band 
and large vacuolated 
area. 
 
Early trophozoite 
       
Regular shape, vacuole 
beginning to retreat due 
to haematin pigment. 
 
Late trophozoite 
       
Regular or irregular in 
shape.  Vacuole half to 
completely filled with 
haematin pigment. 
 
Schizont 
       
Irregular shape with 
multiple nuclei due to 
forming merozoites.  4- 
16 nuclei. 
 
Meroizoites 
release by 
schizont rupture 
 
Erythorycte’s integrity 
destroyed as mature 
merozoites are released 
into circulation 
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CHAPTER THREE 
 
PHARMACODYNAMIC STUDY OF DIHYDROARTEMISININ  
IN AN ASPLENIC MURINE MALARIA MODEL 
 
3.1 INTRODUCTION 
3.1.1 Role of the spleen 
3.1.1.1  Function of the Spleen 
The central role of the spleen, the largest lymphatic organ of the human body, is the 
selective clearance of erythrocytes, microbes and other foreign particles from the 
blood (76, 97, 158, 313, 428).  However, the highly organised architecture of the 
spleen, consisting of lymphoid follicles (white pulp) and intervening sinusoids (red 
pulp) (Fig. 3.1), extends splenic functions to also include phagocytosis, 
immunological reactivity, haematopoiesis and platelet storage (544).  The distinct 
cellular organisation of both the red and white pulp lends itself towards their 
specific functions which are phagocytic activity and immune activity, respectively 
(303, 517, 518).    
 
The success of the red pulp as a filtering organ is due to its unique vasculature, 
where numerous filtration beds, consisting of a three dimensional network of 
branched fibroblastic contractile reticular cells, are interposed between the end of 
an artery and the beginning of a vein (71, 428, 544) (Fig. 3.2).  After filtering through 
the red pulp, where the cells are in intimate contact with immunologic effector 
cells, the blood re-enters the venous lumen by passing through inter-endothelial 
slits (IES) in the splenic sinuses.  The IES measure 1 to 3 μm and in order to pass 
from the cords of Billroth to the venous lumen, cells must be deformable with those 
unable to change shape remaining trapped in the cords of Billroth (428, 544).  Due 
to the contractility of their actin-myosin filamentous cytoskeleton, leukocytes are 
able to easily pass through the IES (303, 426).  Reticulocytes are somewhat less 
deformable than mature erythrocytes and therefore will usually spend 1 to 2 days in 
the cords of Billroth before they are sufficiently mature to resume circulation (518).     
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Figure 3.1 Schema of the spleen.  The afferent splenic artery branches into 
central arterioles, which are sheathed by white-pulp areas; these white pulp areas 
consist of the T-cell zone (also known as the periarteriolar lymphoid sheath, PALS), 
arterioles and B-cell follicles.  The arterioles end in cords in the red pulp, from 
where the blood runs into venous sinuses, which collect into the efferent splenic 
vein.  The larger arteries and veins run together in connective-tissue trabeculae, 
which are continuous with the capsule that surrounds the spleen. [Schematic and 
figure description as presented in (313)] 
 
 
Figure 3.2 Venous sinuses in the red pulp of the spleen.  Schema of a venous 
sinus located in the cords of the red pulp.  Blood from the cords collects in the 
sinuses (shown by arrows).  The venous sinuses consist of a lining of endothelial 
cells that are positioned in parallel and connected by stress fibres to annular fibres.  
Contractility of the stress fibres allows the formation of slits between the 
endothelial cells, thereby regulating the passage of blood and blood cells from the 
red-pulp cords into the sinuses and back into the venous system.  Because the red-
pulp cords contain a large number of macrophages, ageing erythrocytes that are no 
longer able to pass through the slits are phagocytosed.  [Schematic and figure 
description as presented in (313)] 
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The immune activity of the white pulp may be attributed to its architecture of 
clusters of T and B lymphocytes, mononuclear phagocytes and reticular cells.  All 
cell types have an active role in the regulation of immune function and host defence 
through antibody and cytotoxic cell production (84, 441).   When foreign bodies 
stimulate antigen presenting cells (including monocytes, macrophages or dendritic 
cells) in the marginal zone of the spleen, adaptive immune responses are most 
often initiated.  After receiving an inflammatory signal from an antigen presenting 
cell, either from the pathogen themselves or from components of the innate 
immune system responding to infection, the antigen presenting cells migrate deep 
into the white pulp and activate naïve and memory T cells which are clustered 
around the periarterial lymphatic sheath (97, 290, 497).    The T lymphocytes are 
then responsible for the generation of an immunological defence against the 
foreign organism (428). 
 
3.1.1.1.1Removal mechanisms of intraerythrocytic bodies 
To maintain a healthy population of circulating erythrocytes, the spleen removes 
those with reduced deformability, IgG sensitisation and those containing 
intraerythrocytic particulate material by three distinct processes  (312, 428, 517). 
(1)  Phagocytic mechanisms due to IgG sensitization of erythrocytes (428, 
544). 
(2) Trapping of deformable erythrocytes in the cords of Billroth (97). 
(3) Removal of intracellular particles through splenic pitting mechanisms 
(20, 289, 312, 346, 428).    
 
3.1.1.1.1.1 Splenic pitting 
The complex architecture of the cords of Billroth results in a reduced blood flow 
through the red pulp which creates a hypoxic, hypoglycaemic environment, that is 
lethal to aged erythrocytes or those with damaged membranes (544).  The reduced 
blood flow through the cords is also important for phagocytosis as it prolongs the 
exposure of erythrocytes to the splenic macrophages, increasing the time for 
detection of surface antibodies or intraerythrocytic inclusions.  Once detected by a 
macrophage, it is thought that attachment between the erythrocyte and 
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macrophage occurs and the inclusion/antibody is removed along with their cell’s 
outer membrane, in a process known as splenic pitting (312, 428, 544).  Although 
this is the most accepted theory, another pitting mechanism has been suggested in 
which pitting occurs whilst the cell is attempting to traverse the IES.  In this 
mechanism, erythrocytes containing intracellular bodies attempt to cross the IES, 
however, they become stuck with the healthy portion of the cell through the IES 
and the intracellular body on the cord side.  It is at this stage that the body is 
‘pitted’ from the cell by splenic macrophages or other phagocytic cells (290, 426).  
Either way, it is believed that the erythrocyte, from which the inclusion was 
removed, is then returned to the circulation and continues its normal circulatory 
functions albeit possessing a slightly more fragile membrane.  The most commonly 
removed intracellular bodies in this process include Pappenheimer bodies, Howell 
Jolly bodies, Heinz bodies and mature or damaged malarial parasites (290).      
 
3.1.1.1.1.2 Immune response 
Although the precise protective mechanisms of the spleen are not completely 
elucidated, as the body’s largest lymphoid organ it is a major site of antibody 
production (428, 453).  Extensive research  has provided valuable evidence that in 
both humans and animals the spleen clears erythrocytes and foreign matter, 
through both rheological and immunological means (453).  However, the precise 
processes involved in the production of antibodies towards malaria parasites is yet 
to be conclusively identified (289, 497).  The most accepted theory is that in the 
removal of erythrocytes with particulate material, the immunological process of 
opsonisation occurs, this being the alteration of target cells to aid in more effective 
and efficient removal.  This involves the binding of IgG antibodies to the surface of 
an erythrocyte containing particulate material. When opsonisation occurs, the cell is 
detected by splenic macrophages and circulating neutrophils and is removed by 
phagocytosis (97, 123, 194, 221, 240).   
 
3.1.2 Removal of malaria parasites 
As the majority of asexual Plasmodium parasites dwell within erythrocytes and 
reticulocytes, the spleen plays a central role in host defence.  This occurs through 
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the elimination of parasites by recognition of altered erythrocyte deformability 
after parasite invasion,  IgG sensitization of erythrocytes as due to the insertion of 
foreign antigens into erythrocyte membranes, modulating parasite antigen 
expression as well as cellular and humoral immune responses of the host (221).   
 
Recent studies in humans suggest that during both acute and chronic malaria 
infections the splenic structure, cellular composition and function may change, 
which appears to be of increasing importance in the stimulation of both rheological 
and immunological functions of the spleen (137, 289, 290, 518). During the course 
of a malaria infection, increased numbers of parasite-specific antibody forming cells 
have been detected in the spleen.   It was observed that the total population of T-
cells (which are native to the white pulp) increased, resulting in a heightened rate of 
immune reactivity against the parasites.  It was also recorded that there was a 
marked increase in the number and function of splenic macrophages, cytokines 
produced by CD4+ T cells and other lymphocytes present within the red pulp (20).  
These findings suggest that there was an interrelationship between the observed 
stimulation and activation of splenic components and the presence of increased 
parasitic load within the host circulation (20).  
 
3.1.2.1 Splenic pitting mechanisms 
Studies using P. falciparum suggest that the elimination of mature parasites from 
the peripheral circulation involves two spleen dependent processes, with the 
primary process very similar to the sequestration mechanisms used to protect 
parasites against removal.  The primary process involves the adherence of 
erythrocytes containing mature stage parasites (parasitised red blood cells; PRBCs) 
to capillary and post-capillary venular endothelium through interactions between 
receptor molecules on the endothelium and parasite ligands found on the surface of 
the infected erythrocyte (20, 97, 347).  The parasite ligand ring-infected erythrocyte 
surface antigen (RESA) is associated with the dense granules of the merozoite which 
is deposited in the erythrocytic membrane during cell invasion and is therefore 
present from an early stage of parasite maturation (290).  Late stage parasites, such 
as trophozoites and schizonts, insert PfEMP1 neoantigens into the erythrocyte 
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exterior membrane.  Both of these parasite antigens act in parasitic antigenicity and 
as ligands mediating the attachment of the cell to venule endothelium (290).  
Adherence of PRBCs to the endothelium stimulates a secondary process leading to 
their removal from the peripheral blood through splenic clearance mechanisms 
after the detection of the endothelium-ligand interactions (20, 129).  Further 
evidence supporting these mechanisms was obtained in human studies using radio-
labelled infected erythrocytes which demonstrated that the spleen removes both 
infected erythrocytes and those sensitized by IgG via the two spleen dependent 
mechanisms (96).  
 
Studies in the 1960s suggested that the spleen could remove intraerythrocytic 
parasites leaving the host cell intact through splenic pitting, however, parasite 
clearance in human malaria was previously considered to be through the obligatory 
destruction of the parasitised erythrocyte (96).  The theory of splenic pitting was 
further demonstrated by Chotivanich et al. (96) who used immunofluorescent 
staining with antibodies against P. falciparum ring-infected erythrocyte surface 
antigen (RESA) to show an increase in the number of circulating erythrocytes that 
detected positive to RESA (showing parasitisation) but did not contain an 
intracellular parasite (290).  These results clarified that splenic pitting was the main 
route of removal of circulating parasites after antimalarial therapy, which also 
explains why after drug treatment in some patients with hyperparasitaemia, the 
parasite count falls dramatically but the red blood cell count remains stable or only 
slightly depressed (20, 96, 321).    
 
Despite the observed stability in red blood cell counts after treatment with 
antimalarials, severe anaemia is one of the most lethal complications, particularly in 
children, with P. falciparum infection (133, 399, 528).  However, it is recognised that 
the anaemia of malaria is multifactorial (316).  Various studies describe potential 
mechanisms for malarial related anaemia including increased surface IgG (528), 
deficiencies in complement regulatory proteins CR1 and CD55 potentially leading to 
complement mediated lysis (468, 528), increased red blood cell susceptibility to 
phagocytosis (3, 399, 528) and insufficient erythropoesis (87) to name a few.  
- 105 - 
 
Although the precise mechanism of malaria related anaemia is unknown, it is widely 
acknowledged that loss of parasitised erythrocytes does not account for the degree 
of anaemia seen in many patients (316, 399).  In fact, a population based study 
demonstrated that whilst 18% of patients (750 of 4,007) in Thailand presented with 
anaemia, the loss of parasitised red blood cells only accounted for <10% of the 
overall blood cell loss (399).   
 
3.1.2.2 Immune response 
In malaria infections the protective immune response stimulated in the spleen may 
be demonstrated by observation of an increased susceptibility and severity of 
infection observed in splenectomized animals (154, 156, 401).  Immunity provided 
by the spleen appears to be directed mainly against intraerythrocytic parasites.  
Recent studies have demonstrated that splenectomy does not affect host 
susceptibility to sporozoite-induced infections or the development of the 
subsequent exoerythrocytic stages of the parasite (453).  The mechanisms of 
immunological protection against malaria infections are not well understood, but it 
is suggested that the spleen is the major site of production of protective antibodies, 
immune defence and the production of antiparasitic antibodies during malarial 
infections (60, 70).   
 
While the natural resolution of a malaria infection is highly dependent on the 
rheological removal mechanisms of the host, the presence and activity of 
antimalarial antibodies is also thought to be of major importance (518).  There is 
evidence that parasitised erythrocytes, particularly those that harbour multiple 
parasite stages, bind a specific antibody on the infected erythrocyte membrane.  
The antimalarial antibody, an IgG isotype, results in the increased recognition of the 
infected erythrocytes to cytotoxic T cells and phagocytic macrophages, leading to 
the removal of the parasite through phagocytic processes (240).  Phagocytosis of 
parasite debris and parasitised erythrocytes has also been demonstrated in antigen-
presenting cells, including macrophages, monocytes, and dendritic cells, in the 
marginal zone of the spleen which may also stimulate adaptive immune responses 
(453).   Evidence from animal models also shows the importance of the host’s 
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defence against malaria infections.  Antigen presentation and recognition during 
the initial infection occurs primarily in the splenic macrophages with the spleen 
continuing to play an important role in the immune responses of the host until cure 
or death (62, 303, 426). In experimental investigations performed by Hunter and 
colleagues (233), the process of opsonisation and subsequent phagocytosis was 
observed in vitro using a model of P. berghei schizont-infected erythrocytes and rat 
macrophages.  It was suggested that the findings in the experimental procedure 
could be correlated with processes observed in the clearance and organ 
sequestration of parasitised cells in vivo (124).    
 
3.1.2.3 Parasite defence mechanisms to splenic clearance 
In order to both maintain and increase parasite biomass in the infected host, P. 
falciparum parasites have developed defence mechanisms to prolong the survival 
time of the parasite within the human host by allowing the parasite to mature and 
reach schizogony (97).  Referred to as parasite sequestration, mature P. falciparum 
parasites insert neoantigens into the surface of the infected erythrocyte which 
enables them to avoid passage through the splenic cords. Of the four established 
human malaria parasites, P. falciparum is the only species which has defended itself 
from splenic clearance by sequestration, and as a result is the parasite species 
responsible for the majority of severe malaria deaths (221).   
 
Throughout its asexual blood stage cycle the P. falciparum parasite decreases the 
possibility of detection through maintenance of erythrocyte membrane integrity or 
as it matures, insertion of neoantigens into the erythrocyte membrane (129). The 
immature ring-form parasite, present in the first 6–8 h of the blood stage cycle, has 
a small, soft morphology that does not perturb the erythrocyte membrane 
configuration or express parasite antigens on the erythrocytic membrane.  
Consequently, the invaded erythrocyte maintains its integrity and avoids detection 
or recognition by the splenic macrophages (129, 221).  As the parasite matures, the 
young flexible form develops into a larger more rigid parasite that is more likely to 
cause damage to the host cell function and membrane integrity.  These changes 
increase the likelihood of recognition by the host’s sensitive defence mechanisms.  
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To compensate for its increased susceptibility, the parasite inserts specific 
neoantigens (including P. falciparum RESA and PfEMP1) into the host erythrocyte 
cell membrane forming electron-dense protrusions on the surface of the host 
erythrocytes (129).   
 
Through interaction of the specific parasite ligand and endothelial receptors, the 
parasitised erythrocytes have the ability to cytoadhere to the vascular endothelium, 
particularly in organs such as the brain, heart and kidney (20, 97, 346).  
Consequently, the parasitised erythrocytes anchored to the epithelium do not pass 
through the splenic filtration system, thereby reducing the likelihood of their 
detection and removal from the host.  Such deep vascular sequestration is thought 
to be a major factor in the beginning of vital organ dysfunction and may also 
contribute to the rapid development of anaemia in the host (97).   As a result of 
sequestration in P. falciparum infections, only ring-form parasites may be observed 
in the peripheral blood (320).   If damage occurs to the malarial parasites during 
their life cycle, usually due to antimalarial therapy, the parasites’ host defence 
mechanisms will be affected leading to their rapid detection by splenic 
macrophages and roving phagocytic cells resulting in their subsequent removal 
(320).   
 
3.1.3 Effect of Splenectomy 
As the spleen is a soft encapsulated organ it remains relatively unprotected within 
the abdominal cavity.  Consequently, the spleen is the most common intra-
abdominal organ to be injured, often requiring its removal in an attempt to stem 
internal bleeding (62).  Whilst low velocity blunt trauma, most often due to 
domestic violence, assault or automobile accidents is the primary cause for 
splenectomy, splenic removal may also be required in cases of splenomegaly or 
cellular damage as a result of infection, inflammation or invasion by cancer cells (36, 
62, 289, 517, 542). 
 
Although the filtration and immune responses of the spleen are important in the 
regulation of homeostasis, the life expectancy of a person may not be impaired 
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after splenectomy (331).  Currently, the only documented consequences of 
splenectomy are related to immune function and a decrease in immunity (69, 195, 
290).  Surgical removal of the spleen has been shown to result in a reduced 
clearance of particulate antigens, be they intracellular (malaria) or extracellular 
(bacteria); diminished response to new antigens, particularly polysaccharides; 
impaired phagocytosis of unopsonized and opsonized bacteria and cells; and 
decreased levels of tuftsin and poperdin (246, 447, 517).  Although lymphoid organs 
involved in immune defences remain (eg. lymph nodes), the response time to 
invading bacterial or pathogenic bodies is delayed.  This may result in a 
splenectomized patient having a far more severe and sometimes life-threatening 
infection, which before splenectomy may have been quickly resolved (97, 240).  
Blood filtration, once a major function of the spleen, is compensated for by the liver 
where Kupffer cells (perisinusoidal macrophages) undertake the majority of 
phagocytic activity.  After splenectomy, it may be histologically observed that the 
number of circulating macrophages and Kupffer cells increase as a splenic 
compensatory mechanism.  Although splenectomy results in the prolonged 
circulation of many foreign bodies or damaged cells, these inferior bodies will 
eventually be removed through phagocytosis within the liver (97).   
 
3.1.3.1 The effect of splenectomy and malaria infection 
During malaria infections the absence of a functioning spleen results in reduced 
immunological and rheological mechanisms necessary for parasite removal, with 
high parasite counts observed in asplenic patients up to several months after drug 
therapy (97, 290, 497).  Morphological studies, observing the circulating parasite 
population, suggested that the majority of parasites remaining in the circulation 
were (in most cases) no longer considered viable, thereby reducing the risk of 
further infections with these parasites (97).  These studies were based on 
microscopic comparisons of drug affected parasites and those not exposed to any 
drug.  The results showed an identifiable change in parasite shape, density and 
structure.  It was found that the shapes of the persistently circulating drug affected 
parasites in asplenic patients were similar to those of parasites detected in an in 
vitro cell culture exposed to the antimalarial artesunate.  The morphological 
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changes in the parasites included a shrunken cytoplasm, rapidly expanding vacuoles 
and pyknotic nuclei, which were highly suggestive of a degenerative process directly 
resulting from the effects of the antimalarial drugs on the active parasites.  It was 
concluded that although the parasites were present, they were no longer viable 
(97). 
 
It has also been shown that during malaria infections in monkeys (particularly P. 
knowlesi (138, 221), P. falciparum (45, 123, 221)  and P. fragile (5, 34, 138, 240)) the 
spleen is essential for maintaining the expression of parasite antigens on the 
surface of the infected erythrocytes, including those cytoadherent ligands that are 
essential for parasite sequestration (449).  These studies have demonstrated that 
the parasite antigens are not present on the erythrocytic membranes in 
splenectomized animals and as a result the infected cells from splenectomized 
animals are unable to sequester in vivo and do not bind to endothelium or 
melanoma cells in vitro.  However, the ability to cytoadhere and express surface 
antigens is restored when these parasites are passaged into intact hosts (449).  A 
number of clinical cases also correlate with the animal findings as in these malaria-
infected splenectomized patients all intraerythrocytic developmental stages were 
observed in the  peripheral blood smears suggesting that the mature parasites are 
not sequestering (5, 34, 138, 240, 290). This may imply that the parasite has the 
capacity to determine whether or not it is required to activate its defence 
mechanisms dependant on the state of splenic clearance.  Although this possibility 
has not been investigated further it could be an important observation, especially 
when considering new drug developments, as a lack of sequestration may result in a 
decreased mortality from cerebral malaria.   
 
3.1.3.2 Asplenic model of malaria infection 
In experimental and naturally occurring malaria models, splenectomy has been 
found to have an adverse effect on the host’s defence against infection, in that 
normally non-lethal infections become lethal and P. falciparum infections are 
always a life-threatening disease (401).  The splenectomized host is also abnormally 
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prone to other health issues including meningitis, septicaemia and pneumococcal 
infections (401).   
 
In studies performed in a splenectomized murine model, hosts with innate 
resistance to infection became susceptible, transient infections became lethal and 
there was a loss of immunity (290).  Consequently, Eling (155) concluded that the 
spleen should be considered essential for the resolution of an acute malaria 
infection or, at least for the induction phase of immunity, to both the avirulent and 
virulent malaria parasites.  This conclusion was more recently challenged based on 
several experimental studies performed in Saimiri monkeys and clinical cases (401, 
449, 542) where it was suggested that the spleen is not essential for the resolution 
of malaria infections.  In a primate experimental model Pye et al. (401) used a total 
of 31 monkeys, of which 6 were splenectomized.  Each monkey was infected with 
an inoculum of 107 parasites of the Indochina 1/CDC malaria strain of P. falciparum.  
Results demonstrated that the splenectomized monkeys had higher peak 
parasitaemias and longer duration of detectable parasitaemia (about 20 days) 
compared to intact monkeys, which had parasite duration of 11–14 days.  In the 
splenectomized population several of the animals required treatment with 
mefloquine when their parasitaemia exceeded 10% of the total erythrocyte count.  
Mefloquine treatment was not required for any of the intact monkey population, to 
aid in parasite resolution (290).  The researchers reported an interesting and 
unexpected observation in the splenectomized monkey population in that a number 
of the animals resolved their infection without antimalarial drug intervention.  This 
indicated that the initiation of effective antimalarial immune responses were 
independent of the spleen (62, 124, 290).  The observations made by Pye et al. 
(1994) were further supported by studies conducted in patients with P. falciparum 
infections (124).  In the human studies the humoral and cellular immune responses 
to blood-stage antigens in splenectomized patients were similar to those individuals 
with spleens.  Thus, the spleen may not be essential for the processes leading to 
parasite clearance in partially immune, splenectomized patients (449, 542).  It may 
therefore be suggested that the involvement of the spleen in the resolution of 
malaria infection is important but not essential.   
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To date only a limited number of case studies describing the pharmacodynamic 
response to antimalarial therapies in the asplenic patient have been referenced (34, 
62, 138, 194, 240, 290, 432, 449, 497).  However, despite similar antimalarial 
therapies being used, the parasitological responses described after antimalarial 
therapy are inconsistent and often contradictory. For example, Thu et al. (497) 
described an asplenic patient who presented with a moderately severe malaria 
infection.  Despite intensive antimalarial therapy over a period of 18 days, including 
the use of oral mefloquine (1 dose), oral artemisinin (6 doses), i.v. artesunate (2 
doses), i.v. quinine (9 doses) and oral quinine (12 doses), a rapid elimination of 
parasites was not observed until 13 days after the initiation of antimalarial therapy, 
with eventual resolution of infection 18 days after the initiation of therapy (in a 
patient with a functional spleen expected resolution of infection would be no more 
than 7 to 10 days with the use of only one of these antimalarial drugs) (497).  The 
conclusion of this clinical case, as with other cases (138), was that the prolonged 
parasitaemia was a direct result of the patient’s asplenic status.  In contrast, further 
clinical cases have demonstrated the clearance of asexual parasitaemia and 
parasitological recovery from infection after a normal duration of antimalarial 
therapy (34, 194).  In fact, using similar antimalarial regimens, Bach et al. (34) 
determined in 33 splenectomized individuals that although asplenic status resulted 
in an increased susceptibility to malaria infection, it did not contribute to the clinical 
outcome of infection (34).  The variability of clinical outcomes described in 
splenectomized patients could potentially be the result of a number of factors 
including; prior immunity to the infecting parasite species, infection with drug 
resistant parasites, selected antimalarial therapy, other pre-existing health 
problems (including haemoglobinopathies), concurrent bacterial or viral infections 
and/or the initial level of parasitaemia.  
 
Therefore, although it is acknowledged that comparison of human and animal 
responses to a particular disease process should proceed with caution, there are 
several explanations for the parasitological responses in animal species and human 
infections to differ so significantly.  Firstly, the apparently contradictory outcomes 
described in the range of case studies in splenectomized patients are compounded 
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by the small number of patients in each report.  The largest cohort of 
splenectomized patients studied for parasitological response was 33 patients with 
the majority of conclusions drawn from single case studies, from a wide range of 
clinical manifestations and different patient ethnicities (34, 194, 290, 432, 497).  By 
contrast, animal models are generally more consistent.  Unlike the clinical setting, 
most aspects of infection and antimalarial therapy within animal models are tightly 
controlled to ensure consistency and reproducibility of results.  For example, within 
an animal laboratory the researcher is able to guarantee infection with a single 
parasite species, a standardised infecting inoculum, a similar level of parasitaemia 
at the time of drug administration, constant environmental influences, controlled 
diet and perhaps most importantly, maintenance of a pathogen-free environment 
to eliminate the possibility of concurrent infections that may alter the course of 
antimalarial therapy.  Animal models also have the capacity to involve large 
numbers within each cohort, which is often not feasible in the clinical setting, 
particularly when studying a specific population.   
 
Secondly, in clinical case studies where delayed parasite removal is noted in 
splenectomized patients (497), the parasitaemia observed in the peripheral 
circulation after antimalarial therapy may include dead or drug affected (non-viable) 
parasites that are still present as a result of the patient’s asplenic status (96, 97).  
Case studies generally fail to indicate whether such a factor was taken into account 
when determining the peripheral parasitaemia, and even if considered, 
differentiating the microscopic changes to parasite structure when affected by 
antimalarial drugs is only reliable if undertaken by an experienced microscopist.  
Therefore, it is possible that in the case studies where a delayed parasitaemia was 
observed, the majority of parasites were killed by early antimalarial therapy but 
their removal from circulation was delayed.  If this were the case, parasitological 
and clinical recovery in the splenectomized patients could have occurred 
significantly earlier than indicated in the report and if so, the results in these case 
studies could be similar to results described in animal models.  It is also possible 
that in the absence of a spleen, the compensatory clearance mechanisms of the 
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liver, observed in simian and rodent models are not as significant, or rapidly 
achieved, in the human host.   
 
3.1.3.3 Antimalarial treatment strategies 
Compared to normal individuals, asplenic people living in malaria-endemic areas are 
more commonly parasitaemic, and have a delayed clearance of parasites after 
treatment (542).  In addition, an asplenic status can result in a malaria infection 
being more severe or even fatal (241).   Ideally, splenectomized individuals living in 
endemic areas should take lifelong antimalarial prophylaxis and be immunized 
against pneumococcal infections, but this is often difficult and prohibitively 
expensive (87, 388, 543).  If the person lives in the tropics, but in an area of low 
transmission (such as the highlands), malaria prophylaxis must be taken when they 
plan to travel into an endemic zone (489).    
 
3.1.4 Study Aims 
The principal aim of this study was to evaluate the effects of DHA in asplenic and 
intact mice infected with P. berghei. Histopathological examination of key organs 
was also performed to investigate the role of the liver, and other key organs, in the 
removal of parasites after DHA treatment in this murine model.  
 
3.2 METHODS 
3.2.1 Materials 
3.2.1.1 Mice 
This study was approved by the Curtin University Animal Experimentation Ethics 
Committee.  Male Swiss mice (5 to 6 weeks of age; average weight 29.5 ± 3.3 g) 
were obtained from the ARC for all experimental work.  Male BALB/c mice (7 to 8 
weeks of age; ARC) were used for weekly passage of malaria parasites.  All animal 
handling and housing procedures were performed as outlined in Sections 2.1.1 and 
2.2.1.    
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3.2.1.1.1  Splenectomy procedures 
All splenectomy procedures were performed by registered veterinarians at the ARC 
on 3-5 week old mice.  After surgery all mice were observed for a period of 2 weeks 
at the ARC laboratories before delivery to the Curtin University Animal Holding 
Facilities.   
 
3.2.1.2 Parasites 
P. berghei ANKA parasites were maintained by continuous weekly blood passage in 
BALB/c mice (Section 2.2.2.1).  A standard inoculum of 107 parasitised erythrocytes 
per 100 μL was prepared by dilution of blood harvested from infected BALB/c mice 
(>30% parasitaemia) in citrate-phosphate-dextrose solution (Section 2.2.2.2) and 
administered by i.p. injection to infect the experimental mice (Section 2.2.1.4).     
 
3.2.1.3 Drug preparation 
DHA (Dafra Pharma N.V., Belgium) was used for all antimalarial therapy 
experimental procedures.  All drug doses were prepared by dissolving the DHA 
powder in a solution of 60% dimethyl sulfoxide (DMSO) in polysorbate 80 (Tween 
80).  In order to ensure all DHA powder was completely dissolved and evenly 
distributed, the drug solution was sonicated for 1-2 min to break down any large 
particles and aid in dissolution.   When completely dissolved, the drug solution was 
drawn into 1 mL syringes for administration using a 26Gx½ inch needle.    
 
3.2.2 Study Design 
3.2.2.1 Single dose pharmacodynamic study 
As clinical case reports show a delayed clearance in peripheral parasitaemia in 
asplenic patients, the basis of this investigation was to determine if a single dose of 
DHA would lead to the successful clearance of parasitaemia in asplenic mice.  The 
aim of this study was therefore to compare the pharmacodynamic response of 
subtherapeutic doses of DHA in malaria-infected intact and asplenic mice.  
 
 Asplenic (n=32) and intact (n=32) mice were inoculated with 107 P. berghei 
parasites. Groups of asplenic (n=8) and intact (n=8) mice were given DHA 
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approximately 56 h after inoculation (anticipated parasitaemia 2-5%, confirmed by 
thin blood film examination) at doses of 0, 10, 30 and 100 mg/kg (Fig. 3.3).  
 
 
 
 
 
 
 
Figure 3.3 Schematic simplifying the experimental protocol for the single dose 
pharmacodynamic study.   1.   Naive asplenic (n=32) and intact (n=32) mice were 
inoculated with 107 P. berghei parasites;  2.  Mice were left for a period of 56 h at 
which time the peripheral parasitaemia was expected to reach 2-5%; 3.  Mice were 
broken into 4 groups of n=8 mice.  Each group of mice received a single dose of DHA 
(0, 10, 30 or 100 mg/kg) by i.p. injection.  Parasitaemia was then monitored through 
the preparation of regular peripheral blood smears.   
 
To monitor peripheral parasitaemia, tail vein bleeds were performed every 4 h for 
the first 52 h after drug administration, then twice daily until the time of euthanasia 
(>40% parasitaemia).  Peripheral blood smears were prepared after each tail vein 
bleed.  Once air dried, each smear was stained with May Grunwald Giemsa then 
observed under 100x oil immersion microscopy.   In addition to determining total 
parasitaemia, parasites were classified into the four erythrocytic maturation stages 
(Fig. 3.4; ring-form, early trophozoite, late trophozoite and schizont) according to 
guidelines from Leiden University Medical Centre (24). 
 
  
 
    
 
    
 
      
Figure 3.4 Maturation stages of P. berghei parasites during the asexual 
erythrocytic cycle. (A) ring-form; (B) early trophozoite; (C) late trophozoite; (D) 
schizont. 
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3.2.2.3 Histopathological study 
Although P. berghei parasites are known to not sequester in the Swiss mouse 
model, mature stage parasites cause disruption to the host erythrocyte surface 
membrane causing it to become rigid and unable to easily transverse the 
microcirculations of organs, particularly in cases of high parasite density (97, 158).  
Furthermore, it would be expected that those organs that perform a blood filtration 
function would demonstrate a higher presence and density of parasites.  As the 
spleen is the primary organ for the filtration of blood, with selective removal of 
infected cells, it would be expected that this organ would demonstrate the greatest 
presence of parasites throughout the stages of P. berghei infection.  However, as 
the asplenic host does not have the capacity to remove the parasites through 
splenic ‘pitting’ or phagocytic mechanisms, it would be presumed that either 
another organ may perform this function or there would be a lack of parasite 
removal after drug therapy.  Therefore, the purpose of this investigation was to 
determine the parasite presence and distribution of P. berghei parasites, 
throughout the course of malaria infection, in treated and untreated intact and 
asplenic mice.  After consideration of the function and microcirculation properties 
of each of the major organs, the liver, spleen, lung and kidney were all selected for 
observation.   
 
To observe the distribution of parasites throughout different stages of P. berghei 
infection, time-points were selected to reflect situations of light, moderate and 
heavy infections as well as key time-points such as the time of drug administration 
in drug treated mice.  Two series of mice were investigated in parallel.  The first 
series of mice (Group A; n=24) consisted of untreated intact and asplenic mice 
where groups (n=4) were euthanized and organs harvested at 0, 36, 56, 76, 96 and 
168 h after inoculation.  A second series (Group B; n=12) of intact and asplenic mice 
were given a single i.p. dose of 30 mg/kg DHA 56 h after inoculation and groups 
(n=4) were euthanized 76, 96 and 168 h after inoculation for organ examination 
(Fig. 3.5).  
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Figure 3.5 Schematic simplifying the experimental protocol for the 
histopathology study.   1.   Naive asplenic (n=36) and intact (n=36) mice were 
separated into 2 groups, Group A (untreated mice; n=24) and Group B (DHA treated 
mice; n=12);  2.  All mice in Group A and Group B were inoculated with 107 P. 
berghei parasites; 3.  Group A mice were broken into 6 groups of n=4 mice which 
were euthanized and specific organs harvested at 0, 36, 56, 76, 96 and 168 h after 
parasite inoculation; 4.  Group B mice were left for a period of 56 h (peripheral 
parasitaemia 2-5%) at which time each mouse received a single dose of 30 mg/kg 
DHA;  5.  Group B mice were broken into 3 groups of n=4 mice which were 
euthanized and specific organs harvested at 76, 96 and 168 h after parasite 
inoculation (20, 40 and 112 h after DHA treatment).  
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At the designated time of organ harvesting each mouse was euthanased by a single 
i.p. dose of sodium pentobarbitone (Section 2.2.1.6), which was carefully injected as 
to not perturb or damage any abdominal organs.  A slightly higher dose of sodium 
pentobarbitone was used in this investigation as it is normal practice to harvest the 
blood volume of the mouse via cardiac puncture and it is desirable to anesthetise 
the mouse, but not interfere with cardiac function. However, in this experiment, no 
blood was harvested from these mice before organ harvest (as to preserve the 
natural distribution of parasites within each of the organs) so a higher dose of 
sodium pentobarbitone was used to ensure prompt cessation of cardiac and 
respiratory function.  Once it was determined that the respiration of the mouse had 
ceased, organ harvesting was performed. 
 
To remove the organs from the mouse without causing unnecessary damage, the 
abdominal cavity was opened as previously described for performing internal 
cardiac punctures (Section 2.2.1.5).   Using sterile surgical equipment, each organ 
was removed in its entirety, washed in 0.9% NaCl solution to remove external 
contaminants, weighed and then observed macroscopically.  The organ was then 
placed in a vial containing a solution of 10% formalin in 0.9% NaCl for fixation. Due 
to their small size, the spleen, heart and kidney were able to be fixed in their 
entirety, however, in order to ensure complete and adequate fixation a single lobe 
of liver (left lobe) was selected for fixation.  As the malaria infection progressed, 
splenomegaly was seen to occur and in many cases only half of the spleen was 
placed into fixative to ensure adequate fixation.  
 
When preparing organs for histological fixation it is common practice to perfuse the 
organs with fixative before they are removed from the animal, to minimise the 
alteration of cell structures as a result of post-mortem effects (426).  However, for 
this study perfusion was deemed unsuitable because forcing the fixative into the 
organ would disrupt the natural distribution of parasites.  Therefore each organ was 
promptly processed and placed in fixative. 
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3.2.2.3.1  Histology 
After removal from the body, each organ remained in fixative until histological 
processing took place (a maximum of 6 months after harvesting).  For histological 
preparation the organs were dehydrated in increasing concentrations of alcohol (70 
to 100%) and finally embedded in paraffin blocks.  The histological preparation took 
place using a Shandon Hypercenter XP enclosed tissue processor (Thermo Fisher 
Scientific, Scoresby, Victoria, Australia).  Each organ section was removed from its 
fixation vial and placed in a cassette which was then loaded into the processing 
racks.  When all samples were loading into the processing racks, these racks were 
inserted into the processor and the cycle initiated.  The purpose of the processing 
cycle was to remove all of the fixative from the tissues through dehydration and 
replacing it with molten paraffin.  This was achieved by taking the samples through 
cycles of increasing concentrations of ethanol, then xylene and finally molten 
paraffin.  The schedule followed during this process was as outlined in Table 3.1. 
 
Table 3.1  Cycle Schedule for the Shandon Hypercentre XP Enclosed Tissue 
Processor. 
 
SOLUTION TIME 
  70% Ethanol  2 h 
  90% Ethanol 2 h 
100% Ethanol 1 h 
100% Ethanol 2 h 
100% Ethanol 2 h 
Xylene 2 h 
Xylene 2 h 
Paraffin wax 2 h 
Paraffin wax vac 2 h 
Paraffin wax vac 30 min 
Paraffin wax vac 30 min 
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Once tissue processing was completed the samples were ready for embedding into 
paraffin blocks.  Embedding took place using the Tissue embedding Centre (Electron 
Microscopy Services, Hatfield, PA, USA).  Solid paraffin was placed in the thermal 
and dispensing consoles and the temperature gauges set to 65oC to ensure a 
smooth consistency.  The embedding plate was cleaned to remove all foreign 
contaminants and the cold plate switched on. When all solid paraffin was melted in 
the thermal and dispensing consoles the tissue cassettes containing processed 
organ samples were removed from the tissue processor and placed into the wax 
bath.  Plastic paraffin embedding cassettes (25 mm diameter) were used to set the 
organ sections.  The organ sections were embedded using the following process: 
1.  A plastic embedding cassette was labelled using a 2B pencil and placed on 
the cold plate facedown and molten paraffin dispensed into the cassette to 
a height of 2–3 mm. 
2. The organ section was placed into the molten paraffin with the cutting 
surface placed facing down. 
3. Liquid paraffin was then slowly dispensed into the cassette as to 
completely cover the organ section and fill the plastic cassette. 
4. Once filled the cassette was left to set on the embedding plate. 
 
This process was followed until all sections were embedded in cassettes and the 
paraffin set to solid wax.  Each cassette was then stacked in cardboard storage 
boxes and placed in a cool dark room until time of cutting.  
 
Tissue sectioning took place using a Leica rotary microtome (Leica Microsystems, 
Gladesville, NSW, Australia) with tissue sections floated on a Leica temperature 
controlled waterbath (Leica Microsystems, Gladesville, NSW, Australia).  Blocks 
were mounted on the microtome and roughly trimmed at 10 μm sections until a 
good clean tissue face was achieved.  Once trimmed, the trimming blade was 
replaced with a cutting blade, which was thoroughly cleaned and inspected for nicks 
which could tear the delicate tissues.  Before sectioning, the steel cutting plate was 
chilled using ice cubes to ensure the thin paraffin sections would not stick to the 
plate. Each block was then sectioned in serial 4 µm slices which consisted of 10 to 
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15 slices of tissue. The tissue ribbons were gently picked up using steel forceps and 
floated in a sectioning water bath set at 30oC. The cut ribbon was floated on the 
heated distilled water until the tissue sections had re-expanded to their original 
shape and size at which time each section was separated and mounted on a clean 
glass slide. All mounted sections were air dried overnight.   
 
After 12 h of air drying, to ensure section stability on the slide, the sections were 
prepared for staining in Haematoxylin and Eosin. The prepared slides were first 
placed in a drying oven set at 60oC for 45 h to melt excess paraffin wax surrounding 
the tissue sections.  The sections were then ready for deparaffinization and staining 
following the procedure outlined in Table 3.2. 
 
Table 3.2 Haematoxylin and Eosin staining procedure (Note: Times were 
variable depending on organ section requiring staining) 
SOLUTION TIME 
Xylene 1 min 
100% ethanol 1 min 
95% ethanol 1 min 
80% ethanol 1 min 
Deionised water rinse (> 30 sec) 
Haematoxylin 5 min 
Deionised water rinse 
Scott’s tap water 5-10 dips 
0.3% Acid ethanol 5-10 dips 
Deionised water rinse 
Eosin 3-5 min 
80% ethanol 30 sec 
95% ethanol 30 sec 
100% ethanol 30 sec 
Xylene > 30 sec 
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Once stained in Haematoxylin and Eosin the tissue sections were left to air dry then 
cover-slipped using DePex as the mounting medium.  The slides were then placed 
on a flat surface for 24 h to allow the mounting medium to dry at which time the 
slides were stored in designated slide storage trays.  Organ sections were examined 
under oil immersion light microscopy for parasite visualization and evaluation of 
tissue morphology. 
  
3.2.2.3.2 Haemozoin quantification 
Several methods have been described for the detection of haemozoin in blood and 
tissues, including microscopy, spectrophotometry, fluorescence and 
chemiluminescence (215, 271, 328, 419, 470, 511).  However, although microscopic 
techniques have been further advanced in more recent years, it remains a useful 
tool only for the identification of pigment rather than as a quantitative measure 
(271, 339, 419, 470).  The use of magnetic field separation, spectrophotometry, 
fluorescence and chemiluminescence are all more sensitive quantitative measures.   
 
 For the purpose of this study an alternative quantification method had to be 
developed to determine haemozoin density in liver sections as the only tissue 
samples that were available were the stained histology samples.  Therefore, a 
microscopic method was developed based on that used for the determination of 
peripheral parasitaemia in blood films.   Liver sections from 4 mice per dose group 
were observed under 100x oil immersion light microscopy. A high resolution digital 
image was taken for 10 consecutive fields of view from each liver section (Olympus 
DP70 digital imaging system, Olympus DP70 controller version 2.1.1.183 and DP 
manager version 2.1.1.163; Olympus Australia Pty Ltd, Mt Waverley, VIC Australia). 
A calibrated scale (200 µm x 150 µm) was superimposed on the digital image and 
the numbers of haemozoin deposits (regardless of size) were counted within the 
defined area. This process was repeated for each of the 10 fields of view with the 
total count used to estimate haemozoin density (haemozoin deposits per mm2). 
 
It is acknowledged that whilst the proposed method does not quantify the mass of 
haemozoin within the liver tissue it does identify the number of haemozoin deposits 
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thus allowing comparison between liver sections and varying time-points from the 
asplenic and intact mouse populations.  
  
3.2.2.3.3 Blood pathology 
Haematological changes, which are the most common complications of malaria 
infections, play a major role in the pathogenicity of infections (463).  These changes 
can involve all blood components and include anaemia, white blood cell changes as 
a result of cytokine induction, thrombopathy and possible coagulopathies (312, 463, 
543).  It is also acknowledged that during malaria infection the increased 
destruction of red blood cells, as well as mechanical destruction to soft organ 
tissues by the rigid parasites, can contribute to selective changes in biochemistry 
(182, 258).  The liver in particular is an organ which is directly affected by malaria 
parasites and as a result the release of liver enzymes into blood circulation is often 
seen to occur as parasitaemia increases (258).    
 
The purpose of this study was to investigate the progressive changes in 
haematology, liver biochemistry and electrolyte levels from groups of asplenic and 
intact mice that were either untreated or received a single dose of 30 mg/kg DHA 
56 h after parasite inoculation.  At each designated time point (0, 36, 56, 76, 96 and 
168 h after inoculation) blood was collected by internal cardiac puncture from each 
infected Swiss mouse (n=6 asplenic and intact mice at each time point). After 
harvesting, the blood from 3 mice at each time point was placed into EDTA 
anticoagulant for haematological testing, whilst blood from the remaining 3 mice 
was placed in lithium heparin tubes for biochemistry.   
 
EDTA samples were processed daily on a Cell-Dyn3200 (Abbott Diagnostics, Illinois, 
USA) to determine full blood parameters as anaemia and thrombocytopaenia are 
recognised features of malaria infection and these specific tests are routinely used 
to monitor disease progression (382). As mouse blood cells are distinctly smaller 
than human cells, the samples were run under the Veterinary mode using a Mouse 
parameter setting.  As cell separation and counting occurs due to pre-calibrated 
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MCV values, the use of this package ensured that red blood cells were counted as 
such, rather than being counted as large platelets in the human mode.    
 
For biochemistry analysis, heparinised blood was immediately centrifuged for 10 
min at 3000 g (Biofuge Primo, Heraeus Instruments/ Kendro Instruments Australia 
Pty Ltd, Lane Cove, NSW, Australia) and the separated plasma was stored in micro-
centrifuge tubes and refrigerated at 4oC until analysed at the conclusion of the 
study.  The plasma was separated from the red blood cell pellet to eliminate the 
possibility of enzyme leaching from the pellet into the plasma which would falsely 
elevate enzyme levels.  The plasma samples were processed in a single batch using 
a Synchron LX® 20 PRO (Beckman Coulter Australia Pty Ltd., Gladesville, NSW, 
Australia) for liver function tests (bilirubin, alanine transaminase (ALT), aspartate 
transaminase (AST) and alkaline phosphatase (AFP)) as indicators of liver damage 
associated with malaria infection.  The same procedure was performed for mice 
treated with DHA (56 h after inoculation) using blood that was harvested at 76, 96 
and 168 h after inoculation.  Both haematology and biochemistry results from intact 
and asplenic mice were compared to determine differences in disease pathology 
between the two groups.   
 
3.3 RESULTS 
3.3.1 Single Dose Pharmacodynamic Study 
3.3.1.1 DHA pharmacodynamics 
Single dose DHA produced a prompt decline in parasitaemia, reaching a nadir 24 h 
after drug administration (Fig. 3.6). The nadir was 2.8, 4.4 and 6.0 fold below 
starting parasitaemia in asplenic mice and 2.7, 5.1 and 6.9 fold in intact mice at 
doses of 10 mg/kg, 30 mg/kg and 100 mg/kg, respectively. Parasite recrudescence 
was observed in all groups of mice. To determine if there was a significant 
difference in the rate of parasite recovery, the time to reach a 5% parasitaemia 
after dosing (t5%) was determined by linear interpolation. The value of 5% was 
selected as the recrudescence comparison time point, as this both reflected the 
maximum parasitaemia at time of dosing, and a previous study had determined that  
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Figure  3.6. Effect of dihydroartemisinin on parasitaemia in intact and asplenic 
mice. Data are shown as mean total parasitaemia (% of infected erythrocytes) + SD 
versus time in relation to the dose of DHA. Mice were inoculated with 107 
parasitised erythrocytes 56 h prior to DHA administration [A: 10 mg/kg DHA, B: 30 
mg/kg DHA, C: 100 mg/kg DHA;  untreated intact mice,  untreated asplenic 
mice,  treated intact mice,  treated asplenic mice; n=8 per group]. 
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a recrudescent parasitaemia reaching 5% in mice would likely lead to a fatal 
outcome, whilst no significant changes would occur in the erythrocyte count (179).    
 
The mean ± SD t5% was 39 ± 5 h, 34 ± 8 h and 48 ± 5 h (P=0.003; ANOVA) in asplenic 
mice, and 32 ± 3 h, 43 ± 7 h and 62 ± 24 h (P=0.004; ANOVA) in intact mice at 10 
mg/kg, 30 mg/kg and 100 mg/kg, respectively. There was a significant difference in 
the t5% between asplenic and intact mice at each dose studied (P=0.004, P=0.044 
and P=0.012 for 10 mg/kg, 30 mg/kg and 100 mg/kg, respectively; t-test).  
 
3.3.1.2 Parasite Staging 
No significant difference in staging profiles was observed between asplenic and 
intact mice, both untreated and DHA-treated (Fig. 3.7). Late trophozoites were the 
predominant stage at each time point. In untreated mice, early trophozoites and 
ring-forms comprised the remainder of the total observed parasitaemia up to 2-3 
days post-dose (4-5 days post infection; Fig. 3.7, panels A and B). Schizonts became 
more prominent than the ring-forms as the infection advanced beyond a total 
parasitaemia of at least 10%. All erythrocytic stages were affected by the 
administration of DHA, with nadir at 20-28 h (Fig. 3.7, panels C-F), clearly 
demonstrating that DHA was broadly effective in this in vivo model.  This finding is 
consistent with other published findings which have shown that artemisinin 
derivatives are effective on all stages of the Plasmodium parasite (238).  
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Figure 3.7 Parasite stage differentiation at varying doses of dihydroartemisinin. 
Data are shown as mean parasitaemia (% of infected erythrocytes) versus time in 
relation to dose (error bars excluded for clarity; n=8 per group). [A: untreated 
intact mice, B: untreated asplenic mice] 
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Figure 3.7  Parasite stage differentiation at varying doses of dihydroartemisinin. 
Data are shown as mean parasitaemia (% of infected erythrocytes) versus time in 
relation to dose (error bars excluded for clarity; n=8 per group). [C: 10 mg/kg DHA 
treated intact mice, D: 10 mg/kg DHA treated asplenic mice, E: 30 mg/kg DHA 
treated intact mice, F: 30 mg/kg DHA treated asplenic mice, G: 100 mg/kg DHA 
treated intact mice, H: 100 mg/kg DHA treated asplenic mice;  mean total 
parasitaemia, ring-forms, early trophozoites, late trophozoites,  schizonts]. 
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3.3.2 Histopathological Study 
3.3.2.1  Histology 
In order to observe pathological changes in tissue sections, as well as the presence 
of malarial parasites and haemozoin deposits, histological sections of spleen, liver, 
lung and kidney sections were observed and morphology compared at 36 h (Fig. 
3.8), 56 h (Fig. 3.9), 76 h (Fig. 3.10), 96 h (Fig. 3.11) and 168 h (Fig. 3.12) after 
parasite inoculation.  Furthermore, organ sections were compared from mice that 
received DHA 56 h after parasite inoculation.  For comparative purposes, these 
organ sections were also taken 76 h (Fig. 3.13), 96 h (Fig. 3.14) and 168 h (Fig. 3.15) 
after parasite inoculation (20, 40 and 112 h after DHA administration).   
 
Liver and lung weights increased as the infection progressed and were significantly 
greater than uninfected mice at 168 h after inoculation in both asplenic and intact 
mice (Table 3.3). A similar outcome was observed in DHA-treated asplenic and 
intact mice (Table 3.3). By contrast, the kidney weight was not affected by malaria 
infection. The mean proportionate weight of the spleen was significantly greater in 
the infected mice, compared to the uninfected animals, from 56 h of infection (the 
time of DHA administration) in treated and untreated mice (Table 3.3).  
 
As anticipated in the intact mice in the study, the spleen increased in size and 
weight as the infection progressed. Along with haemozoin accumulation, organ 
histology showed an increase in the cellularity of both red and white pulp and the 
progressive loss of a defined marginal zone. These expected histological changes 
were associated with increasing parasite burden (15, 210). The increase in red pulp 
cellularity is reported to occur as the phagocytic and erythropoietic activity of the 
spleen is enhanced to replace infected erythrocytes with a healthy population of 
cells (210). White pulp expansion occurs as the immune function of the spleen is 
stimulated by the presence of parasites resulting in both lymphocyte and antibody 
production (15).  In asplenic mice, careful examination of the abdominal cavity 
occurred post mortem to check for any remnants of splenic tissues which may 
account for the increased parasite clearance.  No evidence of residual spleen was 
found in any of the asplenic mice.   
- 129 - 
 
 Intact Mice Asplenic Mice 
 
Spleen 
 
 
 
 
Liver 
 
 
 
 
 
Lung 
 
 
 
 
 
Kidney 
 
 
 
 
Figure 3.8 Light microscopy of Haematoxylin and Eosin stained mouse organ sections 
(x40) 36 h after parasite inoculation. Sections are from the spleen of infected mice 
and liver, lung and kidney sections are from both intact and asplenic mice 36 h after 
inoculation with P. berghei parasites.  Arrows demonstrate the presence of haemozoin 
deposits (), parasitised erythrocytes () and liver Kupffer cells ().   
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Figure 3.9 Light microscopy of Haematoxylin and Eosin stained mouse organ sections 
(x40) 56 h after parasite inoculation. Sections are from the spleen of infected mice 
and liver, lung and kidney sections are from both intact and asplenic mice 56 h after 
inoculation with P. berghei parasites.  Arrows demonstrate the presence of haemozoin 
deposits (), parasitised erythrocytes () and liver Kupffer cells ().   
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Figure 3.10 Light microscopy of Haematoxylin and Eosin stained mouse organ 
sections (x40) 76 h after inoculation. Sections are from the spleen of infected mice 
and liver, lung and kidney sections are from both intact and asplenic mice 76 h after 
inoculation with P. berghei parasites.  Arrows demonstrate the presence of haemozoin 
deposits (), parasitised erythrocytes () and liver Kupffer cells ().   
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Figure 3.11. Light microscopy of Haematoxylin and Eosin stained mouse organ 
sections (x40) 96 h after parasite inoculation. Sections are from the spleen of infected 
mice and liver, lung and kidney sections are from both intact and asplenic mice 96 h 
after inoculation with P. berghei parasites.  Arrows demonstrate the presence of 
haemozoin deposits (), parasitised erythrocytes () and liver Kupffer cells ().   
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Figure 3.12 Light microscopy of Haematoxylin & Eosin stained mouse organ sections 
(x40) 168 h after parasite inoculation. Sections are from the spleen of infected mice 
and liver, lung and kidney sections are from both intact and asplenic mice 168 h after 
inoculation with P. berghei parasites. Arrows demonstrate the presence of haemozoin 
deposits (), parasitised erythrocytes () and liver Kupffer cells ().   
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Figure 3.13 Light microscopy of Haematoxylin and Eosin stained mouse organ sections 
from DHA treated mice (x40) 76 h after parasite inoculation. Mice were inoculated with P. 
berghei parasites then at 56 h of infection were treated with 100 mg/kg DHA.  Sections are 
from the spleen of infected mice and liver, lung and kidney sections are from both intact and 
asplenic mice 76 h after inoculation with P. berghei parasites.  Arrows demonstrate the 
presence of haemozoin deposits (), parasitised erythrocytes () and liver Kupffer cells ().   
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Figure 3.14 Light microscopy of Haematoxylin and Eosin stained mouse organ sections 
from DHA treated mice (x40) 96 h after parasite inoculation. Mice were inoculated with P. 
berghei parasites then at 56 h of infection were treated with 100 mg/kg DHA.  Sections are 
from the spleen of infected mice and liver, lung and kidney sections are from both intact and 
asplenic mice 96 h after inoculation with P. berghei parasites.  Arrows demonstrate the 
presence of haemozoin deposits (), parasitised erythrocytes () and liver Kupffer cells ().   
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Figure 3.15 Light microscopy of Haematoxylin and Eosin stained mouse organ sections 
from DHA treated mice (x40) 168 h after parasite inoculation. Mice were inoculated with P. 
berghei parasites then at 56 h of infection were treated with 100 mg/kg DHA.  Sections are 
from the spleen of infected mice and liver, lung and kidney sections are from both intact and 
asplenic mice 168 h after inoculation with P. berghei parasites.  Arrows demonstrate the 
presence of haemozoin deposits (), parasitised erythrocytes () and liver Kupffer cells ().   
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Sections of liver and spleen showed that after 56 h of infection, both organs were 
accumulating parasitised erythrocytes (Fig. 3.9–Fig. 3.15). This was demonstrated by 
the presence of haemozoin within the splenic cords, an increased number of 
phagocytic cells in the spleen and liver and Kupffer cell hyperplasia within the liver. 
In asplenic mice, parasites were observed in the liver as early as 36 h after 
inoculation (Fig. 3.8) and Kupffer cell hyperplasia became prominent from 56 h of 
infection (Fig. 3.9). Comparison of liver sections from asplenic and intact mice 
indicated a greater density of parasites in asplenic mice throughout the infection 
(Fig. 3.9).  An interesting observation made in liver sections taken from asplenic 
mice was that from 56 h of infection clusters of basophilic staining cells were 
randomly present within the liver lobules (Fig. 3.16).  The clusters of cells could be 
observed in all asplenic liver sections in increasing size (approximately 30-50 cells) 
and numbers as the infection progressed.  These basophilic staining clusters are not 
a unique observation as they have been previously described when looking at the 
increased antibody production within liver tissue during malaria infection in 
splenectomized rats (Fig. 3.16) (545). Liver sections from intact mice did not 
demonstrate the presence of the basophilic clusters until after 96 h of infection, and 
only in sporadic numbers.     
 
Overall, haemozoin density in the liver was significantly greater in asplenic mice, 
compared to intact mice, and the haemozoin density was greater in untreated mice 
than DHA treated mice at the same time post-inoculation (Table 3.3). These data 
provide an indication of total parasite presence in the liver, but may not reflect 
natural parasite accumulation/extraction by the liver if haemozoin transport 
between tissues has occurred (179).  
 
The lungs showed parasite presence from 36 h of infection (Fig. 3.8 to Fig. 3.12) 
with evidence of haemorrhage observed by both gross and histological examination 
after 76 h of infection. Increasing numbers of macrophages and lymphocytes were 
observed as the infection progressed in both intact and asplenic mice. The kidneys 
were generally unremarkable and did not show parasite presence in the tubules 
until 168 h of infection in both intact and asplenic mice (Fig. 3.11).  
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Figure 3.16 (A, B) Light microscopy of Haematoxylin and Eosin stained liver 
sections from asplenic mice (x40) demonstrating the presence of clusters of 
basophilic staining lymphoid cells known as pseudofollicles.  As shown, 
pseudofollicles vary size (number of cells within cluster), shape and distribution 
through the liver section. (C, D) Examples of pseudofollicles in rat liver sections as 
previously described by Weiss (545). 
 
 
Table 3.3 Haemozoin deposits per mm2 of liver from mice inoculated with P. 
berghei parasites. Treated mice were given DHA 56 h after inoculation. Data are 
mean ± SD. 
 Untreated DHA Treated 
 Intact 
(n=4) 
Asplenic 
(n=4) 
Intact 
(n=4) 
Asplenic 
(n=4) 
Time after 
inoculation 
    
0 h 0 0 - - 
36 h 0 5 ± 4 a - - 
56 h 34 ± 10 45 ± 13 - - 
76 h 190 ± 92  532 ± 67 a 64 ± 34b 123 ± 78b 
96 h 215 ± 145 765 ± 117a 127 ± 53 317 ± 87ab 
168 h 1684 ± 242 1776 ± 107 301 ± 137b 809 ± 85ab 
a P<0.05 for comparison between intact and asplenic mice at designated time point (t-test); b P<0.05 
for comparison between untreated and DHA-treated mice at designated time point (t-test) 
20.0 µm 20.0 µm 
A B 
C D 
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The kidneys and lungs were also examined, with particular consideration of parasite 
trapping in the microvasculature. No significant pathological change was observed 
in kidney sections in our study (up to 168 h post-inoculation), suggesting that the 
kidneys did not have a significant role in the removal of parasitised erythrocytes 
from circulation. However, there was a significant increase in the mass of the lungs 
as the infection progressed (Table 3.4). Based on autopsy examination and organ 
histology, this was apparently due to oedema and haemozoin deposition in the 
microcirculation of both asplenic and intact mice. Histological examination of lung 
tissue demonstrated parasite presence from 36 h of infection with evidence of 
haemorrhage observed by both gross and histological examination after 76 h of 
infection. Increasing number of macrophages and lymphocytes were observed as 
infection progressed in both intact and asplenic mice.   
 
3.3.2.2 Pathology  
3.3.2.2.1 Haematology 
During the course of infection, red blood cell indices progressively changed in both 
intact and asplenic mice, as would be expected.  Although total red blood cell count 
(RBCC) and haematocrit (HCT) remained stable in both cohorts of mice for the first 
76 h of infection, at 96 h, when parasitaemia exceeded 10%, both values steadily 
declined with significantly decreased values observed at 168 h in both asplenic and 
intact mice when compared to the RBCC and HCT indices at baseline (Table 3.6).  
After treatment with DHA no statistically significant difference in RBCC was 
observed in intact mice throughout the malaria infection, however, a significantly 
different HCT value was observed at 168 h (Table 3.7).  In treated asplenic mice 
both the RBCC and HCT were significantly different at 168 h compared to both the 
starting indices as well as when compared to intact mice at the same time point 
(Table 3.7). 
 
Haemoglobin concentrations declined in both asplenic and intact untreated mice 
from 36 h after inoculation but this decrease was not statistically significant until 
168 h after inoculation (Table 3.6). A similar pattern was observed in asplenic, 
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Table 3.4  Organ weights as a proportion of total body weight (%TBW) from mice after inoculation with P. berghei parasites.  Treated mice were 
given DHA 56 h after inoculation and blood was harvested 20, 40 and 112 h after dosing (76, 96 and 168 h after inoculation).  Data are mean ± SD. 
 Parasitaemia (%) Liver (%TBW) Lung (%TBW) Kidney (%TBW) Spleen (%TBW) 
Time after 
inoculation 
Intact 
(n=10) 
Asplenic 
(n=10) 
Intact 
(n=10) 
Asplenic 
(n=10) 
Intact 
(n=10) 
Asplenic 
(n=10) 
Intact 
(n=10) 
Asplenic 
(n=10) 
Intact  
(n=10) 
 
Untreated mice          
0 h 0 0 5.5 ± 0.9 5.8 ± 0.1 0.57 ± 0.06 0.60 ± 0.05 0.86 ± 0.12 0.88 ± 0.1 0.31 ± 0.05 
36 h 0.41 ± 0.1 0.39 ± 0.2 5.2 ± 0.1 4.9 ± 0.1 0.51 ± 0.14 0.45 ± 0.15b 0.71 ± 0.09b 0.63 ± 0.12b 0.33 ± 0.12 
56 h 2.3 ± 0.7 3.2 ± 1.4 5.9 ± 0.1 5.8 ± 0.1 0.74 ± 0.06b 0.71 ± 0.08b 0.85 ± 0.08 0.81 ± 0.08 0.58 ± 0.07b 
76 h 9.3 ± 3.4 15.2 ± 9.3 6.5 ± 0.2 6.2 ± 0.1 0.64 ± 0.05 0.72 ± 0.14b 0.86 ± 0.07 0.86 ± 0.1 0.62 ± 0.11b 
96 h 27.1 ± 12.0 28.2 ± 17.1 6.6 ± 0.1 6.6 ± 0.1 0.61 ± 0.07 0.68 ± 0.06a 0.83 ± 0.13a 0.89 ± 0.05a 0.81 ± 0.13b 
168 h 68.1 ± 17.3 66.3 ± 20.0 7.5 ± 0.1b 7.0 ± 0.1b 0.84 ± 0.10b 0.75 ± 0.07ab 0.97 ± 0.14 0.90 ± 0.13 1.0 ± 0.3b 
 
DHA treated mice (56 h after inoculation)      
76 h 0.10 ± 0.01 1.3 ± 0.5a 6.0 ± 0.1 5.9 ± 0.7 0.62 ± 0.05 0.66 ± 0.07 0.87 ± 0.11 0.90 ± 0.14 0.66 ± 0.17b 
96 h 1.5 ± 0.4 2.5 ± 0.8 6.5 ± 0.1 6.1 ± 0.6 0.65 ±0.08b 0.65 ± 0.08 0.88 ± 0.14 0.71 ± 0.12 0.64 ± 0.13b 
168 h 14.6 ± 6.1 30.1 ± 2.5a 7.1 ± 0.1b 7.3 ± 0.5b 0.96 ± 0.08b 0.74 ± 0.06ab 0.91 ± 0.12 0.90 ± 0.11 0.86 ± 0.24b 
  
a P<0.05 for comparison between intact and asplenic mice at designated time-points (t-test); b Parameter significantly different to uninfected animals 
(0 h group, P<0.05, ANOVA; not applicable to parasitaemia).  
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treated mice, but not in intact mice treated with DHA where haemoglobin 
concentration remained stable after treatment with DHA (Table 3.7). 
 
Mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH) values 
remained stable for the entire malaria infection in both asplenic and intact mice, 
although in asplenic mice both the MCV and MCH were increased at 168 h.  However, 
these increases were not significantly different compared to baseline values (Table 
3.6).  However, in treated intact mice, the MCV was significantly lower compared to 
treated asplenic mice at both 96 and 168 h.  The MCH in treated intact mice remained 
stable for the course of infection, however, in treated asplenic mice the MCH was 
significantly decreased compared to baseline values (Table 3.7).   
 
In untreated asplenic mice the red blood cell distribution width (RBDW) was 
significantly increased compared with intact mice at the same time-points of 56, 76, 96 
and 168 h post-inoculation.  At 168 h the RBCDW in asplenic mice was also significantly 
increased compared to the RBCDW in asplenic mice at 0 h (Table 3.6).  The RBCDW 
value for untreated intact mice was only significantly increased at 168 h when 
compared to baseline values (Table 3.6).  After treatment with DHA, the RBCDW in 
both intact and asplenic mice remained consistent through all examined time-points 
(Table 3.7).   
 
Although an initial decrease in white blood cell count (WBCC) was seen at 36 h in both 
intact and asplenic mice, the general trend was an increase in white blood cells during 
the course of infection in both treated and untreated mice (Table 3.6 and Table 3.7).  
However, a statistically significant difference in parameters was only observed at 168 
h.  The total WBCC was also differentiated at each time point with absolute counts for 
granulocytes, lymphocytes and monocytes generally all increasing as expected (Table 
3.6).  After treatment with DHA, the WBCC and absolute differential counts for all 
three white blood cell populations, in both intact and asplenic mice, increased during 
the course of infection (Table 3.7).   
 
Declining platelet counts were seen in both treated and untreated intact mice with a 
statistically significant decrease seen after 36 h of infection in untreated mice (Table 
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3.6). In the asplenic mice, platelet counts fluctuated in both treated and untreated 
mice but were not significantly different to the uninfected animals at any of the 
sample times (Tables 3.6 and 3.7). 
 
3.3.2.2.2 Biochemistry 
ALP and ALT concentrations showed no significant difference throughout the infection. 
Bilirubin concentrations increased during the course of infection but were not 
significantly greater than uninfected mice until 168 h after inoculation in all groups of 
mice (Table 3.8).  
 
The mean AST concentration was significantly higher in all infected mice than in 
uninfected mice (Table 3.8). In the asplenic groups a significant difference in AST 
concentrations was seen when comparing untreated infected and uninfected mice 
(Table 3.8). After treatment with DHA there was a statistically significant increase in 
AST concentrations in infected intact mice compared to uninfected intact mice, 
however, there was no significant difference in AST concentrations between DHA 
treated asplenic and uninfected asplenic mice (Table 3.9). AST concentrations were 
higher in the untreated asplenic mice than in intact mice (statistically significant 56 and 
76 h after inoculation; Table 3.8).  
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Table 3.6  Haematology parameters from mice after inoculation with P. berghei parasites.  Data are mean ± SD. 
Time after inoculation 
 0 h 36 h 56 h 76 h 96 h 168 h 
 Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
             
Parasitaemia (%) 0 0 0.46 ± 0.11 0.35 ± 0.19 1.6 ± 0.3 3.0 ± 0.1 5.1 ± 0.4 5.6 ± 1.2 12.6 ± 6.5 14.3 ± 0.9 51.1 ± 1.2 54 ± 7 
RBCC (x1012/L) 8.60 ± 0.02 8.10 ± 0.78 9.39 ± 0.64 8.44 ± 0.45 8.41 ± 0.58 8.02 ± 0.84 8.67 ± 0.69 8.36 ± 1.7 7.42 ± 0.43 7.86 ± 1.1 4.88 ± 0.81b 3.69 ± 1.05b 
Hb (g/L) 131 ± 4 127 ± 10 139 ± 8 131 ± 4 126 ± 8 123 ± 12 128 ± 11 130 ± 20 117 ± 5 122 ± 11 87 ± 20b 71 ± 20b 
HCT 0.43 ± 0.01 0.42 ± 0.03 0.45 ± 0.02 0.42 ± 0.01 0.41 ± 0.02 0.40 ± 0.03 0.43 ± 0.04 0.44 ± 0.07 0.38 ± 0.00 0.40 ± 0.04 0.25 ± 0.06b 0.21 ± 0.06b 
MCV (fL) 50 ± 1 52 ± 1 48 ± 1 50 ± 1 44 ± 9 50 ± 2 50 ± 1 52 ± 2 50 ± 1 51 ± 2 52 ± 1 55 ± 1a 
MCH (pg) 15.2 ± 0.5 15.6 ± 0.4 14.5 ± 0.2 14.7 ± 0.1 14.5 ± 0.7 15.0 ± 0.7 18.9 ± 0.8 15.5 ± 1.1 14.6 ± 0.53 15.5 ± 1.3 12.2 ± 0.9 19.3 ± 0.31 
MCHC (g/L) 304 ± 3 303 ± 1 301 ± 2 296 ± 7 301 ± 7 301 ± 3 284 ± 3 297 ± 10 294 ± 8 305 ± 11 358 ± 30b 349 ± 11b 
RBCDW 10.0 ± 0.3 11.4 ± 1.2 9.2 ± 0.2 10.4 ± 0.8 9.5 ± 0.3 11.4 ± 0.7 a 10.2 ± 0.2 13.7 ± 1.1a 10.1 ± 0.32 12.1 ± 0.42a 12.2 ± 0.94b 14.7 ± 0.44ab 
             
WBCC (x109/L) 1.4 ± 0.6 1.5 ± 0.7 0.54 ± 0.1 0.54 ± 0.09 2.32 ± 1.67 3.5 ± 2.1 1.8 ± 0.5 2.6 ± 0.6 1.8 ± 0.46 3.9 ± 2.4 4.9 ± 0.8ab 3.1 ± 0.3b 
Gran (x109/L) 0.32 ± 0.46 0.56 ± 0.10 0.13 ± 0.05 0.20 ± 0.11 0.43 ± 0.14 2.04 ± 1.46 0.23 ± 0.31 0.34 ± 0.27 0.39 ± 0.08 0.5 ± 0.4 1.06 ± 0.88 0.35 ± 0.3 
Lymph (x109/L) 0.97 ± 0.27 0.87 ± 0.24 0.19 ± 0.02 0.28 ± 0.0a 0.74 ± 0.11 1.24 ± 0.41 1.43 ± 0.67 1.88 ± 0.18 1.27 ± 0.17 1.33 ± 1.7 2.86 ± 1.71 2.62 ± 0.22b 
Mono (x109/L) 0.07 ± 0.08 0.10 ± 0.09 0.05 ± 0.00 0.07 ± 0.01 0.12 ± 0.04 0.26 ± 0.22 0.13 ± 0.15 0.33 ± 0.23 0.19 ± 0.18 0.04 ± 0.03 0.96 ± 0.72b 0.16 ± 0.19 
% Gran 18 ± 21 34 ± 11 35 ± 10 36 ± 13 25 ± 16 55 ± 9 13 ± 18 13 ± 8 22 ± 2 15 ± 13 23 ± 18 11 ± 8 
% Lymph 79 ± 24 61 ± 14 52 ± 9 52 ± 10 44 ± 27 38 ± 11 80 ± 27 76 ± 11 74 ± 18 60 ± 24 58 ± 30 84 ± 14 
% Mono 4 ± 3 6 ± 3 14 ± 1 12 ± 4 6 ± 2 7 ± 2 7 ± 9 12 ± 8 10 ± 8 25 ± 24 19 ± 13 5 ± 5 
             
Platelets (x109/L) 1022 ± 92 1079 ± 25 802 ± 10b 828 ± 7 845 ± 74b 1173 ± 654 591 ± 81b 888 ± 117a 668 ± 40b 807 ± 160 463 ± 45b 1097 ± 76 
 
a P<0.05 for comparison between intact and asplenic mice at designated time-points (t-test); b Parameter significantly different to uninfected animals 
(0 h group, P<0.05, ANOVA; not applicable to parasitaemia).  Abbreviations – RBCC: Red blood cell count; Hb: Haemoglobin; HCT: haematocrit; MCV: 
Mean corpuscular volume; MCH: Mean corpuscular haemoglobin; MCHC: Mean corpuscular haemoglobin concentration; RBCDW: Red blood cell 
distribution width; WBCC: White blood cell count; Gran: Granulocytes; Lymph: Lymphocytes; Mono: Monocytes).  
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Table 3.7  Haematology parameters from mice that were treated with DHA 56 hours after inoculation with P. berghei parasites.  Blood was 
harvested 20, 40 and 112 h after dosing (76, 98 and 168 h after inoculation). Data are mean ± SD. 
Time after inoculation 
 0 h 76 h 96 h 168 h 
 Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
         
Parasitaemia (%) 0 0 0.45 ± 0.4 0.92 ± 0.5a 3.8 ± 2.2 7.5 ± 3.9a 29.2 ± 13 38 ± 9.1 
RBCC (x1012/L) 8.60 ± 0.02 8.10 ± 0.78 8.27 ± 0.40 7.67 ± 0.93 8.09 ± 0.55 7.64 ± 0.07 7.68 ± 0.38 5.82 ± 0.32ab 
Hb (g/L) 131 ± 4 127 ± 10 124 ± 4 118 ± 10 121 ± 7 119 ± 4 121 ± 4 97 ± 6a 
HCT 0.43 ± 0.01 0.42 ± 0.03 0.42 ± 0.02 0.39 ± 0.03 0.39 ± 0.03 0.38 ± 0.02 0.37 ± 0.01b 0.28 ± 0.02ab 
MCV (fL) 50 ± 1 52 ± 1 50 ± 1 51 ± 3 48 ± 1b 50 ± 3 48 ± 1b 49 ± 1 
MCH (pg) 15.2 ± 0.5 15.6 ± 0.4 15.0 ± 1.2 14.7 ± 0.5 14.4 ± 0.4 15.2 ± 1.2 15.3 ± 1.1 14.6 ± 0.9b 
MCHC (g/L) 304 ± 3 303 ± 1 291 ± 9 292 ± 4 298 ± 7 305 ± 11 317 ± 18 300 ± 13 
RBCDW 10.0 ± 0.3 11.4 ± 1.2 10 ± 1 11 ± 1 10 ± 1 12 ± 1 10 ± 1 12 ± 1 
         
WBCC (x109/L) 1.4 ± 0.6 1.5 ± 0.7 2.1 ± 0.7 2.7 ± 1.1 2.3 ± 7 2.3 ± 0.9 4.8 ± 2.1 6.0 ± 0.9b 
Gran (x109/L) 0.32 ± 0.46 0.56 ± 0.10 0.67 ± 0.42 1.03 ± 0.86 0.55 ± 0.33 0.16 ± 0.15 2.60 ± 1.49b 2.51 ± 0.7 
Lymph (x109/L) 0.97 ± 0.27 0.87 ± 0.24 1.16 ± 0.10 1.34 ± 0.16 1.24 ± 0.24 2.02 ± 0.97 1.34 ± 0.64 2.52 ± 1.42 
Mono (x109/L) 0.07 ± 0.08 0.10 ± 0.09 0.30 ± 0.24 0.32 ± 0.22 0.47 ± 0.46 0.08 ± 0.01 0.83 ± 0.62 0.94 ± 1.2 
% Gran 18 ± 21 34 ± 11 30 ± 9 34 ± 17 23 ± 8 8 ± 8 52 ± 14 42 ± 5 
% Lymph 79 ± 24 61 ± 14 58 ± 15 55 ± 18 59 ± 21 88 ± 8 33 ± 21 41 ± 17 
% Mono 4 ± 3 6 ± 3 13 ± 6 11 ± 7 18 ± 14 4 ± 2 15 ± 8 17 ± 23 
         
Platelets (x109/L) 1022 ± 92 1079 ± 25 784 ± 114 865 ± 141 582 ± 23b 935 ± 92a 227 ± 217b 1266 ± 306a 
 
a P<0.05 for comparison between intact and asplenic mice at designated time-points (t-test); b Parameter significantly different to uninfected animals 
(0 h group, P<0.05, ANOVA; not applicable to parasitaemia).  Abbreviations – RBCC: Red blood cell count; Hb: Haemoglobin; HCT: haematocrit; MCV: 
Mean corpuscular volume; MCH: Mean corpuscular haemoglobin; MCHC: Mean corpuscular haemoglobin concentration; RBCDW: Red blood cell 
distribution width; WBCC: White blood cell count; Gran: Granulocytes; Lymph: Lymphocytes; Mono: Monocytes).  
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 Table 3.8  Biochemistry parameters from mice after inoculation with P. berghei parasites.  Data are mean ± SD. 
Time after inoculation 
 0 h 36 h 56 h 76 h 96 h 168 h 
 Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
             
Parasitaemia (%) 0 0 0.42 ± 0.2 0.63 ± 0.8a 2.9 ± 0.7 4.7 ± 0.8a 12.3 ± 
1.0 
22 ± 4a 37.2 ± 
5.9 
41.2 ± 12.8 79.4 ± 6.1 82.1 ± 3.7 
Total Bilirubin (µmol/L) 10 ± 1a 7 ± 1 12 ± 2 13 ± 2b 14 ± 6 14 ± 7 9 ± 2 9 ± 0b 11 ± 2 12 ± 1b 21 ± 2b 20 ± 4b 
ALP (IU/L) 57 ± 22 41 ± 13 47 ± 11 45 ± 25 34 ± 3a 54 ± 10 39 ± 2 53 ± 10 49 ± 12 47 ± 7 36 ± 8 49 ± 8 
ALT (IU/L) 36 ± 12 38 ± 10 73 ± 34 44 ± 10 48 ± 3 59 ± 17 46 ± 9 63 ± 16 48 ± 12 54 ± 15 30 ± 8a 66 ± 1 
AST (IU/L) 107 ± 19 85 ± 13 134 ± 25 142 ± 18b 148 ± 7ab 155 ± 53b 134 ± 10a 161 ± 4b 140 ± 9 152 ± 16b 165 ± 39 176 ± 19b 
Total Protein (g/L) 43 ± 2 41 ± 3 43 ± 1 47 ± 1 43 ± 1 43 ± 3.5 40 ± 2 40 ± 1 45 ± 3 44 ± 3 46 ± 2 42 ± 2 
Albumin (g/L) 10 ± 1 9 ± 1 10 ± 1 11 ± 2 8 ± 0 10 ± 1 10 ± 1 10 ± 1 11 ± 0 10 ± 1 11 ± 1 11 ± 1 
 
a P<0.05 for comparison between intact and asplenic mice at designated time-points (t-test); b Parameter significantly different to uninfected animals 
(0 h group, P<0.05, ANOVA; not applicable to parasitaemia).  Abbreviations – ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: 
Aspartate transaminase).   
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Table 3.9  Biochemistry parameters from mice that were treated with DHA 56 hours after inoculation with P. berghei parasites.  Blood was 
harvested 20, 40 and 112 h after dosing (76, 98 and 168 h after inoculation). Data are mean ± SD. 
Time after inoculation 
 0 h 76 h 96 h 168 h 
 Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
Intact 
(n=3) 
Asplenic 
(n=3) 
         
Parasitaemia (%) 0 0 1.0 ± 0.2 1.1 ± 0.4 4.1 ± 2.0 11.3 ± 2.1a 33.0 ± 17.4 42.4 ± 8.2 
Total Bilirubin (µmol/L) 10 ± 1 6.5 ± 0.7 11 ± 2 12 ± 5 13 ± 6 11 ± 3 20 ± 4b 17 ± 3b 
ALP (IU/L) 57 ± 22 41 ± 13 43 ± 10 45 ± 13 50 ± 6 45 ± 11 39 ± 13 30 ± 3 
ALT (IU/L) 36 ± 12 38 ± 10 75 ± 15 71 ± 16 76 ± 12a 42 ± 7 133 ± 52 69 ± 16 
AST (IU/L) 107 ± 19 85 ± 13 342 ± 43b 230 ± 72 266 ± 40ab 177 ± 31 351 ± 60ab 197 ± 12 
Total Protein (g/L) 43 ± 2 41 ± 3 41 ± 6 44 ± 11 47 ± 1 41 ± 4 42 ± 2 41 ± 3 
Albumin (g/L) 10.3 ± 0.6 9.0 ± 0.6 10 ± 0 10 ± 1 11 ± 0 11 ± 1 9 ± 1 10 ± 1 
 
a P<0.05 for comparison between intact and asplenic mice at designated time-points (t-test); b Parameter significantly different to uninfected animals 
(0 h group, P<0.05, ANOVA; not applicable to parasitaemia).  Abbreviations – ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: 
Aspartate transaminase).   
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3.4 DISCUSSION 
This series of investigations demonstrates that: 
1. DHA has potent antimalarial efficacy in asplenic and intact mice infected 
with P. berghei malaria.  
2. DHA appears to be effective against most erythrocytic stages of the malaria 
parasite. 
3. The liver is able to remove parasites from the circulation, thus compensating 
for asplenic status in malaria infection (in the murine malaria model).  
 
The single dose-ranging pharmacodynamic study verified that the therapeutic effect 
of DHA extends well beyond the duration of detectable drug concentration.  
Previous studies have identified that DHA has an extremely short elimination half-
life of 12–15 min in mice  (48, 554).   Therefore, it would be expected that the drug 
is effectively eliminated from the blood circulation within a few hours.  However, 
parasite nadir occurred at 24 h after a single dose of DHA, regardless of drug dose, 
followed by parasite recrudescence (Fig. 3.6).  These results indicate that DHA is 
rapidly taken into the red blood cell where it exerts a more prolonged antimalarial 
effect against the intraerythrocytic parasite.  This speculation correlates with the 
observed low plasma DHA concentrations described in the literature (48).  
 
In contrast to case reports of malaria in asplenic patients (34, 290, 497), this murine 
malaria model showed that single dose administration of DHA (10, 30 and 100 
mg/kg) to asplenic and intact mice resulted in similar parasitaemia-time profiles. 
The only significant difference between the pharmacodynamic profiles of asplenic 
and intact mice was during parasite recrudescence, where after high dose DHA 
administration the rate of recrudescence was faster in the asplenic group (t5% 48 h v 
62 h) (Fig. 3.6).  Whilst previous murine studies have shown that splenectomized 
and intact mice infected with P. yoelii did not differ in their course of infection 
(434), and that the effects of splenectomy on the progression of malaria infection 
can be mouse strain dependant (156), it was expected that in the current study a 
significantly delayed and/or less effective parasite clearance would be observed in 
the asplenic mice following drug administration.  The results obtained were 
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therefore surprising.  Although elucidating the precise mechanisms of parasite 
clearance was beyond the scope of the present investigation, further investigations 
were persued into the pathology and histology of blood and organ systems of the 
mouse in an attempt to provide an alternative explanation for the unexpected 
pharmacodynamic findings.   
 
Through the examination and differentiation of the asexual erythrocytic stage 
parasites, it was determined that DHA appears to be efficacious against all of the 
asexual erythrocytic stages (Fig. 3.7).   This finding is consistent with in vitro data, 
showing that artemisinin compounds are effective against most of the P. falciparum 
erythrocytic life cycle (451, 554), and indications of stage-specific activity of 
artemisinin drugs in vivo (554).  The apparent broad spectrum stage efficacy of DHA 
is presumably a result of the novel mechanism of action of the artemisinin 
derivatives.  Although other mechanisms of action have been proposed, interaction 
of the SERCA orthologue should be considered given that DHA is shown to be 
effective against all stages of the parasite, including ring-forms that lack haemozoin 
(34, 290, 497).  
  
It is recognized that differentiating between dead and live parasites in the blood 
circulation and organs is difficult, although differences in parasite morphology have 
been noted after treatment with antimalarial drugs, particularly artemisinin 
derivatives (435). It is possible that ineffective single doses would result in a mix of 
both dead and live parasites in circulation, making it difficult to quantify the viable 
parasite burden. However, due to the rapid clearance (short half-life) of DHA (156), 
drug concentrations beyond the nadir parasitaemia would be negligible. Hence, in 
the absence of drug pressure, the majority of parasites detected would be live and 
viable, as dead parasites would likely have been rapidly removed from the 
circulation by phagocytic mechanisms.  In the case of splenectomy, with a reduced 
parasite clearance capacity, a combination of both live and dead parasites could be 
expected in the circulation.  However, as clearly shown in the asplenic model (Fig. 
3.6) parasite clearance was rapid in both intact and asplenic mice.  Therefore, it is 
presumed that the parasitaemia results reported in this thesis are reflective of the 
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true number of viable parasites in the peripheral circulation at each time point due 
to both the successful clearance of parasites by both asplenic and intact mice, but 
also due to the experience of the microscopist (candidate) at differentiating viable 
parasites and those affected by DHA administration.  
 
In this study, malaria infection caused an increase in liver mass and rigidity, as well 
as changes in organ histology. This was attributed to haemozoin deposition and 
parasitised erythrocyte accumulation in the organ, predominantly through Kupffer 
cell and macrophage phagocytosis, as well as accumulation of the rigid parasitised 
erythrocytes in the liver sinusoids. The observed Kupffer cell hyperplasia and 
hypertrophy also would have contributed to the increased mass of the organ (276). 
Liver integrity was compromised during the infection, in both asplenic and intact 
mice, as reflected by increased levels of bilirubin, ALT and AST (Table 3.8 and 3.9) 
and as previously reported (35). These changes have been attributed to the malaria 
infection, as liver toxicity is unlikely to be caused by DHA (238), although the 
possibility of changes in liver enzyme concentrations due to the injection vehicle 
cannot be excluded. Comparison of asplenic and intact mice revealed little 
difference in liver mass and biochemistry, but a notable contrast was observed in 
the liver histology. Beyond 76 h post inoculation, at a parasite density in excess of 
5%, liver sections from asplenic mice showed occasional clusters of basophilic 
staining cells of varying sizes (30-50 cells per cluster; Fig. 3.16), which were 
consistent with cells of lymphoid origin closely resembling areas of white pulp of 
the spleen.  These clusters were previously described in an asplenic murine malaria 
model where they were identified as ‘pseudofollicles’ (545).  It is thought that 
pseudofollicules are cellular infiltrates of macrophages and lymphocytes of T and B 
cell origin, that act as secondary, ectopic, splenic germinal centres in asplenic mice 
(545). This is consistent with a report suggesting that in the absence of a spleen, 
processing of malaria antigens, previously regulated by the spleen, becomes a role 
of the liver (435).  These observations have so far only been described in the murine 
model which may suggest why mice have the capacity to survive at much higher 
parasitaemia than humans, although such intensive liver histology is not realistic in 
malaria-infected patients.  In all other compared organs (kidney, lungs) there was 
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little difference in the tissue histology between the asplenic and intact mouse 
groups.   
 
Haematology data were broadly consistent with expectations (543). In the advanced 
malaria infection, haemoglobin levels decreased as the parasitaemia exceeded 20% 
in both asplenic and intact mice regardless of drug treatment. This was most likely 
related to well recognized mechanisms such as increased cell haemolysis as a result 
of schizont rupture and erythropoietic depression (87). Furthermore, these 
observations are consistent with human (34) and murine (142) reports showing that 
haemoglobin concentrations were similar in both asplenic and control groups. 
 
In contrast to the haemoglobin data, there was a significant difference between the 
intact and asplenic mice in relation to the platelet counts. In the intact mice 
(treated and untreated), the platelet count decreased as the infection progressed, a 
common feature of malaria infection. However, in asplenic mice the platelet count 
was relatively stable throughout the infection in both treated and untreated groups. 
Although the mechanism of thrombocytopenia during malaria infection is yet to be 
elucidated, in mice infected with P. berghei it is thought to be a result of reduced 
platelet life span, platelet adherence to vasculature and immune mechanisms (188, 
190, 388). The relatively stable platelet count observed in the asplenic mice was not 
expected, as in clinical cases, thrombocytopenia occurs in asplenic patients.  
 
Investigation into plausible explanations for the observed differential pathology 
revealed a number of possibilities: 
a) A Type 1 error as a result of an analytical error due to spurious automated 
platelet determinations could result in a falsely high platelet count as 
observed in the asplenic group.  As the automated cell counter differentiates 
between red blood cells and platelets as a function of size, any circulating 
red blood cells fragments (as a result of erythrocyte rupture during 
merozoite release) would erroneously be counted as platelets.  However, 
microscopic examination of a representative selection of blood films 
determined that the increased platelet count of asplenic mice was not a 
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result of increased numbers of schistocytes/red blood cell fragments or 
other microcytic cells that would create a false positive.  Furthermore, 
examination of blood films from intact mice with thrombocytopenia rules 
out the presence of platelet clumps which may have resulted in a falsely 
decreased platelet count.  Therefore, it is presumed that the observed 
platelet differences are most probably not a result of a Type 1 error.  
b)  As a recognised function of the spleen is as a platelet reservoir, containing 
up to 1/3 of the total circulating numbers, it would be expected that platelet 
counts would be substantially higher after splenectomy due to the lack of 
platelet sequestration.  However, although this may explain why higher 
numbers of platelets are present in circulation it does not account for the 
lack of thrombocytopenia seen in asplenic mice during infection.  
c) The antigenic nature of malaria infections could result in the production of 
antibodies that bind to platelets during malaria infection resulting in their 
sequestration into vascular endothelium.  Alternatively, expression of 
malarial antigens to the surface of thrombocytes may result in splenic 
clearance due to its hyperactivity.    
 
In conclusion, although DHA had similar overall efficacy in asplenic and intact mice, 
this study showed that asplenic mice had a reduced capacity for parasite clearance. 
Although the current findings in asplenic mice did not reflect observations in recent 
clinical case reports, there is a relative paucity of human studies for detailed 
comparison of the results from rodent models. The current study has shown an 
enhanced role of the liver in clearing parasites in asplenic mice following DHA 
treatment.  However, a detailed investigation of the mechanisms of clearing 
parasites in asplenic mice was not feasible in the present study.  Overall, this 
asplenic murine malaria model could be useful in studying the splenic function in 
parasite clearance of new antimalarial compounds.  This study also demonstrates 
the potential value of the model for investigations of disease pathology.  
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CHAPTER FOUR 
 
PIPERAQUINE PHARMACOKINETIC AND  
PHARMACODYNAMIC STUDY 
 
4.1 INTRODUCTION 
4.1.1 Physicochemical properties 
PQ is commercially available as either a base (C29H32Cl2N6; 4,4`-(1,3-propaneiyldi-
4,1-piperazinediyl)bis[7-chloro]quinoline; Molecular weight: 535.51 ), or as the 
water soluble salt, piperaquine phosphate (PQP; C29H32Cl2N6.4H3PO4; 1,3-bis[1-(7-
chloro-4`-quinolyl)-4`-piperazinyl] phosphate; Molecular weight: 927.48) (Fig 4.1) 
(253). PQ base is a highly lipophilic basic molecule with a melting point of 212-213°C 
and poor solubility in water (283, 482), whilst PQP is slightly soluble in acidic 
solutions (482).  Plasma protein binding has also been estimated to be at least 97% 
(231, 232).   
 
 
 
Figure 4.1 Chemical structure of piperaquine phosphate (PQP) (253) 
 
 
PQ has been shown to concentrate moderately in red blood cells, with a mean  
erythrocyte: plasma ratio of 1.5:1 at 46% haematocrit over the plasma 
concentration range 50-500 µg/L (232).  It has also been shown that PQ 
concentrations in EDTA and heparinised blood are equivalent, whilst serum 
concentrations prepared from the same blood are approximately 58% higher (127, 
282).  This is most likely because the clotting process in the anticoagulant tubes 
releases drug which are concentrated in leucocytes or platelets (55, 282).   
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4.1.2 Piperaquine as an antimalarial 
In recent years, the increased incidence and spread of multidrug-resistant P. 
falciparum malaria has meant that new antimalarial drugs or drug combinations are 
essential.  Whilst developing new antimalarial combination therapies, PQ was 
“rediscovered” by Chinese scientists as a suitable drug partner, particularly for 
combination with the artemisinin derivative drugs (127).  To date, two fixed-dose 
combination therapies including PQ and the artemisinin derivatives DHA 
(Artekin®)(27, 61, 94, 127, 139, 252, 253, 477) and artemisinin (Artequick®) (389, 
476) have emerged in the clinical setting with all clinical results to date showing 
excellent tolerability and efficacy (27, 29, 139, 209, 217, 252-254, 305, 413, 456).  
PQ is listed in the Chinese Pharmacopeia and commercially available in China, 
however, it is not yet available in the western world as either single dose or fixed-
dose combination therapies (127, 231, 284, 285, 425, 485).  
 
4.1.3 Animal studies 
Although PQ has been used in monotherapy for many years in China and as an 
emerging candidate for ACTs, there is little preclinical data available in western 
literature on the pharmacokinetic and pharmacodynamic profiles of PQ (127).  
Reports are limited to several animal studies published in Chinese literature in the 
early 1980s, focusing on PQ toxicology and PQ monotherapy (127, 484).   Therefore, 
we rely on more recent animal investigations (484), as well as PQ review articles 
(127), for information about the pharmacokinetics and pharmacodynamics of PQ 
and possible implications for dosing regimens in the clinical setting.  Furthermore, 
no preclinical studies of the combination DHA and PQ were found in a detailed 
literature search. 
 
Chinese pharmacodynamic studies, comparing the efficacy of PQP and PQ base in 
mice infected with CQ-sensitive or CQ-resistant strains of P. berghei, found that PQ 
and PQP have different potencies in prophylactic and therapeutic roles (127).  Qu et 
al. (402) reported that the oral doses of PQ and PQP required to suppress infections 
were significantly different, with PQP apparently more effective at lower doses than 
PQ base (87 ± 4 mg/kg and 65 ± 3 mg of base/kg for PQ base and PQP, respectively; 
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P<0.01) (402).  These results were further supported by Zhu et al. (594) who 
demonstrated that PQP was more potent than PQ base in their model of murine P. 
berghei malaria at doses of 50 and 200 mg base/kg (127, 594).  However, it is 
thought that the difference in efficacy seen between PQ and PQP are more likely to 
be a result of the differences in solubility of the two forms (127).  Further studies 
using the CQ-sensitive and CQ-resistant murine models demonstrated that there 
may be a low level of cross resistance between PQ and CQ, an observation that 
corresponded to later observations in the clinical setting (127, 402).   
 
The pharmacokinetic parameters of PQ have only recently been elucidated in both 
animal models and clinical studies, despite PQ being used as an antimalarial agent 
for over 20 years (127, 232, 425).  In an early pharmacokinetic study in mice, 14C 
labelled PQP was used to determine the accumulation and absorption patterns of 
PQ in mice (95).  The study suggested that PQ had a rapid absorption from the gut, 
with a high systemic availability of 80-90%, and preferentially accumulated in the 
liver, kidney and spleen (95, 127).  Using this method it was also determined that 
PQ had a half-life  of 9 days (95, 127).   However, the validity of these results is 
unclear as the method used to measure the absorption and half-life of PQ is neither 
sensitive nor specific.  Chen et al. (95) measured the total 14C, hence it is unclear if 
there were any radiolabelled metabolites also present at the time of measurement, 
which would contribute to the total 14C measurements made at each time point (95, 
127).  Therefore the results obtained may not reflect the true fate of PQ in the 
murine model.  The pharmacokinetic parameters of PQ in dogs were also described 
in a toxicology study by Sheng et al. (440) where the half-life was reported as 9.4 
days.  However, the accuracy of the reported half-life is unclear as details on how 
the value was calculated were not described (127).  As a result it is important to 
further investigate the pharmacokinetics of PQ in preclinical models to address 
issues such as the erratic absorption of PQ (425), possible enterohepatic 
recirculation (232, 443), parenteral administration, extreme volume of distribution 
(232, 425), or long half-life  (483, 484).   
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A recent study of PQ pharmacokinetics in the rat examined pharmacokinetic 
parameters of PQ after either a single oral dose or i.v. administration (484).  It was 
found that the half-life for PQ after a low dose (13 mg PQP/kg) was 34 ± 19 h and 23 
± 8 h following intravenous and oral administration, respectively.  After high (26 mg 
PQP/kg) dose PQP, a similar half-life of 38 ± 16 h and 25 ± 3 h was obtained for both 
intravenous and oral administration (484).   However, in this study blood samples 
were only collected for 80 h after administration, which does not take into account 
the possibility that PQ could remain in the system for longer than 3.5 days.  Despite 
the short duration of sampling, the authors concluded that as the pharmacokinetic 
properties and metabolism of PQ was similar in the rat to that found in humans, the 
rat is a suitable species for PQ preclinical studies (484).   
 
4.1.4 Study aims 
In order to address the paucity of preclinical pharmacokinetic, efficacy, and safety 
data that are normally required by regulatory authorities and are essential for 
future research, the aim of this study was to obtain robust pharmacokinetic and 
pharmacodynamic data following the administration of single doses of PQ in the P. 
berghei murine malaria model.   To achieve this aim, the study comprised three 
arms: (i) the determination of single dose pharmacodynamic profiles in mice 
infected with P. berghei and given 10, 30 or 90 mg/kg PQP at 2 to 5% starting 
parasitaemia.  Furthermore, at 60 days after drug administration, the 90 mg/kg PQP 
group was reinoculated with P. berghei parasites to test for acquired immunity; (ii) 
the determination of PQ pharmacokinetic parameters in healthy and malaria-
infected mice after administration of 90 mg/kg PQP; (iii) investigation of the 
combination efficacy of 10 mg/kg PQP and 30 mg/kg DHA. 
 
4.2 METHODS   
4.2.1 Materials 
4.2.1.1 Mice 
This study was approved by the Curtin University Animal Experimentation Ethics 
Committee.  Male Swiss mice (5 to 7 weeks of age; average weight 28.9 ± 3.8 g) 
were obtained from the ARC for all experimental work.  Male BALB/c mice (7 to 8 
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weeks of age; ARC) were used for weekly passage of malaria parasites.  All animal 
handling and housing procedures were performed as outlined in Sections 2.1.1 and 
2.2.1.    
 
4.2.1.2 Parasites 
Plasmodium berghei ANKA parasites were maintained by continuous weekly blood 
passage in BALB/c mice (Section 2.2.2.1).  A standard inoculum of 107 parasitised 
erythrocytes per 100 μL was prepared by dilution of blood harvested from infected 
BALB/c mice in citrate-phosphate-dextrose solution (Section 2.2.2.2) and 
administered by i.p. injection to infect the experimental mice (Section 2.2.1.4).    
 
4.2.1.3 Drug Treatment 
PQP was available as a finely crushed powder.  As PQP is only slightly soluble in 
water (231), a uniform suspension had to be prepared for i.p. administration.  To 
prepare the suspension, an accurately weighed mass of PQP was placed in a mortar 
and pestle and several drops (3-5 depending on drug mass) of ethanol added to wet 
the drug.  An accurately measured volume of drug vehicle (Polysorbate 80: glycerol 
80:20% [vol:vol]; drug suspension formulated by Andrzejewski, C. BPharm (Hons), 
Curtin University, 2004) was then added to the drug and well mixed using the 
mortar and pestle.  Care was taken during mixing to prevent the formation of 
bubbles in the suspension.   
 
When administering the doses to experimental mice, 1 mL of suspension was drawn 
from the stock suspension with careful mixing taking place between draws to 
ensure an even distribution of drug throughout the polysorbate 80:glycerol 
suspension.  Due to the high viscosity of the suspension, a 23G needle was required 
for drug administration.  
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4.2.2 Study design 
4.2.2.1 Single dose pharmacodynamic study 
4.2.2.1.1 Dosing 
For the single dose pharmacodynamic study, 3 doses of PQ were chosen for 
investigation, 300 µg, 900 µg and 2,700 µg PQP (approximately 10, 30 and 90 mg/kg 
PQP for 30 g mice; concentration of the PQP suspension was variable and a 
standard 100 µL volume of suspension was administered to the mice).  These doses 
were chosen for investigation as a previous study on the preventive and therapeutic 
effects of PQ in mice infected with P. berghei had demonstrated that the median 
preventative dose of PQ after oral administration was 33.6 mg/kg (402).  Based on 
this premise, the efficacy of PQP was tested in the P. berghei murine malaria model 
using three logarithmically distributed doses.  Considering the observations of Qu et 
al. (402), it was anticipated that the 3 chosen doses (10, 30 and 90 mg/kg PQP) 
would demonstrate ineffective, partially effective and highly effective dosing, 
respectively.   These doses were run in parallel with an untreated control group 
which received only drug vehicle (0 mg/kg PQP) at the time of dosing. 
 
4.2.2.1.2 Drug administration 
Male Swiss mice (n=50) were infected with a standard 107 P. berghei parasitised 
erythrocytes inoculum by i.p. injection. The mice were then divided into 4 
treatment groups consisting of n=8 mice in the untreated control group and n=14 
mice in each of the PQP dose groups.  Sixty-four hours after parasite inoculation, 
when the peripheral parasitaemia had reached a level of 3–5% (confirmed by thin 
blood film microscopy) each mouse received a single i.p. dose of 0, 10, 30 or 90 
mg/kg PQP, depending on their selected treatment group.   
 
After drug administration, the parasitaemia in each mouse was monitored through 
the preparation of peripheral tail vein blood smears which were subsequently 
stained in May-Grunwald Giemsa and then examined under 100x oil immersion light 
microscopy.  In order to characterise the pharmacodynamic response to PQP 
administration with rich data, tail vein bleeds were performed 3 times a day for the 
first 5 days after treatment, twice daily for the next 2 weeks and then daily until the 
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time of euthanasia (>40% parasitaemia, >10% reduction in mouse body weight in 
less than 24 h or termination of the experimental protocol).  Mice were euthanased 
with sodium pentobarbitone injection (50-100 mg/kg i.p.). 
 
4.2.2.1.2 Parasite re-inoculation at 60 days post PQP-administration 
Preliminary pilot studies (Andrzejewski, C. BPharm (Hons), Curtin University, 2004) 
demonstrated that after dosing with 90 mg/kg PQP, all mice survived to the 
experimental end point (56 days) with many mice maintaining persistently low 
parasitaemias.  Therefore, one objective of this investigation was to determine if 
these mice had acquired immunity towards the P. berghei parasites as a result of 
the persistent subclinical levels of infection.    
 
All mice that had initially received a single 90 mg/kg dose of PQP in the single dose 
pharmacodynamic study were re-inoculated with a second 107 P. berghei 
parasitised erythrocyte i.p. inoculum 60 days after drug administration.  
Furthermore, three control arms were run in parallel with the re-inoculated group 
consisting of uninfected age matched mice that received either (a) drug vehicle 
(n=4), (b) 90 mg/kg PQP (n=8) or (c) remained untreated (n=4) on day 0.  These 
groups were required to control for age and/or PQ concentrations, 60 days after 
drug administration.  All control groups were subsequently inoculated with 107 P. 
berghei parasitised erythrocytes 60 days after dosing.  Parasitaemia was monitored 
by daily peripheral blood films as previously described.   
 
4.2.2.2 Pharmacokinetic Study 
4.2.2.2.1 Drug administration and blood sampling 
The pharmacokinetic parameters of PQ were determined in both healthy and 
malaria-infected mice.  To determine the pharmacokinetics of PQ in healthy mice, 
55 male Swiss mice (6 weeks old) received a single i.p. dose of 2,700 µg PQ 
phosphate (PQP; 100 µL of suspension; approximately 90 mg/kg).  This PQP dose 
was selected as pharmacodynamic time-density profiles suggest that 90 mg/kg PQP 
had prolonged antimalarial efficacy and ensured lengthy survival for malaria-
infected mice.  It was therefore desirable to ascertain whether the observed 
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antimalarial efficacy was a result of drug concentrations, immunological 
mechanisms or a combination of the two.  Mice were divided into 11 groups of n=5 
mice, with each group representing a collection time point.   
 
Blood was harvested from each group by cardiac puncture at 0, 2.5 and 8 h, and 1, 
2, 4, 7, 10, 14, 18 and 25 days after drug administration.  Each mouse blood sample 
was placed into a lithium heparin anticoagulant tube (Vacutainer®; Becton-
Dickinson, NJ, U.S.A), centrifuged at 10,000 g for 5 min with the plasma then 
separated and stored at -80oC until HPLC analysis. 
 
A second pharmacokinetic study was conducted using malaria-infected mice.  Male 
Swiss mice (n=100) were inoculated with 107 P. berghei parasitised erythrocytes by 
i.p. injection and then were dosed, 64 h after inoculation, with a single i.p. dose of 
2,700 µg PQP (100 µL of suspension; approximately 90 mg/kg).  Blood was 
harvested from groups of n=5 mice at 0, 2, 4, 6, 12, 16 h and 1, 1.25, 2, 2.3, 3, 4, 7, 
9, 15, 22, 30, 40 and 52 days after drug administration.  All blood samples were 
prepared for HPLC analysis as described previously for the healthy mice.  
 
4.2.2.2.2 Pharmacokinetic analysis 
4.2.2.2.2.1 Preparation of stock solution and standard curve for HPLC assay 
All HPLC analyses were performed by Dr Madhu Page-Sharp (Research Fellow, 
Curtin University / UWA). 
 
Stock solutions of PQP (1 mg/mL PQ base in water) and the internal standard CQ 
phosphate (1 mg/mL CQ base in water) were prepared and stored in the dark at 
4°C.  When stored in these conditions the stock solutions were deemed stable for 
up to 50 days (231).  Working stock solutions were regularly prepared from the 
stock solutions.   For each analytical batch, a 5-point linear calibration curve was 
prepared by spiking blank human plasma with appropriate volumes of the working 
standards.  Quality Control (QC) samples (5 µg/L and 50 µg/L) were also included in 
each analysis. Human plasma was used for all quality control samples as this was 
readily available in large volumes.   
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4.2.2.2.2.2 Piperaquine assay 
Mouse plasma samples were assayed for PQ based on the method published by 
Hung et al. (231) with several minor modifications made as a result of the limited 
sample volume. Briefly, plasma samples (0.5 mL) were spiked with internal standard 
(200 ng CQ), then alkalinized with 0.1 mL of 1M NaOH.  The samples were extracted 
by manual shaking (10 min) with 8 mL of hexane:isoamyl alcohol (90:10). After 
centrifugation at 1,500 g for 10 min, the supernatant (7 mL) was back extracted into 
0.1 mL of 0.05M HCl by manually shaking for 5 min, followed by centrifugation at 
1,500 g for 10 min.  The organic layer was aspirated to waste whilst the HCl layer 
was transferred to a round-bottomed borosilicate glass tube which was then 
centrifuged at 1500 g for 20 min.   The HCl extract was then transferred to an HPLC 
sample vial and a 100 µL aliquot was injected onto the HPLC.   
 
Separations were achieved on a Waters XterraTM RP18 (3.5 µm, 4.6 x 100 mm) 
column attached to a Waters SymmetryTM C18 (5 µm, 3.9 x 20 mm) guard column.  
The mobile phase consisted of acetonitrile (7% v/v) in water containing sodium 
chloride (0.1% w/v), trifluroacetic acid (0.025% v/v) and triethylamine (0.008% v/v).  
The mobile phase was pumped at 1.2 mL/min and the UV absorbance of analytes 
was detected at 340 nm.  
 
The intra-day relative standard deviations of PQ were 10.8, 8.2, and 9.4% at 5, 200 
and 1000 µg/L, respectively (n=5).  Inter-day relative standard deviations were 11.6, 
4.4 and 6.7% at 5, 200 and 1000 µg/L, respectively (n=25). The limit of 
quantification and limit of detection were 1.5 µg/L and 0.7 µg/L, respectively.   
 
All samples were assayed within the frozen storage stability limits for PQ, which had 
previously been established as 12 months (Hung, T-Y, B Med Sci Thesis, University of 
Western Australia, 2003).   
 
4.2.2.3 PQ and DHA combination study 
The combination study compared the pharmacodynamic responses between groups 
of mice that received either single doses of PQP, DHA or PQP + DHA. Male Swiss 
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mice (5-6 weeks; n=50) were inoculated with 107 P. berghei parasitised erythrocytes 
by i.p. injection, then divided into a control group (n=8) and three treatment groups 
(Groups A, B and C; n=14 per group).  Sixty-four h after inoculation Group A mice 
received 10 mg/kg PQP, Group B mice received 30 mg/kg DHA and Group C mice 
received successive doses of 10 mg/kg PQP and 30 mg/kg DHA, by i.p. injection.  
Parasitaemia was monitored by examination of peripheral blood smears.   
 
4.2.3 Pharmacodynamic  analysis 
Peripheral blood films were stained with May-Grunwald Giemsa using a Hema-Tek 
staining machine within an hour of preparation with all films cover-slipped (DePex 
mounting medium) and stored until time of examination (Sections 2.2.2.4 and 
2.2.2.5).  To minimise counting variability, which is inevitable when multiple 
microscopists determine parasitaemia within a single study, all peripheral blood 
smears were examined and parasitaemia determined by the author.  Parasitaemia 
was determined by counting either 30 or 100 fields of view for >0.5% and <0.5% 
parasitised erythrocytes, respectively.  This procedure ensured an acceptable 
standard error of 22% at 0.1%  parasitaemia (277) and a limit of detection in the 
order of 0.002% parasitaemia.  
 
4.2.4 Pharmacokinetic  analysis 
For pharmacokinetic modelling, measured plasma PQ concentrations were 
normalised to a dose of 90 mg/kg PQP (52 mg/kg PQ base), according to the weight 
of each mouse at the time of dosing. Consistent with the principles of destructive 
testing (37, 593), the mean normalised plasma PQ concentration for each group of 
mice was used to estimate the pharmacokinetic parameters of PQ. Pharmacokinetic 
analysis was performed using Kinetica™ Version 4.2 (Thermo Fisher Scientific, Inc., 
Waltham, MA, USA). Non-compartmental analysis of the plasma drug 
concentration-time data was used to estimate area under the curve (AUC; log-linear 
trapezoidal method), terminal elimination half-life (t½), apparent clearance (CL/F) 
and apparent volume of distribution (V/F) (429). A two-compartment model was 
fitted to the data to estimate pharmacokinetic descriptors for the observed biphasic 
elimination (t½α and t½β; weighting = 1/y
2). 
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4.3 RESULTS 
4.3.1 Single dose pharmacodynamic study 
Administration of single dose PQP (10, 30 or 90 mg/kg) resulted in a decline in 
parasitaemia at all doses tested (Fig. 4.2). The nadir parasitaemia in the 10 mg/kg 
group occurred 36 h after dosing and was 12.8 ± 3.1 fold below the pre-dose 
parasitaemia. Parasite nadir was immediately followed by parasite recrudescence 
and a rapid rise in parasitaemia until time of euthanasia. The median survival time 
was 10 days (range 5 to 12 days).  
 
After a single dose of 30 mg/kg PQP, the parasitaemia immediately declined and fell 
below the limit of detection (0.002%) 1.8 days after dosing.  However, a detectable 
parasitaemia was observed briefly, 2.5 days after dosing, but otherwise remained 
undetectable until 7-8 days after dosing.  At this time, recrudescence was observed 
and the parasitaemia continued to rise for a further 2-3 days (Fig. 4.2).  From 10-18 
days, the mean parasitaemia remained stable (0.5-2.5%) and then decreased to 
approximately 0.1% from days 22-30. Beyond day 30, the mean parasitaemia slowly 
increased until mice required euthanasia.  The median survival time for the 30 
mg/kg group was 54 days (range 8–59 days).  Within this 30 mg/kg group, 4 mice 
(30%) showed a steady increase in parasitaemia after recrudescence and required 
euthanasia after a median of 22 days (mean parasitaemia 11%).   
 
In the 90 mg/kg group, the mean parasitaemia declined rapidly and was 
undetectable by 36 h after dosing. Recrudescence occurred after 7-8 days in all 
mice, with a mean peak parasitaemia of 1.8 ± 1.6% observed 16 days after dosing. 
The parasitaemia declined and generally remained below 0.1% until the 
experimental end-point, 60 days after dosing. All mice were active, alert and had 
stable body weight throughout the course of the study.  
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Figure 4.2 Parasitaemia-time profile in Swiss mice following a single i.p. dose of 
PQP administered 64 h after inoculation with 107 P. berghei parasitised 
erythrocytes. Data are shown as total parasitaemia (% of infected erythrocytes ± 
SD), commencing from the time of PQP administration. Control (n=8;  ──); 10 
mg/kg (n=14;  ──); 30 mg/kg (n=13;  – –); 90 mg/kg (n=14;  ──). Panel B 
shows an expanded view for the first 5 days after drug administration. 
 
 
 
 
 
A 
B 
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4.3.2 Parasite re-inoculation at 60 days 
All 3 groups of control mice, which were either untreated or received vehicle or 90 
mg/kg PQP on Day 0 and then inoculated with 107 P. berghei parasites on day 60, 
demonstrated similar parasite responses.   After inoculation all groups showed 
rapidly increasing parasitaemias with euthanasia required 4 days after infection as 
peripheral parasitaemias reached >10% (Fig. 4.3).  Mice that had previously been 
inoculated and received 90 mg/kg PQP on Day 0, and were re-inoculated on Day 60, 
remained asymptomatic for two weeks (pre-determined end-point) with only low-
level parasitaemias observed during this period of time (generally <1%) (Fig. 4.3).   
 
4.3.3 Pharmacokinetic Study 
HPLC chromatograms are shown in Fig 4.4.  The CQ internal standard eluted at 1.4 
min whilst PQ eluted at 4.5 min (Fig. 4.4; B).  The chromatogram confirmed that CQ 
was a suitable internal standard as there was adequate separation between the two 
peaks, thus a reduced probability of the peaks interfering with one another.  The 
blank plasma was also shown to be free of endogenous substances (Fig. 4.4; A). All 
analysed mouse plasma samples showed two drug peaks (CQ and PQ) and no 
indication of drug metabolites or other interfering substances (Fig. 4.4; C).  Mouse 
plasma sample 22 (Fig. 4.4; C), taken from a healthy mouse 12 hours after drug 
administration, had a PQ concentration of 136 µg/L.      
 
Pharmacokinetic data from both healthy and malaria-infected mice are summarized 
in Table 4.1 and presented in Fig. 4.5.   The plasma PQ concentration-time profiles 
and pharmacokinetic descriptors were similar in healthy and malaria-infected mice. 
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Figure 4.3  Parasitaemia-time profile in Swiss mice following a single dose of PQP (90 mg/kg; n=14;  ──) at time zero, and also following 
subsequent re-inoculation with 107 P. berghei parasitised erythrocytes at 60 days. Data are shown as total parasitaemia (% of infected erythrocytes 
± SD). Three control groups studied at the 60 day point comprised uninfected Swiss mice that were age-matched and inoculated for the first time 
after 60 days: Untreated at day 0 (n=4;  ──); Vehicle at day 0 (n=4;  ──); PQP 90 mg/kg at day 0 (n=4;  ──).   
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Figure 4.4 High performance liquid chromatography chromatograms for analysis 
of piperaquine concentrations in mouse plasma samples.  Chromatograms 
demonstrate results for A: Blank human plasma; B: Drug Standards; C: Mouse plasma 
sample analysis.  Peaks identified were 1. PQ internal standard (1.4 min); 2. CQ 
standard (200ng; 4.5 min); 3. PQ in mouse plasma sample 22 (136 μg/L) and 4. CQ 
internal standard. 
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Figure 4.5 Concentration-time profile of PQ in mice given approximately 90 
mg/kg i.p. PQP (normalized for pharmacokinetic analysis, Section 4.2.3).  Data are 
given as mean ± SD plasma PQ concentration (n=5) in healthy ( ─ ─) and malaria-
infected ( ──) mice. The lines represent the best fit of a two-compartment model to 
the respective data sets (extrapolated beyond the last data point for healthy mice (25 
days) to facilitate comparisons). 
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Table 4.1  Pharmacokinetic parameters for PQ following i.p. (2,700 µg; 90 
mg/kg) administration in healthy and malaria-infected male Swiss mice.  
Pharmacokinetic parameters were determined using both non-compartmental 
analysis (t1/2, AUC, CL/F and V/F) and from a two-compartment model (t½α and 
t½β).  
 
 
Uninfected mice 
(n=50) 
P. berghei infected mice 
(n=100) 
t1/2  (days) 17.8 16.1 
t1/2α  (days) 0.59 0.35 
t1/2β  (days) 20.7 15.4 
AUC   (mg.h/L) 33.53 27.34 
CL/F   (L/h/kg) 1.55 1.9 
V/F   (L/kg) 956 1059 
 
 
4.3.4 PQ and DHA combination study 
The effects of single dose PQP (10 mg/kg), DHA (30 mg/kg) and a combined dose of 
PQP + DHA (10 mg/kg PQP + 30 mg/kg DHA) are summarized in Figure 4.6 (data 
normalized for clarity)  The starting parasitaemia was 4.5 ± 1.1% for control mice (n=8), 
4.6 ± 1.1% for DHA (n=14), 1.5 ± 0.6% for PQP (n=14; P<0.001 compared to other 
groups; ANOVA) and 3.7 ± 1.5% for PQP + DHA combination (n=14).  Because of the 
differences in the starting parasitaemias between the groups, it was decided to 
normalize the parasitaemias (expressing parasitaemia as a proportion of the initial 
parasitaemia) to facilitate comparison between treatment groups, particularly when 
determining the time to, and level of, parasite nadir.   
 
Parasite nadir occurred at 24, 28 and 36 h after administration of DHA alone, PQP+DHA 
and PQP alone, respectively.  Comparison of parasite nadirs for the DHA, PQP and PQP 
+ DHA treatment groups showed a 11.9 ± 4.8, 12.8 ± 3.1 and 22.4 ± 11.8 fold decrease 
in parasitaemia from the time of drug administration (P=0.007; PQP + DHA compared 
to both DHA and PQP alone; ANOVA).  
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Figure 4.6  Parasitaemia-time profiles in mice as a proportion of parasitaemia at 
the time of dosing (mean ± SD). Mice were given vehicle i.p. (n=8;  ──), 10 mg/kg 
PQP i.p. (n=14;  ──), 30 mg/kg dihydroartemisinin i.p. (n=14;  ──), 10 mg/kg PQP 
plus 30 mg/kg DHA (n=14;  ──). 
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4.4 DISCUSSION 
Using a modified murine efficacy model (Rane) this novel and detailed investigation of 
PQ demonstrated a potent, long lasting antimalarial efficacy in mice infected with P. 
berghei parasites.  Furthermore, the combination of PQP and DHA led to enhanced 
efficacy, compared to either drug alone, with a slightly faster decline in parasitaemia 
and a significantly lower nadir, suggesting an additive effect.   
 
The pharmacokinetic properties of PQ have recently been well established in humans 
with the highly lipid-soluble drug having a long elimination half-life of approximately  
23 days (19-28 days) in adults and 14 days (10-18 days) in children (10, 203, 232, 253, 
254, 286, 425, 443, 480, 484).  Meanwhile, pharmacokinetic parameters of PQ in a 
murine model are scant with a single Chinese report (95) which suggested a half-life of 
9 days in mice using 14C-labelled PQ phosphate.  The current study demonstrated that 
PQ has a long terminal elimination half-life.  Malaria-infected and healthy mice showed 
similar pharmacokinetic profiles with biphasic elimination and a terminal half-life of 
17.8 and 16.1 days, respectively.  Although the half-life determined in this study is 
almost double that previously reported, the method used to determine plasma PQ 
concentration (231) is more robust than the 14C-labelled PQP method used by Chen et 
al. (95), which has been described as problematic (127).   
 
The single dose pharmacodynamic study showed that PQ has a relatively prompt initial 
effect in decreasing the parasitaemia with an ED50 that appears to be in the order of 30 
mg/kg.  An ED50 within this dosing range was presumed because after receiving a single 
i.p. dose of 30 mg/kg PQP, the drug appeared to be relatively ineffective for 1/3 (n=4) 
of mice in this cohort (n=13) whilst the remaining 2/3 of mice showed long lasting 
antimalarial efficacy.  By comparison, an in vivo study of PQ and PQP in a CQ-sensitive 
strain of P. berghei determined that the ED50 of PQ and PQP (base equivalent) was 5.0 
± 0.2 mg/kg and 4.5 ± 0.1 mg/kg, respectively (127, 402).  
 
A single dose of 90 mg/kg PQP was seen to be highly effective for the clearance of 
parasitaemia in all mice.   Initially the parasitaemia fell below the limit of detection for 
approximately one week, at which time peripheral parasitaemia again became evident. 
However, instead of a terminal recrudescence, all mice maintained subclinical levels of 
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infection until the experimental endpoint, 60 days after the initial dose of PQ.  At this 
time all mice were re-challenged, resulting in an apparent resistance to the inoculum 
with no notable changes in parasitaemia observed.  The observed response is highly 
suggestive of the mice having a degree of immunity towards the P. berghei parasites. 
In order to consider the mechanisms responsible for the current observations, further 
investigation into the effect of host age, host immunological status, parasite viability 
and potential drug resistance was conducted in the next phase of PQ studies, which 
are reported in Chapter 5.   
 
Linking the parasitaemia-time profiles for the 90 mg/kg PQ dose group (Figs. 4.2; A and 
B), to the corresponding pharmacokinetic data (Fig. 4.4) indicates that plasma PQ 
concentrations fell from a mean of 250 µg/L, 2 h after the dose, to 45 µg/L 
approximately 36 h after the dose, at which time the parasitaemia was below the limit 
of detection (0.002%). During the period of undetectable parasitaemia, 2-7 days after 
drug administration, the plasma PQ concentration was approximately 20-50 µg/L. In 
most mice, PQ concentrations >10 µg/L persisted for at least 30 days and the 
extrapolated mean plasma PQ concentration at 60 days after dosing (the time of the 
re-inoculation experiment) was 3 µg/L in malaria-infected mice and 5.5 µg/L in control 
mice.  At these low drug concentrations it was presumed that the antimalarial efficacy 
of PQ was insufficient to control or prevent relapsed parasitaemia.  
 
Although the introduction of the potent artemisinin derivatives into the clinical setting 
has proved to be highly successful in the treatment of uncomplicated malaria, their 
characteristics as short acting drugs with high recrudescence rates (in short-term 
dosing regimens) means that it is imperative that they be combined with a second 
antimalarial drug for clinical use (127, 584).  It has been recommended that the 
partner antimalarial should be a long-acting drug with a half-life that extends at least 
two parasite life-cycles (>4 days), have good tolerability, be low cost and have limited 
pre-existing drug resistance (127, 232). In this context, PQ makes a good partner drug 
for the artemisinin derivatives as it has a median half-life that is 3 to 6 times greater 
than that recommended and rates well on tolerability, cost and shows limited 
resistance (127, 232).   
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The purpose of the combination study was to demonstrate the initial response of PQ 
both in direct comparison and in combination with DHA. After a single dose of PQ the 
parasitaemia was seen to remain stable for 12 h before any decline was observed.  In 
comparison, those mice receiving a single dose of DHA demonstrated an immediate 
decline in parasitaemia followed by a rapid rate of parasite recovery as shown 
previously (Chapter 3 and (179)).  Parasite nadir was also seen to differ between the 
two single dose administrations occurring 24 and 36 h after dosing for PQ and DHA, 
respectively. The combined dose resulted in a rapid decline in parasitaemia which was 
consistent with the single dose DHA profile, although the parasite nadir was lower and 
later than the single dose curve.  This therefore demonstrates the influence of PQ in 
the combination dose.  Those mice receiving the combined dose also demonstrated a 
slower rate of parasite recovery and a longer survival time in comparison to the single 
dose administrations.  This suggests that although single dose PQ is an effective 
antimalarial therapy, the rate of parasite decline and overall efficacy is enhanced when 
given in combination with DHA.   
 
The current data suggests an additive interaction between the combined PQ and DHA 
dose, however, the results do not provide enough evidence to dismiss the possibility of 
synergism.  This is consistent with published data in that previous animal models have 
demonstrated additive efficacy between DHA and PQ (27, 512), whilst a recent in vitro 
study conducted by Davis et al. (2006) demonstrated that DHA showed either no 
interaction or was mildly antagonistic when combined with PQ (126).    
 
Despite the persistence of low concentrations of PQ post-treatment, re-inoculation 
with P. berghei parasites shows that the low concentrations of drug in circulation may 
not necessarily impede the development of an infection.  The long elimination half-life 
of PQ is a predisposing factor for the potential emergence of any resistance, which was 
evident when PQ was used as a monotherapy in China in the 1970s (127, 209, 217, 
425).  However, when used in combination with artemisinin derivatives, which have a 
parasiticidal effect that both accelerates therapeutic responses and reduces parasite 
biomass, the extended efficacy of PQ is thought to prevent any potential 
recrudescence.   This would thereby eliminate residual parasites thus reducing the 
number of surviving mutant parasites which in turn prevents any resistance towards 
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either drug (46, 209, 252, 477).  Clinical studies have actually suggested that the 
extended post-treatment prophylaxis of PQ may reduce both relapse and reinfection 
for a period of 4-6 weeks after treatment (27, 209, 408).  As a result, patients remain 
asymptomatic for a longer period, which increases the time for haematological 
recovery, resulting in the risk of anaemia been halved, as well as a reduced gametocyte 
carriage rate (209, 408).  Therefore, it is thought that although the post-treatment 
prophylaxis provided by PQ in this combination therapy will not prevent subsequent 
relapses, this drug combination has the capability of delaying the potential of relapse 
(408).  
 
Results obtained in this series of investigations have determined that in this P. berghei 
malaria model PQ gave effective antimalarial efficacy after single dose administration, 
enhanced antimalarial efficacy when combined with DHA and an extended period of 
post-treatment prophylaxis.  However, the results also raised a number of questions 
relating to whether the demonstrated extended antimalarial efficacy was due primarily 
to PQ or if the animal had acquired immunity towards the infecting species of 
parasites.  In order to address these questions, further investigation into parasite 
viability, drug efficacy, drug resistance and immunological influences was performed 
(Chapter 5).   
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CHAPTER FIVE 
 
PIPERAQUINE EFFICACY STUDY 
 
5.1 INTRODUCTION 
5.1.1 Clinical efficacy of long half-life drugs 
Clinical studies involving the use of contemporary ACT strategies, where PQ has been 
incorporated as a partner to either DHA (27, 29, 127, 139, 209, 217, 244, 252, 253, 305, 
413, 456, 595) or artemisinin (476), demonstrate high efficacy and good tolerability for 
the treatment of both P. falciparum (27, 29, 139, 217, 252, 305) and P. vivax (209, 232, 
253, 336) infections.  The success of these ACT strategies, both in the resolution of 
parasitaemia and the prevention of drug resistance, has been attributed to PQ having a 
long terminal half-life in humans of 12-28 days (232, 286, 480, 481), fulfilling the 
requirement for a partner drug that is a long-acting schizontocide with a half-life 
exceeding 4 days (or two asexual parasite life-cycles) (232, 351).   
 
However, the long half-life of PQ also raises concerns about adverse effects and drug 
resistance (209, 232, 336, 386).   Traditionally, drugs with a long terminal elimination 
half-life have been sought as partner drugs in combination therapies, as the use of a 
single or small number of doses in treatment regimens ensures therapeutic 
compliance.  Also, if used for prophylaxis, treatment is only required on a once weekly 
basis (558).  It is well established that drugs with a long elimination half-life are 
potentially vulnerable to the development of resistance as parasites are inevitably 
exposed to suboptimal/ subtherapeutic drug concentrations for extended periods of 
times when these drugs are used as monotherapy (541, 558).  This phenomenon has 
been described by White (550), who demonstrated how slowly eliminated 
antimalarials such as CQ or PQ present a lengthy opportunity for the selection of 
resistance among sensitive parasites (MIC A; Fig. 5.1).  However, once resistance has 
become established (MIC B), blood concentrations are no longer inhibitory and the 
terminal elimination phase is no longer a factor in parasite clearance (Fig. 5.1; (550)).    
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Figure 5.1 Demonstration of prolonged duration of exposure to subtherapeutic 
concentrations of drug and the subsequent acquisition of drug resistance.   After the 
use of an antimalarial drug with a long terminal elimination half-life, such as 
chloroquine or piperaquine, sensitive parasites (MIC A) are exposed for prolonged 
periods of time to sub-therapeutic blood concentrations of the drug in monotherapy 
facilitating the opportunity for the acquisition of parasite resistance towards the 
antimalarial drug in use.   Once parasites have gained resistance towards the 
antimalarial drug (MIC B), the long terminal half-life effect of the drug is no longer 
effective and blood concentrations are no longer inhibitory.  Diagram from White, 
2004  (550).   
 
5.1.2 Acquired immunity 
In 1980, Bruce-Chwatt (72) wrote “Malaria immunity may be defined as the state of 
resistance to infection brought about by all those processes which are involved in 
destroying the plasmodia or by limiting their multiplication.  Acquired immunity may 
be either active or passive.  Active immunity is an enhancement of the defence 
mechanism of the host as a result of a previous encounter with a pathogen.  Passive 
immunity is conferred by the prenatal or postnatal transfer of protective substances 
from mother to child by the injection of such substances”.   
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Whilst the principal features of naturally acquired immunity have been defined, there 
is currently little known about the underlying mechanisms behind its activation and 
maintenance (25, 140, 144, 229, 321, 369).  The development of clinical and 
parasitological immunity to malaria is evident by the ability of the host to control the 
parasite density and hence the progression of the infection (144, 159).  Although 
achievable after a single infection, acquired immunity is seen to be primarily directed 
towards the erythrocytic stage with induction of adequate protective immunity usually 
requiring repeated infections (144, 159, 592).  Immunity is species specific (102, 245, 
591) but not necessarily strain specific (65, 66, 245).  Furthermore, acquired defence 
mechanisms often have been shown to lose their protective effect soon after the 
exposure to infection is interrupted, with the host becoming susceptible to new clinical 
infections of malaria (140).  The introduction of asexual erythrocytic stage immunity 
has been demonstrated in humans, monkeys, birds and mice (167, 168, 223, 226, 308, 
444, 460, 474, 479).  
 
5.1.3 Relationships between antimalarial therapy and immunity 
Despite the desire to eliminate parasites from infected patients as quickly as possible, 
it must also be considered that when treating patients living in endemic countries it 
may be preferable for the infection to clear through both a combination of active 
antimalarial therapy and the patient’s immunological response mechanisms (157, 304, 
478). This was demonstrated in a study by Enevold et al. (157) where it was observed 
that a child’s naturally acquired immunity enhanced the clinical efficacy of drug 
therapy in the clearance of P. falciparum infections.  These results suggested that 
recovery from malaria may depend on drug efficacy, parasite drug-resistance as well as 
a complex interaction with host factors such as acquired immunity and innate 
resistance (157).  Should a patient have had prior opportunity to acquire immune 
responses towards a strain of Plasmodium, the combination of both the natural 
immune response and drug therapy will strongly influence the rates of recrudescence 
following treatment, the perseverance of subclinical infection which normally would 
promote drug resistance, and the transmission of future progeny of infection (117, 
304).   
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Immunity to re-inoculation has also been shown in mice from which parasites were 
eradicated by use of a curative drug (64).  When this group of mice was challenged 
with a second infection (after treatment with drug), the majority of animals survived in 
comparison to those mice which remained untreated, which succumbed to the 
primary infection (64).  Further studies combining the use of treatment and natural 
immunity for the control of infection, demonstrated that only mice that received sub-
curative treatments, and thus had parasites present for a prolonged period during the 
primary course of infection, could induce a level of protective immunity (64, 113-115, 
287).  
 
5.1.4 PQ resistance in murine models 
The development of PQ-resistant strains of the murine malaria P. berghei were first 
described by Li et al. (279, 280).  Through increasing drug pressure over a period of 5 
months, two PQ-resistant P. berghei strains (P. berghei ANKA and P. berghei K 173), 
were developed using in vitro methods (127, 279, 280).   Although these two in vitro 
PQ-resistant strains were then utilised to test for cross resistance between PQ and a 
range of antimalarial drugs, it was observed that once drug pressure subsided the 
parasites returned to their sensitive phenotype (279, 280).   
 
More recently, an in vivo model of PQ-resistant P. berghei ANKA was described in 
which resistance was selected through continuous drug pressure over a period of 18 
months (259).  However, in contrast to earlier models this line of PQ-resistant malaria 
demonstrated stable selection of PQ-resistance, which was defined by the 
maintenance of the resistant phenotype when drug selection pressure was removed, 
for at least 10 serial passages (177, 259). 
 
5.1.5 Study aims 
Dose ranging studies of sub-therapeutic doses of PQP in the P. berghei murine malaria 
model demonstrated that after high dose (90 mg/kg) PQP a chronic P. berghei 
infection developed that extended to the experimental end-point of 60 days (Chapter 
4; see Fig. 5.2).   Furthermore, when all mice were re-infected with a second 107 P. 
berghei parasite inoculum there was no change in the course of infection, with the 
subclinical chronic infection remaining stable.  The previous study had also shown that 
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25 days after 90 mg/kg PQP, the subclinical parasitaemia was in the order of 1% 
infected erythrocytes and the plasma PQ concentration was approximately 14 µg/L 
(Section 4.3.3). By comparison, at 40 and 60 days the subclinical parasitaemia was 
stable at approximately 0.1% and the plasma PQ concentrations (3 to 7 µg/L) were 
considered unlikely to have an antimalarial effect.  As the previous study did not 
extend beyond 60 days, the present study was designed to clarify the duration of 
antimalarial efficacy.  
 
Therefore, the aims of the present study were to investigate drug efficacy, re-
inoculation outcomes and parasite viability after a single dose of PQP in the P. berghei 
murine malaria model.  The significance of determining all of these factors was to 
provide a greater understanding of how single dose administration of a long half-life 
drug such as PQ, influence parasite pharmacodynamics, mouse immunological 
responses and parasite response to continual exposure to suboptimal drug 
concentrations.  This could clarify the influence of PQ on both parasite and host 
responses.   Furthermore, detailed preclinical pharmacodynamic data for PQ, alone or 
in combination with artemisinin drugs will complement clinical studies, especially 
when there is interest in the therapeutic impact of persistent low PQ concentrations.  
 
5.2 METHODS 
5.2.1 Pharmacodynamic efficacy of 90 mg/kg PQP 
In order to investigate whether the observed prolonged subclinical infection was a 
result of the antimalarial effect of PQ alone or a combination of factors, three distinct 
groups of mice were studied simultaneously.  The purpose of this study design was to 
determine the effects of (i) animal age at time of inoculation, (ii) prolonged presence 
of PQP and (iii) acquired immunity at pre-determined time-points (25, 40, 60, 90 and 
130 days after PQP administration) along the pharmacodynamic curve.    
 
5.2.1.1 Selection of investigation time-points 
After careful consideration of the pharmacodynamic profile of 90 mg/kg PQP in the P. 
berghei murine model, as demonstrated in the previous chapter, investigation time-
points of 25, 40, 60, 90 and 130 days after drug administration were selected.  These 
time-points reflected times of significant change in the drug pharmacodynamics (Fig. 
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5.2).  After drug administration the parasitaemia was seen to rapidly decline, falling to 
undetectable levels by 36 h, with parasite recrudescence observed at 7 days after PQP.  
The parasitaemia was seen to plateau, and then steadily decline about 20-30 days after 
drug administration, with a persistent parasitaemia in the range of approximately 0.01-
0.1% until day 60.   
 
Therefore, the time-points selected for this investigation reflect a period of declining 
parasitaemia (25 days), low level persistent parasitaemia (40 and 60 days), and 
approximately one and two months after the experimental end point of the previous 
study (Fig. 5.2).  
 
Figure 5.2 Pharmacodynamic curve of 90 mg/kg PQP in the P. berghei murine 
malaria model (adapted from Fig 4.2 A, Chpt 4).  Time-points for further investigation 
(; 25, 40, 60, 90 and 130 days after PQ administration) were selected to reflect 
significant periods of time in the pharmacodynamic profile.   
 
 
5.2.1.2 Experimental protocol 
a) Group A (Age control) – Previous studies have identified that the age of a 
rodent, at the time of inoculation with plasmodium parasites, influences the 
course of infection (4, 596).  In particular, it was demonstrated in rats that 
when young (4 weeks) and mature (8 weeks) animals were infected with similar 
inoculums of P. berghei parasites, the young animals were more susceptible to 
infection and had a higher mortality rate, than the older rats (4).  It was 
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therefore desirable in the present study to determine whether there were any 
age related effects on time of inoculation, in the murine P. berghei model.    
 
Uninfected 5-6 week old male Swiss mice (n=20) were given a single 
administration of drug vehicle at Day 0.  At each of the pre-determined time-
points, groups (n=4) of mice were inoculated with a standardised inoculum of 
107 P. berghei parasites by i.p. injection (Fig. 5.3).  The mouse age at each 
inoculation time point was therefore, 9-10 weeks, 11-12 weeks, 14-15 weeks, 
18-19 weeks and 24-25 weeks at 25, 40, 60, 90 and 130 days, respectively.  
Parasitaemia was monitored through the preparation and examination of twice 
daily blood films. Mice were euthanased when parasitaemia exceeded 40%.  
 
b) Group B (PQ control) – The purpose of the second control group was to 
determine the antimalarial efficacy of PQ by establishing whether the PQ 
concentration at each designated time point was sufficient to suppress or 
resolve parasitaemia after inoculation.  
 
Uninfected 5-6 wk old male Swiss mice (n=30) received a single administration 
of 90 mg/kg PQP on Day 0 (Fig. 5.3).  At each pre-determined time point (25, 
40, 60, 90 or 130 days after drug administration) groups of mice (n=6) were 
injected with a standardised inoculum of 107 P. berghei parasites.  Parasitaemia 
was monitored through the preparation and examination of twice daily blood 
films.   
 
c) Group C – The purpose of the primary study group was to determine whether 
those mice that maintained a persistently low parasitaemia after drug 
treatment had acquired a degree of immunity to this strain of P. berghei.  In 
order to determine whether this had occurred, P. berghei infected and PQP-
treated mice were exposed to a second inoculum of P. berghei parasites at 
each designated time-point (25, 40, 60, 90 and 130 days after drug 
administration).  It was expected that if any parasite suppression was observed 
or if a new infection failed to develop, which could not be explained by animal 
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age or drug influences (control arms), this would suggest that a degree of 
immunity to the infecting strain of parasites had been acquired.  
 
The efficacy group consisted of 5-6 week old male Swiss mice (n=50) that were 
initially inoculated with a standardised inoculum of 107 P. berghei parasites.  
When parasitaemia had reached a level of approximately 3-5% (64 h after 
inoculation), each infected mouse received a single dose of 90 mg/kg PQP by 
i.p. injection (Fig. 5.3).  At each designated investigation time point, groups of 
mice (n=6) were re-inoculated with a standardised inoculum of 107 P. berghei 
parasites (from the same initial parasite stock as the initial infection; refer to 
5.2.2) by i.p. injection. Furthermore, at each experimental time point a second 
sub-group of mice (n=4) was used for parasite viability passage (Refer to 5.2.2). 
Parasitaemia was monitored through preparation and examination of twice 
daily blood films until time of euthanasia.  
 
5.2.1.3 Pharmacodynamic profile 
In order to determine the pharmacodynamic time-density profile for this series of 
investigations, the parasitaemia was monitored through the preparation and 
examination of twice daily blood films from all mice. As sub-groups of mice were used 
for further investigations at each designated time-point (25, 40, 60, 90 and 130 days 
after PQP administration) the numbers of mice used to construct the 
pharmacodynamic profile decreased accordingly throughout the experimental period.  
Therefore, for the first 25 days the parasitaemia curve reflects the mean parasitaemia 
for n=50 mice from Group C, between 26 and 40 days n=40 mice, between 41 and 60 
days reflects the mean parasitaemia for n=30 mice, between 61 and 90 days is the 
mean parasitaemia for n=20 mice and between 91 and 130 days reflects the 
parasitaemia of n=10 mice.  The mean parasitaemia for the entire Group C mice has 
been reported. 
 
In a complementary arm of the Group C investigations, a group of age-matched mice 
were simultaneously infected with 107 P. berghei parasitised erythrocytes but 
remained untreated, thereby acting as a control for the parasite inoculation (Fig. 5.3).   
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Figure 5.3 Schematic describing the experimental protocol for each of the 3 arms 
investigated in this study. Group A consisted of uninfected mice that received drug 
vehicle on Day 0 with groups of mice infected at each experimental time point to 
determine if mouse age at time of infection affected the course of infection.  Group B 
consisted of uninfected mice that received PQP on Day 0 with groups of mice 
inoculated with parasites at each time-point.  This control group was run to determine 
whether 90 mg/kg PQP was efficacious against infection at each experimental time 
point.  Group C consisted of infected mice that were treated with PQP on Day 0.  At 
each experimental time point a group of mice was re-inoculated with parasites to 
determine if the experimental mice had acquired immunity towards the infection 
whilst blood was harvested from a second sub-group of mice for passage into naive 
hosts to test for parasite viability.  Furthermore, two separate control arms that 
consisted of groups of naive mice were inoculated with either a 105 or 107 P. berghei 
inoculum at each time point to demonstrate a normal time-density profile with 
inoculums of this size.   
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5.2.2 Parasite viability 
This arm of the study was designed to evaluate the viability of parasites from 
previously infected, treated mice with subclinical parasitaemia. Although parasites 
were present in the peripheral circulation, albeit at low levels, it was not known if 
these parasites were dead or drug affected and therefore unable to produce progeny, 
or whether drug or immune mechanisms were able to suppress the parasitaemia by 
preventing replication. This was investigated by removing blood (containing parasites) 
from the host, washing the red blood cells to remove any drug or antibodies and then 
passaging the washed cells into uninfected, naive mice.  
 
Included in this component was an evaluation of P. berghei resistance to PQ.  It has 
been well documented than when used in monotherapy, parasites have had the 
propensity to develop resistance mechanisms against PQ.  Furthermore, several 
publications have demonstrated the acquisition of resistance to PQ in rodents, 
although this is predominantly obtained through repeated exposure to drug pressure 
(259, 402).  However, it was of interest in the present series to observe whether there 
was any difference in the pharmacodynamic response of 90 mg/kg PQP when 
administered to mice that had been inoculated with parasites from treated (Group C) 
hosts with subclinical infections.    
 
5.2.2.1 Experimental design 
At each designated time point (25, 40, 60, 90 and 130 days) blood was harvested from 
a sub-group of Group C mice (n=4) via cardiac puncture. The blood was centrifuged at 
3,000 g for 5 min and the plasma was separated, measured and stored at -80oC for 
later PQ analysis. The red blood cells were washed 3 times in 0.9% w/v NaCl 
(centrifuged each time for 5 min at 3,000 g), with care taken to remove all of the 
washing saline and buffy coat, in which sensitised leukocytes or free antibody may be 
present. The packed red blood cells were then re-suspended in the same volume of 
0.9% w/v NaCl as the plasma that was originally removed from the packed 
erythrocytes. A blood smear was prepared using the red blood cell suspension to 
estimate the parasitaemia for the donor sample.  
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Passage of the red blood cell suspension to naïve recipient mice was dependent upon 
the level of parasitaemia. In general, the parasitaemia was <1% and recipient mice 
were inoculated with a 1:5 dilution of the original suspension (200 µL i.p. injection). 
Where the parasitaemia was >1%, the parasite suspension was diluted to provide a 
standard inoculum of 105 P. berghei parasites in 100 µL.  Each of the four donor 
inoculums was passaged into a group of naïve male mice (5 weeks old; n=5) resulting in 
a total group size of 20 for each time point (Fig. 5.4). Simultaneously, a group of naive 
untreated age-matched mice (n=4) were inoculated with a 105 P. berghei inoculum to 
act as a control arm for the viability study. Five days after inoculation, three of the 
mice from each group of recipients were treated with a single 90 mg/kg i.p. dose of 
PQP and the remaining two mice per group remained untreated (Fig.5.4). Hence, at 
each time point both the parasite viability and the effect of PQ were evaluated. 
Parasitaemia was monitored by twice daily peripheral blood films. 
 
5.2.3 Pharmacokinetic parameters 
The plasma PQ concentration was determined in both malaria-infected (n=4) and 
uninfected age-matched control mice (n=2) at each time point (25, 40, 60, 90 and 130 
days). Blood was harvested by cardiac puncture, centrifuged at 3,000 g for 5 min and 
the plasma was separated and stored at -80oC until analysed using a validated HPLC 
assay with limits of quantification and detection of 1.6 µg/L and 0.7 µg/L, respectively 
(231, 254). The mean plasma PQ concentration was compared with data from the 
previous pharmacokinetic study (Chapter 4; Section 4.3.3). 
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Figure 5.4 Schematic simplifying the experimental protocol for testing parasite 
viability and drug response.  Groups of mice (n=4), initially infected then treated with 
90 mg/kg PQP at Day 0 (Group C), had blood harvested at each experimental time 
point for testing of parasite viability and drug response. 1.  At each experimental time 
point, blood from each mouse was harvested via cardiac puncture, washed to remove 
antibodies or residual plasma PQ concentrations, then prepared for inoculation to 
recipient mice;  2.  The prepared blood was injected into 5 naive mice by i.p. injection; 
3.  Mice were returned to cages with peripheral blood films prepared twice daily to 
monitor parasitaemia; 4.  Five days after inoculation with donor blood, 3 out of the 5 
mice received a single i.p. dose of 90 mg/kg PQP whilst the remaining two mice 
received drug vehicle.  Parasitaemia was monitored in all mice through preparation of 
twice daily blood films until time of euthanasia (parasitaemia > 40% or at experimental 
end-point, 25 days after inoculation) 
 
 
  
25 days  
 
 
 
Mice infected with 10
7
 
  
Drug vehicle 90 mg/kg PQP 
1. 
2. 
3. 
4. 
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5.3 RESULTS 
5.3.1 PQ pharmacodynamics. 
Administration of a single dose of 90 mg/kg PQP resulted in a rapid decline in 
parasitaemia which fell below the limit of detection (0.002%) by 36 h after dosing (Fig. 
5.5).  In all mice, recrudescence occurred 7-8 days after drug administration, with a 
mean peak parasitaemia of 1.32% ± 0.56% at 13 days. The parasitaemia remained 
relatively stable for approximately 8 days and declined to a mean of 0.03% by Day 25 
(Fig. 5.5). Thereafter the mean parasitaemia remained below 0.015% until 80 days 
after dosing, beyond which there were no detectable parasites in any mice up to and 
including the experimental endpoint of 130 days after initial dosing.  These findings 
were consistent with the previous study (Chapter 4).  
 
5.3.1.1 Group A  
Group A control mice that were initially uninfected and untreated then inoculated at 
each pre-determined time (25, 40, 60, 90 or 130 days), showed similar parasite 
density-time profiles to those in previous studies (Chapters 3, 4 and (49, 467)). This 
was characterised by rapidly rising parasitaemias until the time of euthanasia (6-8 days 
after inoculation; peripheral parasitaemia >40%; Fig. 5.6).  Hence, in this model, mouse 
age (between 5 and 25 weeks) did not influence the course of P. berghei infection. 
 
5.3.1.2 Group B 
Group B uninfected control mice, that received 90 mg/kg PQP on Day 0 and were 
inoculated for the first time at each experimental time-point, demonstrated a modest 
suppressive effect against the malaria parasites in the 25 day cohort only (Fig. 5.7). 
This cohort of mice had a mean parasitaemia approximately 10 fold lower than 
controls and a median survival time of 15 days (Fig. 5.7). By contrast, no apparent 
parasite suppression was seen at any other time-point, with median survival times of 
8, 8, 8 and 7 days for the 40, 60, 90 and 130 day cohorts, respectively. In the latter 
groups, parasite density-time profiles and survival times were comparable to those for 
Group A control mice that received only drug vehicle.  Therefore, it may be suggested 
that 90 mg/kg PQP was mildly suppressive until approximately 25 days after drug 
administration. 
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5.3.1.3 Group C 
Data for Group C mice that were previously inoculated and received 90 mg/kg PQP on 
Day 0, are shown in Figure 5.8. The cohort that was re-inoculated on day 25 
maintained a low, subclinical parasitaemia (<0.015%) with all mice remaining 
asymptomatic for 4 weeks (pre-determined endpoint of re-inoculation study; Fig. 5.8). 
A similar outcome was seen at 40, 60 and 90 days, with all mice remaining 
asymptomatic and peak parasitaemias of 0.03%, 0.3% and 0.9%, respectively. In 
contrast, mice re-inoculated 130 days after initial drug administration (which had been 
aparasitaemic for >50 days) showed a rapidly increasing parasitaemia, with a median 
survival time of 10 days (Fig. 5.8).   
 
The naive control group, which was run in parallel with the re-inoculation study, 
confirmed that the standard inoculum of 107 parasitised erythrocytes injected into the 
experimental mice would lead to predictable outcomes of a rapidly increasing 
parasitaemia and lethal outcome within one week (as seen in previous chapters).  
Therefore, this control arm adequately established that the parasite inoculum 
prepared for re-inoculation purposes was consistent with expected pharmacodynamic 
responses obtained in naive mice.  
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Figure 5.6  Parasitaemia-time profiles from the parasite re-inoculation arm of the 
study. Untreated uninfected age-matched Group A control mice (n=4 at each time 
point) that were inoculated with 107 P. berghei parasitised erythrocytes at pre-
determined times (, 25 days; ,40 days; , 60 days; , 90 days; , 130 days). Data 
are shown as total parasitaemia (mean percentage of erythrocytes infected ± SD), 
commencing from the time of inoculation. (see also text, sections 5.2.1.2a and 5.3.1.1). 
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Figure 5.7 Parasitaemia-time profiles from the parasite re-inoculation arm of the 
study. Drug efficacy was assessed through the use of age-matched uninfected (Group 
B) mice that received a single dose of 90 mg/kg PQP at day 0 and later infected with 
107 P. berghei parasitised erythrocytes at each pre-determined time point (n=6 at each 
time-point: , 25 days; ,40 days; , 60 days; , 90 days; , 130 days). Data are 
shown as total parasitaemia (mean percentage of erythrocytes infected ± SD), 
commencing from the time of inoculation. (see also text, sections 5.2.1.2b and 
5.3.1.2).  
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Figure 5.8 Parasitaemia-time profiles from the parasite re-inoculation arm of the 
study. Infected mice treated with 90 mg/kg PQP (Group C) at day 0 were re-inoculated 
with a second inoculum of 107 P. berghei  parasitised erythrocytes at each study point 
(n=6 at each pre-determined time point: , 25 days; , 40 days; , 60 days; , 90 
days; , 130 days. Data are shown as total parasitaemia (mean percentage of 
erythrocytes infected ± SD), commencing from the time of inoculation. (see also text, 
sections 5.2.1.2c and 5.3.1.3). 
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5.3.3 Parasite viability and drug resistance study. 
Blood harvested from Group C mice at the 25 day time-point (mean parasitaemia 0.03 
± 0.04% at time of harvesting) was shown to contain viable parasites, as all naïve mice 
inoculated with the donor red blood cell suspensions developed infections.   Mice 
receiving drug vehicle five days after inoculation progressed to experimental endpoints 
(high parasitaemia) with a median survival of 19 days (Fig. 5.9). Following 
administration of 90 mg/kg PQP five days after inoculation, parasitaemia in the treated 
mice was not markedly different to that for the vehicle group, and the median survival 
was also 19 days. A similar outcome was observed in the 40-day mice (Fig. 5.10) with 
the data from both the 25 day and 40 day groups indicating that the parasites were 
resistant to PQ.  
 
Blood harvested from the Group C mice at 60 days after drug treatment (mean 
parasitaemia 0.004 ± 0.006%) showed that viable parasites were present in only two of 
the donor mice, with the blood from two of the donor mice not producing a detectable 
parasitaemia in any of the naïve mice inoculated. In the 10 naïve recipient mice that 
developed an infection from the red blood cell suspension, mice that received drug 
vehicle five days after inoculation had a median survival of 10 days (n=4; Fig. 5.11). 
Administration of PQP to the remaining mice (five days after inoculation) resulted in a 
prompt decline in parasitaemia and recrudescence in all recipients (n=6; Fig. 5.11). 
Recipients from one donor (n=3) had a progressive infection that reached 10% 
parasitaemia within 25 days. However, the three recipients from the other donor 
showed a response to PQ that was consistent with successful treatment.  
 
The naive control arm, which was run in parallel with each viability experiment, 
demonstrated the expected pharmacodynamic response for mice inoculated with a 
105 P. berghei parasitised erythrocytes, consistent with Gibbons et al. 2007 (179).   
Furthermore, this control arm demonstrated that the 90 mg/kg PQP dose was 
efficacious, as all naive mice treated with the drug preparation exhibited the expected 
pharmacodynamic response. Therefore, this control arm adequately established that 
there were no inconsistencies with parasite inoculum or drug preparation.  
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Figure 5.9 Parasitaemia-time profiles at 25 days.  Parasitaemia-time profiles in 
naïve Swiss mice (n=5) after inoculation with red blood cell suspensions harvested 
from previously inoculated and PQP-treated mice (n=4) at 25 days after initial drug 
administration. Five days after inoculation, three out of five mice from each donor 
group received a single i.p. dose of 90 mg/kg PQP. Inoculations from the four PQP-
treated mice that were harvested at Day 25 produced a viable infection in all 20 
recipient mice. The untreated mice (; n=8) and PQP-treated mice (; n=12) had 
similar parasite density-time profiles, apart from Days 7 and 8 (2-3 days after PQ 
administration), and the median survival time was 19 days in both groups. Data are 
shown as total parasitaemia (mean percentage of parasitised erythrocytes infected 
± SD), commencing from the time of red blood cell passage. 
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Figure 5.10 Parasitaemia-time profiles at 40 days.  Parasitaemia-time profiles in 
naïve Swiss mice (n=5) after inoculation with red blood cell suspensions harvested 
from previously inoculated and PQP-treated mice (n=4) at 40 days after initial drug 
administration. Five days after inoculation, three out of five mice from each donor 
group received a single i.p. dose of 90 mg/kg PQP. Inoculations from the Day 40 
mice produced viable infections in all recipient mice ( untreated, n=8;  treated, 
n=12) and a similar profile to the Day 25 mice. Data are shown as total parasitaemia 
(mean percentage of parasitised erythrocytes infected ± SD), commencing from the 
time of red blood cell passage. 
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Figure 5.11 Parasitaemia time-profiles at 60 days.  Parasitaemia-time profiles in 
naïve Swiss mice (n=5) after inoculation with red blood cell suspensions harvested 
from previously inoculated and PQP-treated mice (n=4) at 60 days after initial drug 
administration. Five days after inoculation, three out of five mice from each donor 
group received a single i.p. dose of 90 mg/kg PQP. In the Day 60 group, viable 
infections were produced from only two of the four donor mice. Untreated 
recipient mice (; n=4) had a median survival of 10 days. Treated recipient mice 
(; n=12) showed different profiles, with the cohort from one donor mouse having 
a progressive infection (  ) and the other cohort having a strong 
response to PQP treatment (– – –).  Data are shown as total parasitaemia (mean 
percentage of parasitised erythrocytes infected ± SD), commencing from the time of 
red blood cell passage. 
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In the 90 day cohort mice, recipients from only one donor mouse developed a 
detectable infection (Fig. 5.12). All other recipients, from the other three donors, 
remained parasite free throughout the 30 day monitoring period. In mice with a 
positive infection, the lag period for the infection to develop suggested a low 
parasite count in the red blood cell suspension (inoculum). Furthermore, in these 
recipients PQ administration had little effect on the developing parasitaemia as the 
median mouse survival time (20 days) was similar to the mice given vehicle.  
 
In the final subset (130 days), none of the recipient mice developed an infection 
during the 30 day monitoring period.  This indicated that no viable parasites were 
present in Group C mice four months after inoculating and subsequent treatment 
with PQP.  
 
5.3.4 PQ concentrations 
The mean plasma PQ concentrations from malaria-infected mice (n=4) at each time 
point were 15 ± 8, 11 ± 1 and 2 ± 2 µg/L for 25, 40 and 60 days after PQP 
administration, respectively. Plasma PQ concentrations at 90 and 130 days were 
undetectable (Fig. 5.13). The plasma PQ concentrations in the present study were 
found to be comparable to the mean plasma concentration-time profile obtained in 
the previous chapter (Fig. 4.5, Chapter 4) Plasma PQ concentrations in uninfected 
control mice were 13.3 µg/L at 25 days (n=1), 4.9 µg/L at 40 days (n=1), 1.4 and 1.6 
µg/L at 60 days (n=2), 1.9 µg/L and undetectable at 90 days (n=2) and undetectable 
130 days (n=2) after PQP administration.  
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Figure 5.12 Parasitaemia-time profiles at 90 days.  Parasitaemia-time profiles in 
naïve Swiss mice (n=5) after inoculation with red blood cell suspensions harvested 
from previously inoculated and PQP-treated mice (n=4) at 90 days after initial drug 
administration. Five days after inoculation, three out of five mice from each donor 
group received a single i.p. dose of 90 mg/kg PQP. In the Day 90 group, a viable 
infection was found in recipients from only one donor mouse and, although 
development of the infection was delayed, the parasite density-time profile of the 
untreated mice (; n=2) was similar to the treated mice (; n=3).  Data are shown 
as total parasitaemia (mean percentage of parasitised erythrocytes infected ± SD), 
commencing from the time of red blood cell passage. 
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Figure 5.13 Plasma PQ concentrations in mice given PQP at approximately 90 
mg/kg i.p. (normalized for pharmacokinetic analysis). Data are given as mean ± SD 
plasma PQ concentration for malaria-infected mice at 25, 40 and 60 days after 
treatment with PQP (; n=4). The lines show the mean concentration-time profile 
(two-compartment model) for healthy (- - -) and malaria-infected mice (        ) as 
shown in Fig. 4.5, Chapter 4 (pg 166).  
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5.4 DISCUSSION 
The purpose of the current investigation was to perform a series of viability and re-
inoculation experiments to determine whether the previously observed, chronically 
low parasitaemia in PQ treated, P. berghei infected mice was a result of drug 
pressure, immune response or potentially a combination of both.  Whilst specific 
immunological testing involving the use of monoclonal antibodies and/or labelled 
CD4+ and CD8+ T-cells would have added further support to the investigation, it 
was beyond the scope and resources of this study.  Therefore, the conclusions from 
this study are based on the pharmacokinetic data and observed pharmacodynamic 
responses. 
 
Pharmacodynamic data obtained for Group A mice demonstrated that when 
inoculated at each of the experimental time-points, the previously uninfected, 
untreated mice developed lethal infections.  This suggests that in this P. berghei 
model, mouse age at the time of inoculation does not influence the course of 
infection.  A similar finding has been previously reported where it was shown that 
age had no influence on the progression or lethality of P. berghei infections in mice 
(192, 387).  By contrast, adult rats (>12 weeks) have an increased ability to clear P. 
berghei parasites and decreased mortality compared to young rats (4 weeks), albeit 
there was no significant difference in the initial progression of infection between 
the studied groups (4, 192, 387).  This would therefore suggest that the differences 
in observed disease progression, in the young and adult rat groups, was due to an 
age-associated deregulation of immune responses to primary infection (4).  By 
comparison, in the present studies, all experimental mice were obtained at an initial 
age of 5-6 weeks and by the time of inoculation would all be considered mature.  
Hence, it may be concluded that in these studies ‘mouse age’ at the time of 
inoculation may be excluded as a factor in improving survival.   
 
The duration of therapeutic effect after single dose 90 mg/kg PQP, was evaluated in 
Group B mice after their inoculation with P. berghei parasites.  The 
pharmacodynamic profiles clearly demonstrated that plasma PQ concentrations 
were only mildly efficacious at approximately 25 days after drug administration, 
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with mild parasite suppression being observed (Fig. 5.7).  Analysis of plasma 
concentrations at each time point correlated with the pharmacodynamic 
observations.  At 25 days, when modest parasite suppression was observed, the 
mean plasma PQ concentration was 15 ± 8 μg/L.  Plasma concentrations at 
subsequent time-points (< 10 μg/L) correlated to a lack of parasite suppression. 
Therefore, it was concluded that in this murine malaria model the contribution of 
residual PQ concentrations <20 μg/L was low, whilst PQ concentrations <10 μg/L 
were ineffective.  Although direct comparisons to human studies are not plausible, 
these findings are consistent with a recent report suggesting that plasma PQ 
concentrations >30 μg/L are required for successful treatment in clinical malaria 
(397).   
 
Persistence of residual drug concentrations is a concern in the context of the 
selection of drug resistant parasites to long half-life partner drugs in ACTs, such as 
PQ.  The most significant influence on the efficacy of antimalarial therapy is the 
parasite’s ability to acquire and/or maintain drug resistance.  General 
characteristics of the drug are perhaps the most important determinants in parasite 
resistance, particularly in regard to drugs with a long half-life such as mefloquine or 
PQ (548, 566).  However, exposure to persistent subtherapeutic concentrations that 
inhibit, rather than clear, parasitaemia may exert substantial residual selection 
pressure (541, 548, 558, 566).  Another issue to consider is the maintenance of 
adequate drug concentrations over a long period of time being important for the 
clearance of parasites within an infected individual.  Subtherapeutic concentrations 
may eliminate the most susceptible parasites but not clear more resilient forms.  As 
a result, eventually the necessary therapeutic dose required for therapy may 
increase beyond the maximum tolerated, thus drug resistance would emerge (566). 
Based on the results in this study, it is feasible that re-emergence of PQ resistant 
strains of P. falciparum, which in the 1980s led to the abandonment of PQ as an 
antimalarial agent (127, 386, 541), could occur as a result of residual PQ 
concentrations following ACT in endemic areas.  However, to date, there are no 
clinical reports of resistance to PQ as a result of PQ-based ACT, which may reflect 
the high success rates associated with this regimen (27, 29, 139, 252, 253, 336, 413, 
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456, 477). That is, by curing the infection (parasite elimination) there is no residual 
biomass exposed to prolonged, low drug concentration.  
 
In the current study, when parasites from previously treated mice were passaged 
into a naive host, the viable parasites appeared to not be affected by PQP, with 
parasite growth continuing at a constant rate after drug administration.  Whilst 
inadequate drug formulation was considered, the corresponding control arm (naive 
mice inoculated with a fresh P. berghei inoculum and similarly treated with 90 
mg/kg PQP) demonstrated the expected drug efficacy post drug administration.  
Therefore, the parasites’ lack of response to a second 90 mg/kg PQP exposure 
appeared to be more indicative of drug resistance.  By comparison, selected PQ 
resistance in a P. berghei ANKA murine malaria model after drug pressure was 
recently reported (259).  Initially the ED90 for PQ was determined to be 3.52 mg/kg, 
however, after continued drug pressure over >27 passages, resistance was obtained 
which was reflected by an altered ED90 of 68.86 mg/kg (259).  Furthermore, if drug 
pressure was removed it was observed that parasites slowly returned to being 
sensitive towards the drug.   These results therefore suggest that it is plausible for 
P. berghei parasites to become resistant to PQ, however, it has previously not been 
described after a single prolonged exposure. Therefore, although the current 
parasite responses to repeated drug administration do suggest attainment of at 
least partial resistance, the small sample size and study design precludes definitive 
conclusions.  Further studies, using a larger cohort of mice and appropriate 
immunological investigations, could provide more information on the mechanisms 
of resistance to PQ.    
 
Parasite re-inoculation at 25, 40, 60 and 90 days after PQP administration in Group 
C mice, failed to establish a lethal infection with all mean parasitaemias remaining 
below 1%.  However, when re-inoculated at 130 days after PQP, all mice developed 
a lethal infection.  Given that plasma PQ concentrations were shown to be 
ineffective at curbing parasitaemia at any of these time-points, the results are 
indicative of an immune response being mounted towards the infection.  Acquired 
resistance is considered to be the predominant factor in the development of 
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chronic P. berghei infections in mice (19, 114, 115).   Murine P. berghei studies, 
using Atabrine or Manzamine A as treatment therapy, have independently 
demonstrated the expression of chronic P. berghei infections, which resulted in 
either fatal relapses (as late as 100 days after treatment) or spontaneous cure (19, 
115).  Furthermore, mice that exhibited chronic infections were shown to survive 
for extended periods of time after re-infection with a second P. berghei inoculum 
(115).  These results, in conjunction with those obtained in the present study; 
suggest that if drug therapy has the ability to reduce the initial parasite burden to 
subclinical levels, the mouse immune system has the capacity to limit parasitaemia 
to low density chronic infections and a subsequent acquired partial immunity 
towards infection (114, 115, 278).   
 
Investigations into murine host responses to infection have demonstrated that the 
immune response mounted towards malaria infection has the capacity to eradicate 
parasites after further challenge, at least within an interval of 4 to 6 weeks (332, 
333).  Once infection was resolved and parasites were no longer present in 
circulation, the titre of humoral protective factor was seen to wane markedly within 
2 to 3 weeks of recovery from the P. berghei infection and as a result mice were 
once again susceptible to infection (332, 333).  These observations further support 
the theory that if drug treatment has the ability to reduce parasitaemia to a critical, 
but as yet unknown, parasite density for a period of time, the mouse immune 
system has the ability to clear remaining parasites from the infected animal.  This 
would then protect the mouse from further infection from the same parasites.   
 
The extended period of the present study ensured that the full scope of drug 
efficacy, parasite viability and host response components could be evaluated. It was 
found that the mean parasitaemia beyond 60 days was very low (<0.01% where 
detectable) and, possibly due to the low parasite densities, the inoculation success 
was 50% and 25% at 60 and 90 days, respectively. Treatment with PQ also showed a 
variable response, with some infected recipients in the 60 day group showing 
evidence of drug resistance and others showing susceptibility to drug (although 
immediate drug effects were less than the standard response in control mice). Re-
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inoculation of experimental mice with P. berghei parasites also failed to establish 
lethal infections at these time-points, suggesting persistence of immunity at a low 
parasitaemia and in mice with recently cleared infection.  
 
The peripheral parasitaemia remained undetectable from 80 days after the original 
treatment with PQP, indicating that infections had resolved or the residual parasite 
biomass was very low (<0.001%; approximately 160,000 parasites in comparison to 
a starting biomass of 500 million parasites). At the final time point of our study, 
passaging of blood into control mice failed to establish an infection and, in contrast 
to earlier times, the second P. berghei inoculum led to a typical, lethal infection. 
These results suggest that any immunity or immunological memory was absent, a 
finding that is also consistent with the view that maintenance of immunological 
memory requires continuous exposure to the parasites (220, 414).  
 
The present study may have been limited by the relatively small number of donor 
mice used to demonstrate parasite viability at each studied time-point. At the 25 
and 40 day time-points, where parasite responses were consistent, the small 
sample size was not a conflicting issue. However, as time progressed the variability 
of parasite viability increased and by 60 days only 50% of the donor parasite 
inoculums from Group C mice proved to be viable upon re-inoculation. It is possible 
that a more accurate outcome could have been achieved if the number of donor 
mice was increased at each time-point.  
 
In conclusion, the present study has demonstrated that the P. berghei murine 
malaria treatment model can be a valuable preclinical conceptual tool for 
investigation of the pharmacodynamic effects of antimalarial drugs such as PQ. It 
was found that PQ has a substantial antimalarial effect in this model, which appears 
sufficient for a host immunological response to be established. The study also 
suggests that residual PQ concentrations could lead to the development of PQ-
resistant parasites if initial ACT was not curative and/or a new infection arose 
during the early post-treatment period.  
 
- 204 - 
 
CHAPTER SIX 
 
INVESTIGATION OF THE PHARMACOKINETICS AND 
PHARMACODYNAMICS OF CHLOROQUINE IN MICE 
 
6.1 INTRODUCTION 
Since the discovery and development of chloroquine in the 1030s and its clinical 
application in the 1940s, CQ is still an important antimalarial drug today, particularly 
for the treatment of P. vivax malaria (REF). The clinical pharmacokenitics of CQ and 
its principal metabolites have been extensively studied in a variety of ethnicities, 
following various routes of administration, and in healthy subjects and malaria 
patients  (6, 9, 74, 100, 135, 146-148, 153, 170-173, 199, 201, 254, 264, 270, 273, 
338, 357, 359, 364, 410, 420, 490, 491, 504, 513, 514, 529, 549, 553, 559, 562).   
However, despite the intensive research into this drug and its metabolites in 
numerous populations, the pharmacokinetic parameters of the drug remain highly 
variable, if not inconclusive.  For example, the terminal elimination half-life of CQ, 
reported from clinical studies, ranges from 3 to 1512 h (74, 146-148, 169-173, 199, 
201, 264, 273, 357, 410, 491, 504, 513, 514, 540, 562).  This significant variability 
may be attributed to different analytical techniques, whether plasma, serum or 
whole blood was used for analysis, or even incorrectly assuming that the tissue 
distribution phase was the elimination half-life.   However, as drug administration 
and dosing regimens are often intimately linked with the reported terminal 
elimination half-life, it is concerning that there is a wide range of values for CQ, a 
potentially toxic drug, with a narrow therapeutic index (131). This point alone 
supports the strategy of acquiring basic pharmacokinetic information from 
preclinical models so that suitable and safe dosing regimens can be determined and 
implemented into the clinical setting.   
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6.1.1 Animal investigations 
6.1.1.1 Pharmacodynamic efficacy  
The pharmacodynamic efficacy of CQ has been previously investigated in a 
preclinical murine study observing the influence of initial parasite load and starting 
day of drug administration on the outcome of treatment, using both the Peter’s 4 
day test as well as treating post inoculation (239).  An outbred mouse model 
inoculated with P. berghei NK61 parasites was used for all investigations.  The 
results suggested that a complex relationship existed between the parasite load and 
efficacy of CQ (239).  For example, mice dosed for four consecutive days with 20 
mg/kg CQ before inoculation with 108 P. berghei parasites showed an undetectable 
parasitaemia until day 8 post-infection, with parasites observed from day 10 and 
eventual death by day 22 of infection (239).  Conversely, all mice inoculated with ≤ 
107 P. berghei parasites showed no presence of parasitaemia for the monitored 
period.  In experiments where mice were dosed post inoculation it was 
demonstrated that in mice inoculated with 103 P. berghei parasites, if parasitaemia 
at the time of treatment was ≤0.1%, all infections resolved with no parasite 
recrudescence observed up to the experimental endpoint.  By comparison,  if 
peripheral parasitaemia was ≥0.1% at time of treatment, 20 mg/kg CQ was shown 
to decrease the parasitaemia to undetectable levels until 7 days after treatment, 
however, parasite recrudescence soon followed and all mice died with progressively 
increasing parasitaemia by day 24 after CQ treatment (239).  The authors concluded 
that in this in vivo antimalarial “drug-assay” model, several factors such as initial 
parasite load and the starting time of treatment influenced the drug response in the 
host (239).    
 
This study may be relevant for other preclinical models, as it suggests the possibility 
of a threshold parasitaemia which could directly correlate to the treatment 
outcome.  Furthermore, in the context of dose regimen considerations, this study 
indicates that  at higher parasite burdens either a higher dose of CQ is required to 
resolve the infection or, if CQ toxicity prevents a higher dose being administered, a 
different antimalarial treatment strategy is required.  In regards to murine 
treatment models, where it is important to observe the entire pharmacodynamic 
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response of the trial antimalarial, it highlights the importance of using parasite 
inocula > 107 P. berghei parasites. Further investigation into the influence of initial 
parasite load could provide useful preliminary data for the construction of 
comprehensive mathematical models.  Such mathematical modelling could prove 
useful in the clinical setting where the selection of antimalarial therapy and 
corresponding treatment outcomes could be predicted given the initial blood 
parasitaemia.    
 
Further efficacy data has been collated using murine malaria models including the 
determination of the minimum effective dose of CQ being 10 mg/kg (51, 239), and 
establishing that the acute lethal dose 50% (LD50) of CQ in mice after i.p. injection 
was 79 mg/base/kg (range 68-78 mg/base/kg) (Table 6.1) (306). 
 
Table 6.1 Parameters of toxicity of chloroquine (CQ) (306).   Data given as 
means ± standard error  
**Original table modified to include murine data relevant to this chapter. 
 
Route of 
administration 
Acute LD50 
mg/base/kg 
 
Tolerated Dose 
mg/base/kg per day 
CQ  CQ 
Intravenous 25 ± 2†  – 
Intraperitoneal 79†, 68–78‡    >40,  >155†,§ 
Oral 387 ± 50†, 1,000‡           400 = LD10
‡ 
 
† Data from the files of the Sterling-Winthrop Research Institute 
‡ Data from Wiselogle, F.Y., 1946  (564) 
§ Five-day test 
 
Murine models have also played an integral role in the investigation of the 
mechanism of action of CQ. Whilst a range of studies have determined that CQ 
affects Plasmodium parasites in several ways, including (i) interaction of CQ with 
parasite DNA (101, 108, 109, 202, 493), (ii) inhibition of parasite feeding by CQ 
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administration (372, 424), and (iii) accumulation of CQ in the acidic food vacuole of 
the parasite (11, 174, 175, 185, 211), perhaps the most significant results have been 
in the study of the effect of CQ on haem polymerisation (166, 295, 296, 375, 452).   
Morphological studies observing the effect of a single dose of 40 mg/kg CQ on P. 
berghei malaria showed a progressive aggregation of malarial pigment within the 
parasite (296).  This effect was first observed within 30 min and was essentially 
complete within 4 h of drug administration.   However, by 8 h after CQ there was a 
noticeable decline in the percentage of pigment-containing parasites and within 48 
h very few parasites contained pigment (296).  Further investigation using electron 
microscopy showed that the malaria pigment granules were accumulating within 
large vesicles that were limited by a single membrane.  Within 1 h of CQ 
administration, these newly formed large vesicles also contained membrane bound 
inclusions of parasite cytoplasm and later, at 3–4 h, small vesicles contained 
unidentified material (296).   These microscopy studies suggested that the 
formation of haematin pigment by the parasite may serve to concentrate the drug 
within the parasite, particularly in the digestive vesicles.  It was further concluded 
that such an effect would account for the selective toxicity of CQ for the 
erythrocytic malarial parasites (296).   This conclusion is further supported by 
murine studies which have demonstrated an accumulation or clumping of pigment 
granules in murine trophozoites (98, 375, 538).  Furthermore, Peters demonstrated 
that a CQ-resistant line of P. berghei demonstrated significantly less pigment 
formation than a similarly treated CQ-sensitive P. berghei strain, which similarly 
suggests that the process of haemozoin formation is associated with the mechanism 
of action of CQ (375).   
 
Similarly, in vitro studies have demonstrated the stage specific affinity of CQ along 
with an increased accumulation of pigment granules within the parasite after CQ 
administration (452, 471, 472, 587).  In their investigation of the inhibition of haem 
polymerase by CQ, Slater and Cerami (452) used an in vitro model to identify 
specific aspects of the mechanism of action of CQ.  The results obtained in this 
study closely correlated to those published in earlier murine studies (452) although 
it has been more recently suggested that in order for in vitro investigations to 
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reflect the true nature of haem polymerisation, specific preformed parasite haem 
polymers must be first added to the culture (166).  Therefore, it may be suggested 
that both the in vitro and murine malaria preclinical models have contributed 
valuable, and correlating, information on the mechanisms of action of CQ.   
 
6.1.2 CQ Pharmacokinetics 
Preclinical pharmacokinetic studies in a variety of animal models have been 
reported, with all studies suggesting CQ has a long elimination half-life (8, 78, 396, 
494).  In healthy dogs after i.v. administration of 2 mg/kg CQ, the terminal 
elimination half life of CQ was estimated at 12.6 ± 1.84 days (8).  Comparison of the 
pharmacokinetic parameters in both healthy and malaria-infected (P. knowlesi) 
Rhesus monkeys determined that the plasma CQ half-life was significantly increased 
in infected compared to healthy (P<0.05) (396). It was postulated that the 
significant difference in the elimination half-life of CQ in the infected monkeys could 
be due to hepatic involvement during malaria infection (396).  This conclusion is 
further supported by an in vivo rat model which showed a decreased liver blood 
flow during malaria infection, therefore suggesting that the variations in hepatic 
metabolism could result in inconsistent CQ pharmacokinetics (148).   Furthermore, 
investigations in the tissue distribution of CQ in monkeys and albino rats showed 
that CQ is extensively distributed, with the liver, spleen, kidney and lungs being the 
main repositories (7, 148, 306, 307). 
 
Although murine malarias serve as preferable in vivo models for drug testing, the 
pharmacokinetic parameters of CQ in mice are limited.  Three studies have been 
published on the pharmacokinetic paramters of CQ in mice (14, 78, 494).  They have 
involved healthy mice administered s.c. 30 mg/kg CQ (494), and orally 100 mg/kg 
CQ (14), and in both healthy and malaria-infected mice administered s.c. either  5, 
10 or 50 mg/kg CQ (78).  However, all studies have limitations, especially 
incomplete pharmacokinetic analysis (78, 494).  For example, in one study (78),  
pharmacokinetic analysis only included data up to 120 min post-dose and the 
reported values do not represent terminal elimination but instead indicate tissue 
distribution (78).  Furthermore, no study takes into account the presence or 
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concentrations of CQ metabolites, such as desethylchloroquine (DECQ).  All studies, 
however, produced interesting assumptions which, to date have been used as 
preclinical pharmacokinetic values for CQ. After measuring blood CQ concentrations 
at 0.5, 1, 2 and 4 h, Thompson et al. (494) suggested that the time of peak CQ 
concentration was 2 h after dosing.   After observing the blood CQ concentration-
time profile in healthy mice, Cambie et al. (78) estimated the distribution of CQ to 
be 40 min, which was quite similar to the distribution of CQ in humans using a 
double decay model.  Furthermore, Cambie et al. reported that the rate of CQ 
elimination in malaria-infected mice is strongly influenced by the parasite load at 
the time of treatment.  It was observed in mice with a heavy infection (21-25% 
parasitaemia) of P. chabaudi, at the time of CQ administration, that the V/F, AUC, t½ 
and tmax of CQ were all significantly increased (78).  However, as t½α was not 
significantly different between mice with heavy infections and control mice, it was 
suggested that the increased tmax of CQ in heavily infected mice was due to an 
increase in t½β.  This observation was hypothesised to be a result of an increased 
capacity of the blood compartment to accumulate drug in those mice with a heavy 
load of parasites, thus the rate of drug efflux was smaller than the rate of influx 
(78).  It was concluded that CQ was dynamically retained in infected erythrocytes 
and that the blood CQ concentration was considerably lower than that found in 
healthy controls or those with low level parasitaemia, thus accounting for the low 
drug elimination rate observed in heavy infection (78).    
 
In order to address the paucity of pharmacokinetic data available for CQ in the 
murine malaria model the purpose of the present investigation was to produce 
robust pharmacokinetic data and corresponding pharmacodynamic data, for CQ in 
the P. berghei malaria model.  Furthermore, as preclinical pharmacokinetic studies 
have been restricted to CQ alone, a further aim of the study was to investigate the 
pharmacokinetic profile for DECQ, the major metabolite of CQ.  These 
pharmacokinetic data for CQ and DECQ in the P. berghei murine malaria model are 
expected to be a valuable guide for researchers using CQ in murine malaria studies.  
 
 
- 210 - 
 
6.2  METHODS 
6.2.1 Pharmacodynamic evaluation of single and multiple doses of CQ 
As the pharmacodynamic properties of CQ have been studied to some degree in 
murine malaria models (373, 374, 378, 381, 383), the focus of the present 
investigation was the pharmacokinetic properties of CQ, and the biologically active 
metabolite DECQ, after single and multiple dose administrations.  In conjunction 
with this novel pharmacokinetic data, the pharmacodynamic responses would 
provide a unique evaluation of the effect of CQ in mice with established P. berghei 
infections.  
 
A dose of 50 mg/kg CQ was selected for use in both the single and multiple dose 
studies.  Previous pilot studies conducted in our laboratory (Jillian Stoney, BPharm 
(Hons) thesis (467)) evaluated single dose (10–50 mg/kg. Fig. 6.1A.) and multiple 
dose regimens (Fig. 6.1B.).  Consideration of the results obtained in these studies, as 
well as toxicity data obtained for i.p. dose administration (LD50 after i.p. dosing in 
mice 79 mg/base/kg (306)) resulted in the selection of the 50 mg/kg dose, which 
after single dose administration, was expected to give a significant, yet 
subtherapeutic, antimalarial response.   
 
For multiple dose administrations, 50 mg/kg CQ also was selected for 
pharmacokinetic analysis with 5 doses given at 24 h intervals.  This dosing regimen 
was chosen because it had been observed in the pilot study (where doses were 
given 12 h apart; Fig. 6.1B.), that the antimalarial efficacy of CQ was extended when 
the treatment course was spread over more than one parasite erythrocytic cycle (24 
h in P. berghei).  Therefore, it was expected that although each individual dose 
would be subtherapeutic, the dosing regimen over a total of 4–5 parasite 
erythrocytic life cycles, could lead to parasitological cure.   
 
6.2.1.1 Pharmacodynamic analysis 
To monitor the pharmacodynamic effect of single and multiple doses of CQ on the 
parasitaemia of mice involved in the pharmacokinetic study, peripheral blood films 
were prepared and parasitaemia determined using two different subsets.   
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Figure 6.1A.  Parasitaemia-time profile in Swiss mice following administration of 
single i.p. doses of CQ administered 65 h after inoculation with 107 P. berghei-
parasitised erythrocytes (↑).  Data are shown as total parasitaemia (mean 
percentage of erythrocytes infected ± SD), commencing from the time of CQ 
administration.  Symbols: , control (n=4); , 10 mg/kg CQ (n=9); , 20 mg/kg 
(n=7); , 30 mg/kg CQ (n=9); , 50 mg/kg CQ (n=7). [Data from J. Stoney, BPharm 
(Hons) (467)]. 
 
Figure 6.1B.  Parasitaemia-time profile in Swiss mice following administration of 
either a single i.p. dose of 50 mg/kg CQ (↑x 1), a three dose regimen of CQ (↑ x 3; 
20, 20 and 10 mg/kg), or a five dose regimen of CQ (↑ x 5; 10, 10, 10, 10, and 10 
mg/kg) with the first dose administered 65 h after inoculation with 107 P. berghei-
parasitised erythrocytes, and subsequent doses administered ever 12 h.  Data are 
shown as total parasitaemia (mean percentage of erythrocytes infected ± SD), 
commencing from time of initial CQ administration.  Symbols: , control (n=4); , 
50 mg/kg CQ (n=7); , 3 dose regimen (n=8); , 5 dose regimen (n=8). [Data from 
J. Stoney, BPharm (Hons) (467)]. 
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Firstly, in both the single and multiple dose pharmacokinetic studies 10 mice (the 
mice grouped in the last 2 pharmacokinetic time-points i.e. 5 and 7 days for the 
single dose study and 21 and 30 days for the multiple dose analysis) were bled twice 
daily and parasitaemia determined.  These data were used to construct 
comprehensive parasite density-time plots which represented the 
pharmacodynamic effect seen in each cohort of mice after CQ therapy.   
 
In addition, peripheral blood films were prepared from every mouse immediately 
prior to dosing and at the time of blood collection and euthanasia.  The mean 
parasitaemia for each group of mice was determined and these were plotted on the 
pharmacodynamic curve produced from the representative mice, signifying 
parasitaemia from the second subset.   
 
All peripheral blood smears were prepared and stained, and parasitaemia 
quantified, as described in Chapter 2, Sections 2.2.1.3, 2.2.2.4 and 2.2.2.5. 
 
6.2.2 Pharmacokinetics of CQ and DECQ in mice 
6.2.2.1 Drug preparation for animal dosing 
All drug solutions were prepared from a single source of CQ diphosphate salt which 
was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
 
To determine the required mass of CQ diphosphate salt to administer the required 
CQ dose, all mice were weighed prior to dosing.  Whilst individual mouse weights 
were recorded (important for dose normalisation during pharmacokinetic 
modelling), the average mouse weight was used when calculating the mass of 
required CQ salt (MW base: 319.8; salt: 515.9) needed to administer a 50 mg/kg 
dose of CQ.  As CQ diphosphate salt is readily soluble in water, the accurately 
weighed CQ diphosphate was dissolved in half the required volume of deionised 
water by vortex and, if necessary, sonification.  After dissolution, the solution was 
made to volume and passed through a Millex®-HV 0.45 μm filter unit (Millipore S.A., 
Molsheim, France).   
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6.2.2.2 Single dose pharmacokinetic study 
Pharmacokinetic parameters for CQ and DECQ were determined from 125 
uninfected male Swiss mice (6-7 weeks old; mean weight 33.8 ± 2.8 g) and 125 
malaria-infected mice (6-7 weeks old; mean weight 31.7 ± 2.9 g) which had been 
inoculated with 107 P. berghei parasitised erythrocytes 64 h prior to dosing. A 
standard 100 μL volume of drug solution was administered to each mouse i.p. as a 
single dose of 1,500 μg CQ. 
 
To determine a robust pharmacokinetic profile of single dose 50 mg/kg CQ in mice, 
blood was harvested from groups of mice (n=5) at 0, 10, 15, 20, 30, 45, 60, 75, and 
90 min, 2, 2.5, 3, 4, 5, 8, 12, 18, 24, 30, 36, 48 and 56 h, and 3, 4, 5, and 7 days after 
drug administration.  All blood samples were collected by the author, and accurate 
records were taken for the time of drug administration and the time of blood 
harvest was calculated.  For earlier time-points (10, 15, 20, 30, 45, 60, 75, and 90 
min, 2, 2.5, 3, 4, and 5 h), the CQ drug solution was administered at 5 min intervals 
between each mouse within the group (n=5) to ensure that blood could be 
harvested at the required time-point.  
 
At each pharmacokinetic data point, mice were anaesthetised with 50-100 mg/kg 
sodium pentobarbitone 5–10 min prior to blood collection.  Blood was harvested by 
cardiac puncture in a single draw using a 1 mL syringe (Terumo) and 26Gx½ inch 
needle (Terumo) and placed into 1 mL lithium heparin tubes (Vacutainer®, Beckton-
Dickinson, NJ, USA).  The tubes were then mixed well by manually inverting the tube 
>10 times.  At the completion of the time point, all five blood tubes were 
centrifuged at 3,000 g for 10 min and the plasma separated and stored at -80oC 
until analysed by HPLC (254).  During separation care was taken to minimise the 
contamination of the plasma by constituents of the buffy coat (white blood cells 
and platelets).   
 
A blood smear was prepared from each mouse blood sample at the time of 
harvesting to determine the peripheral parasitaemia.   
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6.2.2.3 Multiple dose pharmacokinetic study 
The pharmacokinetic properties for CQ and DECQ were determined in a multiple 
dose study using a total of 125 uninfected male Swiss mice (6–7 weeks of age; mean 
weight 30.8 ± 3.1 g) and 125 malaria-infected male Swiss mice (6–7 weeks of age; 
mean weight 29.2 ± 3.1 g) that had previously been inoculated with 107 P. berghei 
parasitised erythrocytes, 64 h before initial drug administration.  A total of five 
doses of 1,500 μg i.p. CQ were administered at 24 h intervals (as CQ phosphate 
solution in water; 100 μL injection volume).  Each mouse was weighed prior to dose 
preparation on each day with the average mouse weight determined for dose 
calculations. 
 
Blood was harvested for pharmacokinetic analysis from groups of mice (n=5) by 
cardiac puncture at 4, 8, 12, and 24 h after the first dose, 24 h after the 2nd, 3rd, and 
4th dose, then 1, 2, 4, 6, 8, 12, and 18 h after the fifth dose and at 5, 5.25, 5.5, 6, 6.5, 
7, 8, 10, 15, 21 and 30 days after commencement of the dosage regimen.  All blood 
samples were harvested and processed as described in Section 6.2.2.2.   
 
To monitor the pharmacodynamic effect of CQ on parasitaemia in mice used in the 
pharmacokinetic study, peripheral blood films were prepared and parasitaemia 
determined using two different subsets.  Firstly, in both the single and multiple dose 
pharmacokinetic studies 10 mice (the mice grouped in the last 2 pharmacokinetic 
time-points; i.e. 5 and 7 days for the single dose study and 21 and 30 days for the 
multiple dose analysis) were bled twice daily and parasitaemia determined.  The 
data were used to construct comprehensive parasite density-time plots which 
represented the pharmacodynamic effect seen in each cohort of mice after CQ 
therapy.  In addition, peripheral blood films were prepared from every mouse 
immediately prior to dosing and at the time of blood collection and euthanasia.  The 
mean parasitaemia for each group of mice was determined and these were plotted 
on the pharmacodynamic curve produced from the representative mice.  This 
procedure was followed for both the single and multiple dose cohorts.   
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6.2.3 HPLC analysis of CQ and DECQ 
All HPLC analysis was performed by the research group analyst, Dr Madhu Page-
Sharp, according to an established method (254), as described below.  
 
6.2.3.1 Materials 
CQ diphosphate was obtained from Sigma-Aldrich (St. Louis, MO) and DECQ 
dioxalate was from Starks Associates (Buffalo, NY).  The internal standards 
amodiaquine (AQ) and PQ were purchased from Sigma (Stockholm, Sweden) and 
Yick-Vic Chemicals and Pharmaceuticals Ltd. (Hong Kong), respectively.  Acetonitrile 
was obtained from Merck (Damstadt, Germany).  All other solvents and chemicals 
were of HPLC or analytical grade. 
 
6.2.3.2 Preparation of stock solution and standard curve 
Stock solutions of CQ and DECQ were prepared separately, equivalent to 1 mg/mL 
base in water.  PQ was initially chosen for use as the internal standard, however, AQ 
was added as a second internal standard, should any interference occur with the 
primary standard.  For each analytical batch a 5-point linear calibration curve with a 
blank standard was prepared by spiking human plasma with appropriate volumes of 
working standards.  Quality control samples (5 μg/L and 50 μg/L) were included for 
each analysis.  All samples were assayed within the storage stability period of 6 
months for CQ (unpublished data).   
 
6.2.3.3 CQ and DECQ assay 
CQ and DECQ were extracted based on a previously published method (254). Briefly, 
plasma standards and samples (500 µL) were spiked with internal standard (PQ; 200 
ng and AQ; 200 ng) and mixed with 5 mL of t-butylmethyl ether and 200 µL of 5M 
sodium hydroxide and then manually shaken for 10 min.  All tubes were then 
centrifuged at 1,500 g for 10 min, with 4.5 mL of the organic phase then transferred 
into clean tubes and back extracted into 0.1 mL of 0.1 M HCl by shaking for 5 min.  
This procedure was then followed by centrifugation for 10 min at 1,500 g after 
which time the organic layer was aspirated to waste.  The HCl layer was transferred 
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to a round-bottomed borosilicate glass tube and re-centrifuged at 1,500 g for 20 
min after which 60 µL aliquots were injected onto the HPLC column.  
 
The HPLC system comprised of Hewlett Packard model 1100 with a gradient pump, 
autosampler and a variable wavelength UV detector (Agilent Technology, 
Waldbronn, Germany). Analysis of chromatograms was undertaken using 
Chemstation Software (Version 9, Agilent Technology, Waldbronn, Germany). 
 
Separation was performed on a Gemini C6-phenyl 110A (150 x 4.6 mm, 5 μm) 
column connected to a Gemini C6-phenyl (4 x 3.0 mm) guard column (Phenomenex, 
Lane Cove, NSW, Australia) at 30oC. The mobile phase contained 0.05M KH2PO4 
adjusted to pH 2.5 and 13% v/v acetonitrile. The mobile phase was pumped at 1 
mL/min and analytes were detected by their UV absorbance at 343 nm. The 
approximate retention times for PQ, DECQ, CQ and AQ were 2.5, 4.2, 5.2 and 6.8 
min, respectively (Fig. 6.2).  Two small peaks were also observed at 6.0 and 7.5 min 
(either side of AQ internal control), however, their identities were not further 
investigated and remained unidentified.   
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Figure 6.2 High performance liquid chromatography chromatograms for 
analysis of chloroquine and desethylchloroquine concentrations in mouse plasma 
samples.  Chromatograms demonstrate results for A: Blank human plasma; B: Drug 
Standards; C: Mouse plasma sample analysis.  Peaks identified were 1. PQ internal 
standard (2.5 min); 2. DECQ standard (200 ng; 4.2 min); 3. CQ standard (200 ng; 5.2 
min); 4. AQ internal standard (6.8 min); 5.  PQ internal standard; 6.  DECQ in mouse 
plasma sample 20 (182 μg/L); 7. CQ in mouse plasma sample 20 (925 μg/L); 8. AQ 
internal standard. 
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The intra-day relative standard deviations (RSD’s) for CQ were 7.8, 4.2 and 3.6% at 5 
µg/L, 500 µg/L and 3,000 µg/L, respectively (n=5), while inter-day (RSDs) were 8.3, 
5.8 and 5.2% at 5 µg/L, 500 µg/L and 3,000 µg/L, respectively (n=25). The intra-day 
relative standard deviations (RSD’s) for DECQ were 6, 4.9 and 3.4% at 5 µg/L, 100 
µg/L and 1,000 µg/L, respectively (n=5), while inter-day (RSDs) were 7.9, 6.3 and 
5.4% at 5 µg/L, 100 µg/L and 1,000 µg/L, respectively (n=25).   The limit of 
quantification and limit of detection was 1.2 µg/L and 0.6 µg/L for CQ and 1 µg/L 
and 0.5 µg/L for DECQ, respectively, with a signal to noise ratio of 3. 
 
6.2.3.4 Pharmacokinetic analysis 
For pharmacokinetic modelling, measured plasma concentrations were normalised 
to a dose of 50 mg/kg CQ, according to the weight of each mouse at the time of 
dosing.  Consistent with the principles of destructive testing (37, 593), the mean 
normalised plasma concentration for each group of mice was used to estimate 
pharmacokinetic parameters.  Pharmacokinetic analysis was performed using 
KineticaTM Version 4.4 (Thermo Fisher Scientific, Inc., Waltham, MA, USA).  Non-
compartmental analysis of the plasma concentration-time data was used to 
estimate AUC (log-linear trapezoidal method), t½, CL/F and apparent V/F for the 
single dose data.  A two-compartmental model was fitted to the data to estimate 
pharmacokinetic descriptors for the observed biphasic elimination of CQ (t½α and 
t½β; weighting = 1/y
2).  A two-compartment model (weighting = 1/y2) with first-order 
absorption was fitted to the DECQ plasma concentration-time data to estimate the 
formation rate constant (DECQ from CQ; kF). 
 
6.3 RESULTS 
6.3.1 Pharmacodynamic evaluation of single and multiple doses of CQ 
The complete (7-day) pharmacodynamic response to a single dose of 50 mg/kg CQ 
was determined in a representative group of 10 mice (final 2 groups for blood 
collection) and complemented by inclusion of the parasite density data for each 
sampling point in the pharmacokinetic arm of this study (Fig. 6.3).  Administration of 
a 50 mg/kg i.p. dose of CQ resulted in a rapid decline in parasitaemia with parasite 
nadir reached 79 h after drug administration at a mean parasitaemia of 0.01 ± 
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0.02%.  This represented a 406 fold decrease when compared to the starting 
parasitaemia.  Parasite nadir was followed by an exponential rise (approximately 10 
fold) in parasitaemia for > 3 days with all mice demonstrating high density 
parasitaemias at the experimental end-point (7 days).   
 
In mice receiving a series of five 50 mg/kg doses of CQ administered 24 h apart, a 
prompt decline in mean parasitaemia was observed, falling below the limit of 
detection (0.002%) 54 h after the initial dose (Fig. 6.4).  Parasites remained 
undetectable for a further 8 days until time of recrudescence, 10 days after the 
initial dose.   From 14 to 21 days, the mean parasitaemia remained relatively stable 
(0.37 to 0.59%) and then steadily decreased until it again fell below the limit of 
detection, 24 days after the first dose of CQ.  The parasitaemia remained 
undetectable until the experimental end-point, 30 days after the initial CQ dose.  
There was no statistically significant difference between parasitaemias determined 
from the representative groups of mice to that determined from each group of mice 
at time of euthanasia. 
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Figure 6.3.  Parasitaemia-time profile in mice following administration of single 
i.p. doses of 50 mg/kg CQ, 64 h after inoculation with 107 P. berghei-parasitised 
erythrocytes.  Data are shown as mean parasitaemia ± SD, from the time of drug 
administration (↑), in Swiss mice monitored for the duration of the study (, n=10) 
and from groups of mice whose blood was harvested at each pharmacokinetic time 
point (, n=5 per group). 
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Figure 6.4.  Parasitaemia-time profile in mice following administration of multiple 
doses of CQ (50 mg/kg CQ administered 65 h after inoculation with 107 P. berghei-
parasitised erythrocytes, then single i.p. doses of 50 mg/kg CQ given every 24 
hours for 4 days) (↑).   Data are shown as mean parasitaemia ± SD in both Swiss 
mice monitored for the duration of the study (, n=10) and from groups of mice 
whose blood was harvested at each pharmacokinetic time point ( n=5 per group). 
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6.3.2 Pharmacokinetics of CQ and DECQ in mice 
The plasma CQ and DECQ concentration-time profiles following single dose and 
multiple doses of CQ are shown in Figure 6.5 and Figure 6.6, respectively.  The 
elimination Cmax, tmax, t½, CL/F and V/F of CQ were 1,708 µg/L, 20 min, 46.6 h, 9.9 
L/h/kg and 667 L/kg, respectively, in healthy mice and 1,436 µg/L, 10 min, 99.3 h, 
7.9 L/h/kg and 1,122 L/kg in malaria-infected mice (single dose data; non-
compartmental analysis). The Cmax, tmax, and t½ of DECQ were 614 µg/L, 4 h, and 
32.6 h, respecitively, in healthy mice and 345 µg/L, 2.5 h and 74.4 h in malaria-
infected mice.  
 
Based on the two-compartment model, t½α and t½β were 3.3 and 53 h, respectively, 
in healthy mice and 4.7 and 163 h in malaria-infected mice (Fig. 6.5; Panel A; Table 
6.1).  CQ and DECQ data were incomplete (analytes not detected) after 7 days in the 
multiple dose study, hence detailed pharmacokinetic data could not be obtained 
from the two-compartmental model.  Based on the control and malaria-infected 
data from the single and multiple dose studies, the mean rate of formation of DECQ 
from CQ (kF) was 0.63 ± 0.55 h
-1 and the formation half-life (t½,Formation) was 1.7 ± 1.0 
h.  The mean t½α from these four sets of data was 4.2 ± 0.7 h. The metabolic ratio of 
DECQ to CQ was estimated at 1.08 and 0.62 for healthy and malaria-infected mice, 
respectively.  
 
Table 6.1  Pharmacokinetic parameters for CQ following i.p. (1,500 µg; 50 
mg/kg) administration in healthy and malaria-infected male Swiss mice.  
Pharmacokinetic parameters were determined using both non-compartmental 
analysis (t1/2, CL/F and V/F) and from a two-compartment model (t½α and t½β).  
 Uninfected mice P. berghei infected mice 
t1/2  (h) 46.6 99.3 
t1/2α  (h) 3.3 4.7 
t1/2β  (h) 53 163 
CL/F   (L/h/kg) 9.9 7.9 
V/F   (L/kg) 667 1,122 
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Figure 6.5  Concentration-time profile of CQ [Panel A] and DECQ [Panel B] in 
mice given a single dose of approximately 50 mg/kg i.p. CQ (as CQ phosphate; 
data normalised for pharmacokinetic analysis). Data are mean ± SD (n=5) plasma 
CQ concentration [Panel A] in healthy ( ――) and malaria-infected ( —) mice 
and plasma DECQ concentration [Panel B] in healthy (――) and malaria-infected 
(—) mice.  The lines represent the best fit of a two-compartment model to the 
respective data sets. 
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Figure 6.6   Concentration-time profile of CQ [Panel A] and DECQ [Panel B] in mice 
given five doses of approximately 50 mg/kg i.p. CQ (as CQ phosphate) at 24 h 
intervals. Data were normalised for pharmacokinetic analysis and are mean ± SD 
(n=5) plasma CQ concentration [Panel A] in healthy ( ――) and malaria-infected 
( —) mice and plasma DECQ concentration [Panel B] in healthy (――) and 
malaria-infected (—) mice. The lines represent the best fit of a two-compartment 
model to the respective data sets. 
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6.4  DISCUSSION 
The current study demonstrated that the P. berghei murine malaria treatment 
model is suitable for detailed preclinical investigation of antimalarial compounds, 
particularly intensive pharmacokinetic studies. Furthermore, this is the first 
investigation which comprehensively describes the pharmacokinetic properties of 
CQ and DECQ, in both healthy and P. berghei infected mice.  Furthermore, this 
study provides detailed pharmacodynamic data that demonstrate the rate of 
antimalarial response and provides an understanding of ‘curative’ effects of CQ in 
murine models.   
 
To date, murine studies of CQ have not reported comprehensive pharmacokinetic 
data in either healthy nor malaria-infected mice, due to their short sampling periods 
(longest sampling period is 24 h) and/or small sample sizes (14, 78).  The ability to 
compare results obtained from these studies is also hindered as Cambie et al. (78) 
determined CQ concentrations in whole blood after subcutaneous injection, whilst 
Ali et al. (14) established pharmacokinetic parameters in plasma after oral dosing.  
The purpose of the present study was therefore to improve the body of data by 
determining the pharmacokinetic parameters of CQ and DECQ in both healthy and 
P.  berghei infected mice.     
 
To determine the pharmacokinetic parameters of CQ and DECQ in this study it was 
decided to analyse the plasma drug concentrations, as a robust analytical method 
was already available within the laboratory and had been used in previous clinical 
studies (253, 254, 257).    However, CQ has a high blood: plasma ratio (>5:1) and is 
thought to be retained within infected erythrocytes hence plasma CQ 
concentrations are likely to be considerably lower than those found in healthy 
controls (78) and pharmacokinetic parameters will be matrix dependent (148, 264, 
504).  Despite this concern, a study by Frisk-Holmberg et al. (173) demonstrated 
that in healthy subjects there is a direct correlation between the plasma and whole 
blood CQ concentrations.  Furthermore, whilst it is acknowledged that serum CQ 
concentrations are higher than corresponding plasma CQ concentrations, due to the 
release of platelet and leukocyte bound CQ during the clotting process, if 
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centrifuged correctly plasma CQ concentrations will reflt a comination of free and 
plasma protein bound CQ (148).  It is therefore presumed that although parasitised 
erythrocytes would accumulate more of the drug than non-parasitised erythrocytes, 
a light infection (<5% parasitaemia) would not be expected to significantly change 
the CQ concentrations or pharmacokinetic properties (78).  Conversely, it has been 
shown that heavy infections will significantly alter the pharmacokinetic profile of 
CQ; in particular the V, AUC and elimination half-life (78, 396).   Considering these 
findings in relation to the present study, it is unlikely that the parasitaemia had 
significant effect on the plasma CQ concentration, particularly at the time of 
treatment when peripheral parasitaemia was <5%.  However, during post-
treatment recrudescence, towards the latter stage of sample collection, there may 
be some misrepresentation of plasma CQ concentrations as a result of the 
increasing parasitaemia.   This was shown in a morphological study by Macomber et 
al. (295) in a P. berghei murine model, where 4 h following i.p. administration of 40 
mg/kg CQ the erythrocyte CQ concentrations was  approximately 100 times higher 
than corresponding plasma CQ concentration in infected mice, whilst in uninfected 
mice there was little accumulation of CQ into erythrocytes. Furthermore, CQ 
concentratiosn in erythrocytes progressively fell as the parasitaemia (295).   
 
In the single dose pharmacokinetic study the pharmacokinetic profiles of healthy 
and P. berghei infected mice appeared to be quite similar. However, in the multiple 
dose study there appeared to be a significant difference in the plasma CQ 
concentrations from 120 h after starting CQ treatment (Fig. 6.6).  The reasons for 
the variation in pharmacokinetic profiles, after the final 50 mg/kg CQ dose, are at 
this time unclear and it was beyond the scope of the study to explore this finding.  
However, accumulation of CQ in parasitised erythrocytes was considered unlikely 
because the pharmacodynamic profile demonstrates that the parasitaemia at this 
time was undetectable and the DECQ concentration-time profile was similar in 
malaria-infected and control mice.    
 
A general limitation of all murine malaria studies is that direct extrapolation to 
human infections is not usually possible.  However, murine malaria 
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pharmacokinetic/ pharmacodynamic models can be comparable to strategies used 
in the clinical setting (122).  Therefore, such models could play an important role in 
the investigation of outcomes of antimalarial drug therapy both in single or 
combination therapies, in the development of new regimens as well as in the design 
of new drugs or drug combinations (122).   Animal models also offer an opportunity 
for detailed investigations into the mechanisms of disease and the subsequent 
therapeutic response.  For example, the current study demonstrates that although 
CQ has a rapid effect on eliminating parasite burden, single dose administrations 
are inadequate for resolving infection, even at higher doses (50 mg/kg CQ base; 
lethal dose suggested to range between 68-78 mg/kg base in mice (306)).  
Furthermore, investigation of a series of multiple dose treatment regimens showed 
the importance of selecting a suitable dosing regimen, as resolution of infection was 
only observed after repetitive high doses of CQ spread of several parasite life-
cycles.   
 
Pharmacodynamic data from the current multiple dose study demonstrated that in 
the P. berghei model, the immune system has a role in drug efficacy.  Despite 
parasite recrudescence occurring 10 days after the initiation of therapy, a fatal 
parasitaemia was not observed in any mice with parasitaemias <0.5%.  
Furthermore, two weeks after parasite recrudescence was noted, the mean 
parasitaemia fell below the limit of detection (0.002%), with all mice appearing 
healthy and aparasitaemic for the remainder of the investigation.  As the 
pharmacokinetic data demonstrated that plasma CQ concentrations were not 
detectable after 7 days, it may be concluded that the observed decline in 
parasitaemia, and eventual resolution of infection, was due to a combination of 
initial parasite reduction after drug administration and the stimulation of an 
immune response.   A similar pharmacodynamic response was observed after high 
dose PQP (Chapters 4 and 5) at which time it was concluded that the resolution of 
infection was a result of both pharmacological and immunological mechanisms.   
 
In conclusion, this study has shown that the P. berghei murine malaria model has 
the potential to be a valuable conceptual model for the comparison of single dose 
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and multiple dose therapies.  Importantly, where immune and other regulatory 
mechanisms may be integral features, the murine model is a useful extension of 
more rapid, comparatively high-throughput in vitro studies.  Despite WHO 
recommendations due to widespread CQ-resistant malaria (584), CQ monotherapy 
remains a popular choice of antimalarial for the prevention and treatment of 
uncomplicated malaria (111, 135, 513, 549, 556, 559, 562, 586).   As a result, 
preclinical investigations into adequate treatment regimens (for single dose 
therapies) and acceptable combination therapies are of the utmost importance 
(357, 383, 522, 549).   In light of this, the present study demonstrated the 
pharmacokinetic properties of CQ and its metabolite DECQ in both healthy and P. 
berghei infected mice, observations that are believed to significantly contribute to 
the preclinical knowledge of this drug, which to date has not been adequately 
investigated.   
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CHAPTER SEVEN 
 
CONCLUSIONS 
 
Murine malaria models have proved to be important in the preclinical evaluation of 
antimalarial compounds and their therapeutic regimens.    Furthermore, a well 
selected murine model can provide valuable insight on the pathology and 
immunology of malaria infection in the infected host.  The Rane murine malaria 
model was initially proposed for the testing of antimalarial drug activity, using 
‘death’ and ‘survival’ as descriptors of success.  As a result, this model proved to be 
highly successful in the screening of potential antimalarial compounds. For the 
studies described in this thesis, it was thought that after minor modifications, the 
outcomes of the Rane model could be extended, thus allowing further investigation 
into descriptive pharmacokinetics, dose-ranging pharmacodynamics, organ 
histopathology and immunological interactions.  Hence, this series of studies was 
designed to investigate the pharmacodynamic and pharmacokinetic relationship of 
a range of antimalarial drugs, both novel and established, in mice.  This was deemed 
important, due to limited published (Western) literature wth detailed murine 
phamacodynamic-pharmacokinetic investigations of DHA, PQ and CQ.  Whilst it is 
acknowledged that murine investigations are not readily comparable to the clinical 
setting, it is also suggested that the results obtained in these studies will prove to 
be valuable for more detailed preclinical research into antimalarial drug 
combinations and treatment regimens.   
 
The research investigations presented in this thesis have demonstrated that the P. 
berghei murine malaria model provides a valuable conceptual model for the study 
of single dose, multiple dose and combination therapy pharmacodynamic and 
pharmacokinetic responses, which is clearly neither ethical nor feasible in the 
clinical setting.  In vitro culture models also lack the immune and regulatory 
mechanisms of a living model and therefore the immunological responses observed 
in these studies, which proved to be important in the maintenance of subclinical 
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levels of infection, would not be able to be observed or considered in an in vitro 
model.  Furthermore, pharmacokinetic data obtained from the present 
investigations have demonstrated that the P. berghei malaria model can provide 
robust evidence for ‘concentration efficacy thresholds’ with antimalarial drugs.   
 
The study of DHA efficacy in intact and asplenic, healthy and P. berghei infected 
mice demonstrated that DHA had a potent antimalarial effect in both populations.  
Furthermore, an investigation into the stage specificity of DHA against P. berghei 
parasites showed that this antimalarial drug was effective against all of the 
erythrocytic stage Plasmodium parasites.  Histopathological investigation of key 
organs (liver, kidney and lung) indicated an enhanced role of the liver in asplenic 
mice, which was a likely compensatory mechanism for the clearance of parasites in 
this population of mice.   
 
Although PQ has been utilized as an antimalarial compound in the clinical setting 
since the early 1960s, to date there is little published data on the efficacy or 
pharmacokinetic-pharmacodynamic relationship of PQ in mice.  The present 
detailed investigations therefore provided a valuable insight into this novel 
antimalarial drug.  Single dose-ranging PQ studies demonstrated a potent, long 
lasting antimalarial effect in mice infected with P. berghei parasites.  Furthermore, 
this antimalarial efficacy was shown to be enhanced when mice were treated with a 
combination of PQ and DHA.  High dose PQP (90 mg/kg) administration resulted in a 
pharmacodynamic profile that suggested a period of post-treatment prophylaxis, 
which was further investigated to determine if this effect was due primarily to drug 
administration, the acquisition of immunity towards the infecting parasite strain or 
a combination of factors.   A series of viability and re-inoculation experiments 
looking specifically at parasite viability, drug efficacy, drug resistance and 
immunological influences demonstrated that whilst PQ provided a substantial 
antimalarial effect, the period of post-treatment prophylaxis was predominantly a 
result of immunological mechanisms.  Furthermore, the study suggested that 
residual PQ concentrations could lead to the development of PQ-resistant parasites. 
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The pharmacokinetic investigation of CQ in the P. berghei malaria model was 
performed because despite the extensive use of CQ as a comparator drug in 
preclinical efficacy investigations, there remains a paucity of murine 
pharmacokinetic data.  This investigation found little difference, after single dose 
administration, between the pharmacokinetic profiles of healthy and P. berghei 
infected mice.  However, after multiple dose administrations of CQ, a significant 
difference in the plasma CQ concentrations was observed.   Corresponding 
pharmacodynamic data demonstrated that after multiple doses of CQ (5 x 50 
mg/kg), parasitaemia was suppressed for a sufficient period of time in which an 
immunological response could be mounted towards infection.  
 
The present series of investigations established that this P. berghei murine model is 
suitable for detailed preclinical investigations of antimalarial compounds, 
particularly intensive pharmacokinetic studies. Whilst the current studies appear to 
be the first to comprehensively describe the pharmacokinetic properties of PQ, CQ 
and DECQ, in both healthy and P. berghei infected mice, novel pharmacodynamic 
and immunological responses to the administration of DHA, PQ and CQ have also 
been demonstrated.    It is therefore concluded that the work described in this 
thesis will be viewed as a valuable contribution to the preclinical investigation of 
antimalarial drugs.  
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APPENDIX 1 
MURINE SEROLOGY 
 
Murine Virus Monitoring Service 
101 Blacks Rad 
Gilles Plan 5086 
South Austalia 
Telephone: +61 8 8261 1033 
Fax:              +61 8 8261 2280 
 
SEROLOGY 
‘All samples will be tested by ELISA for antibody directed against: Cilia Associated 
Respiratory Bacillus (CAR), Murine Cytomegalovirus (CMV), E. Cuniculi (CUN), 
Ectromelia Virus (ECT), Hantaan Virus (HAN), Lymphocytic Choriomeningitis Virus 
(LCM), Mouse Adenovirus (MAD), Mouse Hepatitis Virus (MHV), Minute Virus of 
Mice & Mouse Parvovirus (combined test using recombinant antigen PARV – rNS1), 
Polyoma Virus (POL), Mycoplasma pulmonis (PUL), Pneumonia Virus of Mice (PVM), 
Reovirus Type 3 (REO), Epidemic Diarrhoea of Infant Mice (ROT), Sendai Virus (SEN), 
Theiler’s Murine Encephalomyelitis Virus (TMV) and Clostridium piliformis (TYZ).’ 
 
All results will be reported as: 
POS = Positive 
NEG = Negative 
EQU = Unconfirmed low level reaction 
NS = Non-specific reaction 
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APPENDIX 2 
REAGENTS AND BUFFERS 
 
A2.1 Acetic Acid; 1 M 
 Acetic acid, glacial (17.43 M)    57.4 mL 
 Water       to 1 L 
 
A2.2 Alsever’s Solution 
 Dextrose (anhydrous)     20.5 g 
 Trisodium citrate (Na3C6H5O7.2H20)   8.0 g 
 Sodium chloride     4.2 g 
 Citric acid (monohydrate)    0.5 g 
 Water        to 1 L 
 
A2.3 Citrate-Phosphate-Dextrose Solution; pH 6.9  
 Trisodium citrate (Na3C6H5O7.2H2O   30.0 g 
 Sodium dihydrogen phosphate (NaH2PO4.2H2O) 0.16 g 
 Dextrose (anhydrous)     2.0 g 
 Water       to 1 L 
 
A2.4 Formaldehyde-Citrate Solution 
 Formaldehyde solution (40% w/w CH2O)  10 mL 
 Trisodium citrate solution (109 mM)   to 1 L 
 
A2.5 Glycerol in Alsever’s Solution    
 Glycerol      100 mL 
 Alsever’s solution     to 1 L 
 
* Sterilised by filtration (0.45 μm Millex ®-HA filter unit; Millipore, Bedford, MA) 
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A2.6 Phosphate Buffer 
 Potassium dihydrogen phosphate (KH2PO4)  2.72 g 
 Disodium hydrogen phosphate (Na2HPO4)  11.36 g 
 Water        to 1 L 
 
A2.7 Sorenson’s Phosphate Buffer (pH 7.0) 
 Potassium dihydrogen phosphate (KH2PO4)  3.75 g 
 Disodium hydrogen phosphate (Na2HPO4)  5.56 g 
 Water       to 1 L 
 
A2.8 Trisodium Citrate Solution 
 Trisodium citrate (Na3C6H5O7.2H2O)   32 g 
 Water       to 1 L 
